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Abstract
Cardiovascular disease (CVD) remains a leading cause of premature death worldwide.
Despite advances in treatment of ischemic diseases including myocardial infarction and
peripheral arterial disease (PAD), there remains a need for effective revascularization
therapies. Although early cell therapy trials investigated use of mononuclear cells from
autologous bone marrow, emerging evidence indicates that purified progenitor cell
populations are required to induce optimal vascular regeneration. In addition, autologous
cells show reduced efficacy due to CVD-related progenitor dysfunction. This thesis presents
preclinical studies characterizing several blood-derived cell types for the development of
cellular therapies to treat PAD, focusing on the use of allogeneic umbilical cord blood (UCB)
hematopoietic progenitor cells (HPC) and bone marrow multipotent stromal cells (MSC).
First, I demonstrated that human UCB cells prospectively purified based on high aldehyde
dehydrogenase activity (ALDHhi), promote the recovery of perfusion and vascularization in
mice with acute unilateral hindlimb ischemia. Unfortunately, the rarity of ALDHhi cells
impedes clinical implementation for patients with PAD. To address this issue, I developed ex
vivo culture protocols to increase the number of ALDHhi cells available for therapy. I
demonstrated that after a 20-fold increase in total cell number, expanded HPC maintained
robust vascular regenerative functions. Indeed, expanded UCB promoted endothelial cell
survival and endothelial cell tubule formation by paracrine mechanisms. Notably,
intramuscular injection of HPC significantly augmented recovery of perfusion and increased
vascularization in the injured limb, and increased recovery of limb usage within one week of
therapy. MSC have been widely investigated for vascular regenerative cellular therapies,
however substantial variability between donor sources indicating a need for better markers to
select pro-angiogenic MSC subsets for clinical applications. I demonstrated that MSC
retaining high ALDH activity after expansion effected increased endothelial cell
proliferation, survival, and tubule formation using in vitro systems. Taken together, my work
establishes the value of ALDH as a marker of cells with increased vascular regenerative
potential. My work also reveals that UCB ALDHhi cells, their ex vivo expanded HPC
progeny, and MSC retaining high ALDH-activity after expansion represent promising
candidates for future development of vascular cell therapies for PAD and CVD.
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Chapter 1

1

Introductioni

1.1 Cardiovascular disease
Despite significant progress and advances to improve treatments and management,
cardiovascular disease (CVD) remains the leading cause of premature death worldwide
and represents a huge burden on the health care systems in North America1,2. Broadly,
CVD includes a diverse array of conditions and affecting the heart and blood vessels.
Common classifications of CVD include both chronic conditions such as ischemic heart
disease, peripheral vascular disease, cerebrovascular disease and heart failure and acute
conditions like myocardial infarction and stroke. CVD accounts for roughly one third of
all deaths and it is estimated that CVD and stroke-related healthcare costs for patients are
now in excess of $300 billion in the US alone1-3.

1.1.1 Atherosclerosis
One common risk factor of CVD is atherosclerosis1,4-6. Atherosclerosis is characterized
by the progressive development of complex lesions or plaques that protrude from the
vascular lumen effectively narrowing the blood vessel1,3-5,7. In response to stressors like
dyslipidemia, hypertension and inflammation, arterial blood vessel endothelial cells
(ECs), which normally do not adhere circulating white blood cells, begin to express
adhesion molecules, effectively attracting monocytes to the vessel intima8.

These

monocytes differentiate into tissue resident macrophages, which engulf lipoprotein from

i
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the interstitium and become foam cells. This stage is called the fatty streak, named for the
appearance of the accumulated lipid filled foam cells in the developing lesion8. In the
developing atheroma, SMC are recruited from the medial layer to the intima where they
proliferate with the foam cells. Lipid pools form in the core of the lesion between the
ECs and the accumulating foam cells and SMC comprising the pathologic intimal layer9.
The lipid core becomes increasingly apoptotic and necrotic as SMC and foam cells die
and release accumulated intracellular lipids and cholesterol. Advancing plaques become
increasingly fibrotic and calcified as the lumen of the blood vessel becomes narrowed7.
As the lesion becomes larger and more fibrotic there is increased risk of developing what
is called the vulnerable plaque, characterized by a thin fibrous cap, a large lipid-rich
necrotic core, more inflammation and possible neovascularization and haemorrhage. The
vulnerable plaque is more prone to initiating thrombosis where a part of the plaque breaks
off and enters the circulation10, or the lesion may become complicated resulting in a
hematoma if it becomes vascularized by recruiting new blood vessels8. Plaque rupture or
thrombosis can lead to the acute ischemic events of myocardial infarction or stroke7.
Chronic reduction in blood flow to the heart or peripheral tissues due to severe
narrowing, or stenosis, leads to overt tissue ischemia. Broadly, it has been shown that
many factors influence the risk and development of atherosclerotic CVD including
physical activity, cigarette smoking, cholesterol levels and blood pressure11,12.

1.1.2 Chronic vascular diseases
Ischemia is characterized by insufficient blood flow to a given tissue or organ. Chronic
ischemia due to atherosclerosis in the limbs or extremities, like the lower leg, is called
peripheral arterial disease (PAD)13. In contrast, coronary artery disease (CAD) presents
where there are atheromatous lesions stenosing the coronary arteries feeding the
myocardium of the heart which can lead to heart failure14. The epidemiology of vascular
disease is relatively well described and is associated with increased age, and major risk
factors for the development and progression of vascular disease include, smoking and
diabetes mellitus15,16. More than half of patients with CAD have type 2 diabetes mellitus
associated with insulin resistance and the severity and rate of progression of vascular
disease complications is increased in patients with diabetes16. Furthermore, diabetes is
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associated with increased risk for developing PAD. Patients with diabetes have higher
rates of PAD and higher rates of intermittent claudication and poor wound healing in the
peripheral extremities17,18.

1.1.2.1

Coronary artery disease

CAD is a major component of CVD, contributing to millions of deaths each year due to
myocardial infarction and affecting many more people who a debilitated by permanent
disability due to progressive heart failure5. The treatment of CAD has improved greatly
since the Coronary Artery Surgery Study (CASS) clinical trial first demonstrated the use
of coronary artery bypass surgical intervention19. It is estimated that 1% of the Western
world is affected by congestive heart failure and the mortality in late stage heart failure is
very high, estimated to be above 60% within 10 years in patients above 6514,20. Currently,
the best treatment for end stage heart failure is heart transplantation21. Unfortunately,
heart transplantation is only an option for a very small subset of patients as there are too
few donors to meet the demand for potential recipients. Furthermore many patients do not
meet the eligibility criteria for transplantation and do not have any remaining viable
medical or surgical options22. In these patients there is a need for alternative therapeutic
strategies as well as preventative therapies to reduce progression to end stage heart
failure.

1.1.2.2

Peripheral arterial disease

Peripheral vascular or peripheral arterial disease (PAD), like CAD, is generally caused by
macrovascular atherosclerotic plaque progression leading to arterial stenosis13,23-25. Other
major factors related to PAD incidence are advanced age, smoking and diabetes26,27. PAD
of varying severity is extremely widespread and is estimated to affect more than 27
million people in North America and Europe28. The most common symptom in the
diagnosis of PAD that presents in patients is intermittent claudcation, or limping
associated with muscle cramping after moderate exertion and tends to present first in the
distal extremity of the calf muscle24. As the arteries of the lower extremities become
more severely narrowed the symptoms in the patient worsen. PAD is graded by severity
based on degree of tissue ischemia, commonly using the Rutherford scale29.

The most
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common therapy for PAD has focused on smoking cessation, increasing exercise to
induce improved collateralization by arteriogenesis, pharmacological vasodilatation, and
surgical revascularization30. Unfortunately, the progression of PAD severity advances
aggressively culminating in the most severe form of PAD, critical limb ischemia
(CLI)24,31,32. CLI is characterized by pain at rest and/or tissue loss in the ischemic limb24.
Patients with PAD and concomitant diabetes and atherosclerosis often show endothelial
dysfunction in the microcirculation in addition to the stenosis further complicating
treatment in CLI as vascular regeneration is impaired23,24. In CLI there is a significant
mismatch in the metabolic demand of the affected area and the ability of the vasculature
to adequately perfuse the tissue23,33. This perfusion insufficiency causes pain at rest and
can lead to persistent non-healing ulcers increasing the risk for co-infection of the
wounds23.

CLI patients have poor prognosis, leg amputation is required in 30% of

patients after 1 year with CLI and mortality at 1 year is greater than 20%28. Notably, CLI
patients have very poor psychological quality of life indices, about the same level as
terminally-ill cancer patients32.

Despite the benefit of surgical revascularization and

endovascular catheterization, it is estimated that more than 50% of patients are ineligible
for these treatments due to co-morbidity or anatomic complexity34. The lack of effective
therapy for many CLI patients indicates a need for improved revascularization strategies.

1.2 Vascular biology
Blood vessels are the primary conduits though which blood flows to carry oxygen, carbon
dioxide, nutrients, hormones, and blood cells to and from every organ of the body35. The
fundamental structural unit of the blood vessel is the EC.

The endothelium comprises

the single inner layer of the blood vessel surrounding the central lumen through which the
blood flows. ECs play an important role in the regulation of blood flow and serve as a
barrier between the blood and interstitium. Because of a short diffusion distance (0.1 to
0.2mm) the entire body must be highly vascularised with a branching network of blood
vessels36,37.
Capillaries are the smallest blood vessels and consist solely of a single layer of ECs
surrounded by occasional pericytes.

In larger vessels, arterioles and venules, the
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endothelium is surrounded by pericytes and connective tissue. Larger and more complex,
in arteries and veins the inner layer of ECs is surrounded by a basement membrane and
supportive perivascular cells including pericytes and a thick layer of smooth muscle cells
(SMC)37. The heart pumps oxygenated blood from the lungs at high pressure through
arteries to arterioles and finally to capillaries where nutrient and gas exchange occurs.
From the arterial capillaries flow continues into venous circulation and passes from
capillaries to venules to larger veins and back to the heart at lower pressure and speed. To
accommodate higher pressure of arterial circulation, arteries have thicker layers of SMC
compared to veins35,38,39.
ECs help mediate local responses to injury and inflammation by modulating thrombosis
and by permitting blood-derived immune cells to pass through to the interstitium40-42.
ECs are a heterogeneous cell type and display phenotypic differences between arterial
and venous circulation and between organ source and size of vessel35,38,39,42. In the
healthy adult, ECs are primarily quiescent and have low turnover within the vessel. They
are protected from injury by autocrine survival and maintenance signals, such as vascular
endothelial growth factor-A (VEGF-A), angiopoietin-1 (ANG-1) and fibroblast growth
factors (FGFs)

42-44

. Due to their involvement in oxygen supply, blood vessels express

oxygen sensors like prolyl hydroxylase domain 2 (PHD2) and hypoxia inducible factors
like hypoxia-inducible factors 1α and 2α (HIF-1α and HIF-2α)36,45-47. These permit the
ECs to respond appropriately to changes in oxygen levels36. In the perfused vessel,
adjacent ECs form a tight monolayer interconnected by junctional molecules like VEcadherin. The pericytes that surround the vessel share a basement membrane with the
ECs and express factors like VEGF-A and ANG-1 that normally maintain homeostatic
quiescence in the ECs36,48.

1.2.1 Vascular development
The formation of the vasculature is an important early step in organogenesis during
development of the embryo because as an organism grows it needs a more advanced
system for oxygen and nutrient exchange and to remove metabolic waste37,49. In the
developing embryo the vasculature forms by two primary processes, vasculogenesis and
angiogenesis. In vasculogenesis, mesodermal precursor cells migrate, aggregate and
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differentiate de novo into a hemangioblast, a common precursor of both blood and
ECs37,49,50. These hemangioblasts create new blood vessels and form the primary vascular
plexus of capillaries. Subsequent expansion and remodeling of the primary capillary
plexus occurs by angiogenesis which encompasses many steps including adhesion,
migration, proliferation, differentiation and tube formation from the already existing
vessel36,44,49.

1.2.1.1

Vasculogenesis in development

Vasculogenesis is the de novo formation of blood vessels from mesodermal progenitor
cells. In the mouse the earliest marker of the hemangioblast is Flk1 also known as
vascular endothelial growth factor 2 (VEGFR2). VEGFR2 is the primary receptor for
VEGF-A. Flk1 marks a subset of Brachyury-positive (mesodermal) cells in the primitive
streak which migrate to the extra-embryonic endoderm and form the vascular plexus, part
of which will form blood islands. The outer cells in the blood islands are ECs while the
inner cells become hematopoietic progenitor cells49. The hemangioblast theory has been
supported by findings from human embryonic stem cell in vitro differentiation studies51
and in vitro differentiation of isolated hemangioblasts from mouse embryos52. After the
formation of the vascular plexus, angiogenesis becomes the primary mechanism by which
blood vessels develop and remodel in the embryo proper.

1.2.2 Angiogenesis
Angiogenesis is defined as the growth of new blood vessels from the preexisting
vasculature44. There are two main types of angiogenesis that occur, intussusceptive and
sprouting angiogenesis.

The primary difference is that sprouting angiogenesis is

relatively slow and involves proliferation of ECs and subsequent invasion of vascularized
tissues by the growing EC pool44. Intussusceptive angiogenesis involves preexisting,
perfused blood vessels which remodel into new vessels and occurs without need for EC
proliferation53. Sprouting angiogenesis occurs when ECs become activated by increased
levels of angiogenic growth factors like VEGF-A, angiopoietin-2 (ANG-2), and
FGFs43,54,55. Chemokines which are released by hypoxic or inflammatory cells will also
initiate pro-angiogenic activation in ECs56. Broadly, angiogenesis includes extracellular
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matrix and basement membrane remodeling, increased EC migration, and induction of
EC proliferation leading to the formation of new blood vessel branches.

1.2.2.1

VEGF and NOTCH signaling in angiogenesis

VEGF signaling causes ECs to reduce VE-cadherin expression and EC-EC junctions
loosen, increasing permeability allowing plasma proteins access to the interstitium
around the vessel, laying down a scaffold for EC migration57. Single EC are selected to
become the tip cell which lead the growing endothelial tube towards the angiogenic
signal58. In response to a VEGF-A gradient, tip cells upregulate expression of Delta-like
ligand 4 (DLL4) which activates NOTCH signaling in adjacent EC cells leading to
downregulation of VEGFR-2 and establishment of a stalk cell phenotype58. This makes
stalk cell less responsive to VEGF signaling compared to tip cells and the stalk cells
become proliferative, causing the growing vessel sprout to lengthen by cell division. The
tip cells develop filopodia enabling them to sense environmental signals and guidance
cues to direct the growing vessel branch towards an angiogenic stimulus. Macrophages
have been shown to act as myeloid bridge cells that help fuse the sprouting vessels with
other growing branches enabling contiguous blood flow in a process known as vascular
anastomosis36,59,60. Although initiated by activated ECs, complete angiogenesis is a
complex process requiring the integration multiple cell types and signaling pathways.

1.2.2.2

Angiogenesis in hypoxia

Hypoxia, or low oxygen tension, is an important mediator of angiogenesis47,61. The HIFs
are transcription factors composed of an oxygen-sensitive α-subunit (HIFα) and a stable
β-subunit (HIFβ), also called the aryl hydrocarbon nuclear translocator (ARNT) which
together regulate expression hypoxia-responsive elements47,62.

Under normal oxygen

tension, or normoxia, HIFα is hydroxylated by prolyl-hydroxylase domain (PHD)–
containing enzymes and subsequently ubiquitinated, tagging it for proteasomal
degredation62. PHD requires oxygen to hydroxylate HIFα and is therefore are unable to
initiate degradation of HIFα during hypoxia63. Stable HIFα forms heterodimers with
HIFβ and translocates to the nucleus where is regulates expression of hundreds of genes
that regulate angiogenesis including VEGF-A45,46,64. Many other angiogenesis-related
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genes have been shown to be regulated by hypoxia, further increasing the complexity of
the angiogenic process65-69.

1.2.2.3

Angiopoietin and FGF signaling in angiogenesis

The angiopoietins, ANG1 and ANG2, are important regulators of EC quiescence and
angiogenesis55. Homeostasis and response to angiogenic activation is regulated by
angiopoietin signaling through the TIE receptors TIE-1 and TIE-2. ANG-1 is the primary
agonist of TIE-2 and depending on signaling context, ANG-2 is a generally considered a
competitive antagonist of ANG-1/TIE-2 signaling axis70. Recently ANG-2 has also been
shown to be a context-dependent TIE-2 agonist. Quiescence in EC is maintained by
ANG-1 signaling through TIE271. ANG1 also promotes mural cell/pericyte coverage and
increases deposition of basement membrane, further increasing vessel stability55. In
response to angiogenic stimuli, the tip cells and sprouting EC release ANG-2. ANG-2
competitively inhibits TIE-2 signaling thereby increasing pericyte detachment, vessel
permeability and endothelial branch formation70,72. In response to ANG-2, pericytes
initiate proteolytic degradation of the basement membrane by releasing matrix
metalloproteinases (MMPs) and detach from the vessel wall36. FGF signaling induces
angiogenesis directly in ECs or indirectly by activating secretion of other angiogenic
factors from neighboring cell types43. Furthermore, low levels of active FGF signaling is
necessary in quiescent blood vessels as inhibition of FGFR signaling leads to vessel
regression73.

1.2.2.4

Extracellular matrix modification in angiogenesis

In vascular homeostasis the basement membrane between the ECs and perivascular cells
helps maintain EC quiescence. During angiogenesis the basement membrane is degraded
and the ECM begins to be remodeled by proteases like the MMPs44,74. Proteolytic
degradation of the extracellular matrix (ECM) liberates further VEGF and FGF release
from deposits in the ECM as it is remodeled to be more accommodating to migrating and
proliferating ECs44,74,75. Matrix remodeling by MMP activity promotes EC migration and
tube formation by creating a pro-angiogenic microenvironment74,76.
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1.2.2.5

Chemokine signaling in angiogenesis

Chemokines have been demonstrated to play a role in the regulation of angiogenesis in a
number of pathophysiological conditions including ischemia36,56. Chemokines can exert
their role in angiogenesis both directly via actions on ECs and indirectly by recruiting
leukocytes and modulating growth factor signaling. Chemokines are a family of secreted
proteins classified into subgroups based on the spacing and presence of four conserved
cysteine residues, C, CC, CXC, and CX3C chemokines77. Several members of the CXCL
family have been demonstrated to promote angiogenesis including CXCL1 (GRO-α),
CXCL5 (ENA-78), CXCL8 (IL-8), and CXCL12 (SDF-1)78-80. The mechanism by which
CXCL12 promotes angiogenesis is particularly well established81,82. Angiogenic VEGF
signaling has been demonstrated to induce EC and perivascular expression of the
chemokine SDF-1/CXCL12 which in turn recruits circulating pro-angiogenic myeloid
progenitor cells to the vasculature83.

These bone marrow (BM) derived angiogenic

hematopoietic cells are proposed to provide critical paracrine support enhancing both
inflammation and angiogenesis81-84.
Of the CC family cytokines, CC2L (MCP-1, monocyte chemoattractant protein-1)85 and
CCL5 (RANTES)86,87, have been notably demonstrated to be angiogenic85,88. MCP-1 is
highly upregulated in vascular smooth muscle cell after injury to the blood vessel89,90.
MCP-1 signaling induces recruitment and transendothelial migration of monocytes and
into the intima of the injured vessel91. MCP-1 has been demonstrated to be an important
mediator of monocyte-EC adherence which were shown to increase vascular regeneration
and revascularization in a balloon-mediated endothelial injury model92. Other studies
have also implicated MCP-1 in recruitment of monocytes and macrophages and
mediation of angiogenesis during wound repair93,94. MCP-1 has also been implicated in
directly promoting angiogenesis by activating chemokine receptors on ECs95. RANTES
has been shown to be necessary for angiogenesis to occur in rats with peripheral ischemia
through proposed recruitment of myeloid cells to the site of injury87. RANTES, which
stands for regulated upon activation, normal T-cell expressed and secreted, also plays an
important role in recruitment of monocytes and circulating angiogenic hematopoietic
progenitor cells which modulate angiogenesis and vascular repair86,96,97. CX3CL1 has
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been demonstrated to promote angiogenesis directly in ECs from skin by recruiting
angiogenic lymphocytes98.

In a similar fashion, other chemokines have been shown to

modulate vascular repair and interact differentially with endothelium in various organs
further underscoring the phenotypic differences in ECs by tissue residence and location in
the vascular network.

1.2.2.6

Vascular remodeling and resolution of angiogenesis

Most of the newly formed blood vessel networks formed during angiogenesis after
vascular trauma are chaotic, tortuous and form many dead ends not forming a complete
loop from arterial to venous circulation99. As such, these vessels are poorly perfused and
considered immature, as they lack tight EC-EC VE-cadherin junctions and are
consequently leaky.

Furthermore, most newly sprouted vessels contain very few

pericytes to stabilize them100,101.

For the new vessel to become functional and stable it

must resume its quiescent state and recruit pericyte support102. The recruitment of
pericytes to the newly formed vessel is mediated primarily by the platelet derived growth
factors (PDGFs), angiopoietins and transforming growth factor-β (TGF-β) 55,102-104. In the
growing vessel branch ECs secrete PDGF-B to recruit pericytes to stabilize the nascent
vessel103.
As blood flow is restored to a tissue the hypoxic stress is reduced and consequently, there
is a decrease in secretion of angiogenic growth factors and activation of ECs. As the
peak of vessel density is reached in the wound bed of ischemic tissue, anti-angiogenic
signals begin to outweigh angiogenic stimuli and further sprouting is stopped as the
vascular network begins to be pruned back to homeostatic levels105,106.

Fluid flow forces

or shear stress in newly perfused branches initiates pro-survival mechanisms helping to
prune the branching network to ensure optimal blood flow107. While only a minority of
vessels newly perfused by blood flow will mature and recruit perivascular support and
ECM remodeling108, the majority of vessel branches which are not adequately perfused
will undergo regression107. The generally accepted mechanism by which regression and
vascular network pruning occurs is through apoptosis, programmed cell death109,110.

11

During maturation and regression of the vascular network after injury or hypoxia the
ECM is concurrently remodeled and new basement membrane components must be
deposited surrounding the vessels to be stabilized. MMP-mediated remodeling during
this stage can lead to dissociation of EC-ECM contacts and this has been postulated to
promote regression of unstable non-perfused vessels111. In contrast, tissue inhibitors of
metalloproteinases (TIMPs) and plasminogen activator inhibitor-1 (PAI-1) promote the
deposition of new basement membrane around vessels that undergo subsequent
functional maturation36.

1.2.3 Arteriogenesis
During arteriogenesis pre-existing arterioles undergo considerable remodeling to form
larger, functional collateral blood vessels112. Arteriogenesis is stimulated by increased
shear stress induced by narrowing in major arteries shunting increased flow into the
smaller collateral arterioles113,114. Commonly this occurs as an effect of arterial stenosis
during pathological atherosclerotic arterial disease115. The process of arteriogenesis is
regulated by cytokines like MCP-1 which recruits hematopoietic support cells, and FGF
which is mitogen of both ECs and smooth muscle cells116. Collectively, the effects
modulated during arteriogenesis stimulate extracellular matrix remodeling, and
subsequent formation of multilayered arteries, inclusive of the intima (endothelium,
basement membrane and pericytes) the media (smooth muscle cells and their ECM) and
adventitia (fibroblasts and their extracellular matrix)112.
Arteriogenesis is mechanically driven by increased pressure which increases stress on the
vessel wall; the vessel enlarges until the stress is normalized117,118. The increased shear
stress causes the endothelium of the arterioles to increase expression of adhesion
molecules leading to increased recruitment of monocytes and macrophages which help
drive arteriogenesis119. In addition to recruitment of monocytes, circulating BM-derived
hematopoietic progenitor cells are recruited to growing arteriole and promote further
arteriogenesis81,120-124.

In order to accommodate the growing diameter of the arterioles

the ECM must be remodeled in a process similar to that in angiogenesis115,116,125. Despite
an increase in collateral size after arteriogenesis is resolved, the collaterals still do not
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recapitulate the full conductance of the artery they’ve replaced allowing for the refinenent
of endogenous repair by other pro-angiogenic processes114,115,126.

1.2.4 Postnatal vasculogenesis
Vasculogenesis was originally thought to be restricted solely to embryonic development
until 1997 when Asahara et al. demonstrated evidence for peripheral blood-derived cells
which were termed endothelial precursor cells (EPC)127. Asahara et al. postulated that
since angioblasts and hematopoietic cells arise in development nearly simultaneously in
extra-embryonic blood islands and share expression of many cell surface antigens that
they may share a common progenitor cell (the hemangioblast), which might persist in the
adult organism, as is the case with hematopoietic stem cells. They isolated cells from
human blood based on CD34 expression and from murine blood by Flk-1 (VEGF-R2)
expression and showed some engraftment of transplanted EPC in close association with
the injured endothelium. Because integrated EPC co-stained for mature EC marker they
postulated that this was evidence of a postnatal vasculogenic process.

Many of the

findings of this paper became some of the defining and often controversial characteristics
of a circulating EPC128. Many subsequent studies have shown that several cell types that
have been termed EPC are in fact hematopoietic cells with proangiogenic function and
phenotype128-132.

Many of these pro-angiogenic hematopoietic cells facilitate robust

vascular regeneration without stable integration into the endothelium, in effect supporting
the literature on angiogenesis and arteriogenesis, and raising questions on the clinical
applicability of postnatal vasculogenesis during vascular repair in the adult81,82,124,133-138. In
2007, Yoder et al. defined endothelial colony forming cells129 (ECFC) as putative EPC,
which are rare blood-derived cells that form late-outgrowth adherent colonies of
proliferative cells when propagated under strict EC growth conditions, and can be
isolated at extremely low frequency from human peripheral blood, BM, and umbilical
cord blood (UCB). ECFC are distinguished from pro-angiogenic hematopoietic cell
types in human blood as they were exclusively CD45-, and represented the only cell type
that could integrate directly into perfused vessels in vivo128,130-132,139. It has been proposed
that pro-angiogenic hematopoietic cells and vessel-resident ECFC cooperatively
coordinate the vascular regenerative niche140.
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1.3 Cell therapy for vascular regeneration
The identification of molecular mediators, cells and genes involved in angiogenesis and
arteriogenesis has presented the possibility of new therapeutic approaches to promote
vascular regeneration during CVD3,21,23,33,115,141-143. Many different cell types, including
blood-derived angiogenic cells have been previously implicated in vascular repair and
have been recently investigated in preclinical animal models and in recent human clinical
trials as potential cell therapies for CVD21,23.

1.3.1 Stem cell therapy
A stem cell is defined a cell that can both self renew indefinitely, creating more stem
cells, and differentiate into different, more specialized cell types144-146. Stem cells can be
further classified by their potency, or more specifically their differentiation potential. A
pluripotent cell is capable of differentiating and forming all tissues in the adult organism.
These cells are found during development in the inner cell mass of a blastocyst147.
Pluripotent cells are absent in postnatal tissues but recently Yamanaka et al.
demonstrated that terminally differentiated cells like fibroblasts can be transcriptionally
reprogramed to a pluripotent state148. These cells, called induced pluripotent stem cells,
hold promise in terms of potential ability to make any cell type with one’s one genetics
for possible therapeutic applications149.
In the postnatal, adult organism many tissues contain resident cells that demonstrate stem
cell characteristics.

These multipotent stem or progenitor cells, can form multiple

different cell types, but are generally restricted to one tissue type or germ layer from
which they are derived. An example of the best-characterized multipotent stem cell is the
hematopoietic stem cell which can form all lineages of blood cells found in circulation150.
A progenitor cell can form multiple (multipotent) or one (unipotent) type of more
specialized cell, but has lost the capacity to self-renew over the life of the organism. An
example of a unipotent progenitor cell that has been widely studied in the context of
postnatal vasculogenesis is the endothelial progenitor cell (EPC/ECFC) which can
differentiate into mature ECs129.
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Bone marrow, mobilized peripheral blood and UCB have been intensely studied as easily
accessible and readily-available sources of adult progenitor cells for cell therapy for
CVD21,23. Adult or postnatal progenitor cells obtained from human BM or UCB are
comprised of a heterogeneous array of regenerative cell subtypes and represent
transplantable cells used to reconstitute hematopoiesis in hematological malignancies or
to facilitate the repair of damaged or diseased tissues via paracrine effects128,151-154.
However, with the exception of hematopoietic stem cells (HSC) with the phenotype linCD34+CD38-CD45RA-Thy1+RholoCD49f+, prospective purification of infrequent BM- or
UCB-derived stem and progenitor cells for use in targeted regenerative therapies is
currently underutilized129,150,154. Indeed, non-hematopoietic stem and progenitor cell
subtypes from BM and UCB demonstrate a paucity of specific markers of differentiation
in situ155, and stem cell surface markers can also vary between species, source, and cell
cycle progression156. As described in terms of postnatal vasculogenesis, circulating
EPC/ECFC which can integrate into repairing vasculature or support angiogenesis show
much promise as potential cell therapies for vascular regeneration128.

Many

hematopoietic cells types thought to be EPC in fact represent pro-angiogenic
hematopoietic cells124,140.
Asahara et al. originally identified endothelial precursor cells (EPC) as a population of
circulating progenitor cells in human peripheral blood that differentiate into mature
endothelial cells (EC) in vitro and contribute to vessel formation after transplantation into
SCID mice 127. Later studies showed that these cells expressed the primitive cell markers
CD34, CD133, and KDR (VEGFR-2)157 and can be obtained from other sources such as
BM and UCB158,159. However, this cell phenotype was shared by hematopoietic progenitor
cells, making discrimination of hematopoietic versus endothelial lineage commitment
controversial. Because both myeloid hematopoietic and endothelial progenitor cells have
been shown to promote angiogenesis in mouse models138,160 Yoder et al. functionally
demonstrated that true EPC are plastic-adherent blood-derived cells propagated in strict
EC growth conditions that form proliferative colonies of CD45− ECs capable of forming
perfused vessels in gel implants in vivo, termed ECFC

129

. In contrast, the nonadherent

CD45+ blood-derived cells that co-expressed typical EC markers (CD31) were not actual
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EC precursors but myeloid/macrophage lineage cells, which did not incorporate into
newly formed vessels, yet can contribute to angiogenesis through proposed paracrine
signaling to activated vessel-derived EC124,129,134-136,138.
With accumulating evidence indicating the promise of multiple BM-derived cell
populations for vascular regeneration, clinical trials were initiated investigating the
transplantation of heterogeneous BM mononuclear cells (MNCs) to treat limb
ischemia23,161,162 and to promote cardiac repair21,153,163-165. However, while many of these
trials demonstrated promising results in promoting revascularization, scientists have
undertaken studies to take a closer look at the specific progenitor cell fractions that show
vascular regenerative promise166.
Using nude mice and femoral artery ligation with complete excision of the femoral artery
and vein, López-Holgado et al. demonstrated that treatment with both CD14+ monocytes
and CD133+ cells from mobilized peripheral blood demonstrate significantly improved
perfusion in the surgical limb compared to vehicle treated mice. That research group
showed furthermore that these hematopoietic cell population do not transdifferentiate into
true endothelial cells or EPC167. Lai et al. demonstrated that various sources of EC
support recovery of perfusion in a similar hindlimb ischemia model in SCID mice168.
They showed that human umbilical vein EC (HUVEC), EC derived from embryonic stem
cells, EC derived from induced pluripotent stem cells, and EC derived from patient BM
supported augmented recovery of perfusion compared to vehicle control mice. They
derived EC from BM by plating MNC in endothelial growth media (EGM2) and selecting
adherent cells similar to ECFC derivation as published by Yoder.

Notably they also

demonstrated derivation of EC from human BM was more challenging from patients with
CVD indicating the value of allogeneic transplantation strategies to treat CVD168.
Recently, using a model of very severe induction of ischemic injury by burning the
femoral artery whereby some untreated mice completely lose the surgical limb, Vu et al.
demonstrated that treatment with heterogeneous UCB MNC or ex vivo expanded CD34+
CD133+ cells prevented limb loss and improved recovery of limb function and reduced
necrosis169. Vu et al. termed their cells EPC however they did not show that the CD34+
CD133+ cells they used were non-hematopoietic or that they could directly integrate into
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newly formed vessels making it likely that their “EPC” were in fact a mixture of
endothelial and angiogenic hematopoietic cells as shown by others134,167. Notably, there is
evidence that there is significant variation in the basal recovery rate of perfusion after
femoral artery ligation surgery between different mouse strains, an important caveat for
comparing the magnitude of perfusion recovery results between studies170,171.

1.3.1.1

Mesenchymal stromal cells

Mesenchymal stromal/stem cells (MSC), also refered to as multipotent stromal cells, can
be isolated from bone marrow and other tissues and have been demonstrated to be a
multipotent mesenchymal cell type that differentiate in bone, fat, and cartilage. MSC are
defined by their ex vivo culture method; they must be plastic adherent, express the
markers CD73 (ecto 5’ nucleotidase), CD90 (Thy-1), and CD105 (endoglin) after culture
and must not express hematopoietic markers like CD45, CD14172. In addition, MSC need
to demonstrate the definitive multipotential differentiation into osteocytes, adipocytes and
chondrocytes173. Strictly speaking, MSC should properly be called multipotent
mesenchymal progenitor cells as they have not been demonstrated to display full selfrenewal capacity to meet the full criteria of a stem cell174.
MSC are widely considered as good candidates for allogeneic cell therapy applications
because of their low immunogenicity; they do not express MHC class II (HLA-DR) nor
costimulatory molecules like CD40, CD80 and CD86175.

Furthermore, MSC have been

shown to demonstrate low levels of engraftment and little proliferative capacity after
transplantation, reducing risk of transplant malignancy, but also potentially limiting long
term therapeutic efficacy176. In light of low levels of engraftment the currently hypothesis
regarding MSC contibutions towards regenerative therapy is primarily through the
modulation of the tissue microenvironment as opposed to cell replacement154,177.
MSC have been shown to augment cardiomyocyte178 and EC176,179 survival. MSC have
also been shown to secrete many angiogenic factors including, VEGF-A, FGF-2, ANG-1,
and MCP-1176,179-182. MSC have also been recently identified as a component of vascular
pericytes in multiple human organs that express CD146 in situ and help stabilize newly
formed vessels when co-transplanted with ECs in vivo183,184. MSC have furthermore been
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shown to play an important role in immunomodulation presenting interesting potential
paracrine applications in auto-immune disease and inflammatory conditions185. Taken
together these findings show the considerable promise of MSC from human BM or UCB
as a potential source for vascular regenerative cell therapies.

1.4 Aldehyde dehydrogenase: a functional marker of stem
cells for cell therapy
In order to simultaneously isolate stem and progenitor cells from multiple lineages, BM
or UCB mononuclear cells (MNC) can be purified based on a conserved stem cell
characteristic, high levels of aldehyde dehydrogenase (ALDH) activity, an intracellular
enzyme first reported to be highly expressed in primitive hematopoietic186, and neural
progenitor cells 187.
ALDH1A1 activity is involved in oxidation of vitamin A to retinoic acid and is
predominantly implicated in the protection of long-lived cells from oxidative damage186.
Most notably, ALDH activity is downregulated as primitive cells differentiate towards
maturity, making ALDH activity a unique function to distinguish essential regenerative
precursors from expendable cells. Our group and others have recently shown that high
ALDH activity is also a property shared by regenerative progenitors of endothelial and
mesenchymal lineages134,188. Purification of BM or UCB cells based on high ALDHactivity can be used to simultaneously isolate adult stem and progenitor cell subtypes for
the preclinical development of regenerative therapies inducing tissue repair. Focusing on
transplantation studies using human ALDH-expressing progenitor cells for hematopoietic
reconstitution, blood vessel formation, and islet regeneration in immunodeficient mice,
the Hess laboratory aims to understand how the multiple progenitor subtypes act together
to formulate a regenerative niche and to coordinate complex regenerative processes.

1.4.1 FACS purification of multiple human progenitor subtypes using
ALDH activity
Intracellular ALDH activity can be quantified using a fluorescent substrate for ALDH,
termed Aldefluor reagent

186

. First synthesized by Clayton Smith’s group in 1999,

Aldefluor reagent is a Bodipy fluorochrome conjugated to an aminoacetaldehyde
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molecule, an uncharged moiety that can freely cross through the cell membrane. Once
inside the cell, cytoplasmic ALDH1A1 converts Aldefluor into a metabolized by ALDH
into an anion that becomes trapped in the cell due to its negative charge. Under
pharmacological inhibition of ABC transporters contained within Aldefluor buffer, cells
with high ALDH activity retain Aldefluor substrate and fluoresce brightly, while cells
with lower ALDH activity are more dimly fluorescent. Thus, high-speed fluorescenceactivated cell sorting (FACS) can efficiently purify UCB or BM MNC with low side
scatter and low versus high ALDH activity. The integrity and function of the isolated
cells are not compromised by this procedure since upon removal of the Aldefluor buffer,
ATP-binding cassette transporters become reactivated, and Aldefluor is actively effluxed,
returning the cell to its original state. Thus, the Aldefluor purification procedure is
clinically applicable for the efficient sorting of multiple functional human progenitor cell
types based on a highly conserved stem cell function. The amount of ALDH activity in
all viable cells falls along a spectrum from low ALDH activity (ALDHlo) to high ALDH
activity (ALDHhi), where ALDHlo versus ALDHhi cells are distinguished by cluster gating
using diethylaminobenzaldehyde or DEAB, a pharmacological inhibitor of ALDH1A1.
The basic premise of the Aldefluor assay to assess ALDH activity with FACS is
summarised in Figure 1.1.
It has previously been shown that purified ALDHhi cells from BM and UCB highly coexpressed stem cell-associated surface markers (CD34, CD133, c-kit) and were enriched
for multipotent hematopoietic and mesenchymal stromal progenitors, as well as precursor
cells with endothelial colony forming cell (ECFC) capacity in vitro134,156,188,189. In contrast,
ALDHlo cells were primarily comprised of mature leukocytes (primarily T- and B-cells)
and demonstrated little progenitor function in vitro134. Therefore, high ALDH activity
simultaneously purifies multiple progenitor cell subtypes ideal for lineage-specific
expansion in vitro. Subsequently, purified ALDH-purified mixed progenitor cells or their
ex vivo expanded progeny can be assayed for regenerative functions after
xenotransplantation into a variety of immunodeficient models of tissue damage.
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Figure 1.1. Schematic overview of FACS isolation of ALDHhi cells using Aldefluor.
(A) Aldefluor passively diffuses into cells where is metabolized by ALDH into an anion
which can no longer diffuse out of the cell, this leads to accumulation of a fluorescent
signal that can be detected and selected by FACS. (B) DEAB inhibition of ALDH
activity identifies ALDHlo population for gating. (C) Aldefluor labeling allows efficient
selection of ALDHhi cells from a heterogenous population of UCB MNC by FACS.
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1.4.2 Cells with high ALDH activity possess hematopoietic
repopulating capacity
Hematopoietic stem cells (HSC) and lineage-specific hematopoietic progenitors are
responsible

for

the

replenishment

and

maintenance

of

blood

after

BM

transplantation190,191. These cells can be isolated from BM, cytokine-mobilized peripheral
blood, or UCB based on expression of the cell surface markers CD34 and CD133, and
assayed for hematopoietic repopulating function after transplantation into sublethally
irradiated nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice192-194.
Storms et al. first established that the ALDHhi fraction of human UCB was enriched for
primitive hematopoietic progenitors in vitro and was depleted of lineage-committed
hematopoietic cells186. Subsequently, prospective lineage depletion in combination with
the commercially available Aldefluor reagent (Stemcell Technologies, Vancouver,
Canada) was used by our group to demonstrate that transplantation of human UCB
ALDHhi cells into NOD/SCID mice resulted in multilineage human hematopoietic
engraftment156. Greater than 70% of the UCB ALDHhi cell population co-expressed the
HSC-associated cell surface markers CD34 and CD133156. ALDHhi CD34+ cells were
highly enriched for short-term myeloid progenitors while ALDHhi CD34− cells
represented precursors to the CD34+ population that also demonstrated NOD/SCIDrepopulating cell (SRC) capacity195-197.
Our laboratory has also demonstrated that while both ALDHhi CD133− and ALDHhi
CD133+ cells demonstrated clonogenic hematopoietic progenitor function in vitro, only
the ALDHhi CD133+ population was able to engraft the murine BM after intravenous
injection198. Furthermore, prospective selection based on both high ALDH activity and
CD133 increased the frequency of SRC by tenfold compared to selection by CD133
alone.

Notably,

ALDHhi

CD133+

cells

demonstrated

enhanced

hematopoietic

repopulating function in serial secondary transplants while maintaining primitive
hematopoietic phenotypes (CD34+CD38−)198. In addition to long-term hematopoietic
repopulating function, human UCB ALDHhiCD133+ cells also showed previously
unrecognized engraftment in nonhematopoietic tissues such as the liver, lung, heart,
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brain, pancreas using the highly sensitive human cell-tracking NOD/ SCID MPSVII
model199.
Later

studies

established

that

hematopoietic

engraftment

after

human

UCB

transplantation in immunodeficient mice occurs faster with increasing ALDHhi cell doses
200

. Similar to CD34 expression, clinical reconstitution rates following transplantation of

BM or mobilized peripheral blood can be directly correlated with the number of ALDHhi
cells infused201,202. As a result of these promising preclinical data and direct potential for
clinical translation, recently completed clinical trials designed to assess the safety and
efficacy of transplanted allogeneic human UCB ALDHhi cells to enhance the rate of
engraftment in the treatment of haematological dysfunction (www.clinicaltrials.gov trial
no. NCT00692926) have been reported. In summary, high ALDH activity is now well
established as a functional characteristic of repopulating hematopoietic cells, and ALDH
activity appears to be a superior indicator of the quality of BM or UCB samples for
transplantation compared to standardized CD34+ counts201.

1.4.3 Cells with high ALDH activity for vascular regeneration
Although the ALDHhi population from human BM or UCB is more than 90%
hematopoietic in origin, it has been shown that the ALDHhi fraction of BM is also
significantly enriched for ECFC compared to ALDHlo cells and that high ALDH activity
was downregulated as a result of differentiative culture in vitro134. Thus, consistent with
the classification by Yoder et al., true ECFC initially possesses elevated ALDH activity.
Nagano et al. expanded EPC in culture from UCB and subsequently sorted the CD45EPC progeny based on ALDH activity203. Interestingly, they found that the more
differentiated ALDHlo outgrowth population was more proliferative in vitro and showed
higher expression of hypoxia-inducible factors (HIF1α), VEGF, and the chemokine
receptor CXCR4 under hypoxic conditions. They further showed that the cultured
ALDHlo outgrowth represented more mature EC that recruited effectively to the site of
ischemia and reduced necrosis in a mouse skin flap model of ischemic wound repair203.
Consistent with the idea that high ALDH activity simultaneously purifies stem and
progenitor cells from multiple lineages, our group and others have shown that in addition
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to HSC and tubule-forming EPC, the BM ALDHhi fraction was highly enriched for MSC
that efficiently differentiated into fat, cartilage, and bone in differentiation cultures in
vitro

134,189

. Capoccia et al. went on further to describe that transplanted human BM

ALDHhi mixed progenitor cells transiently recruited to areas of ischemia and augmented
the recovery of blood flow (perfusion ratio of ischemic/control limb of 0.7±0.1) by
stimulating the endogenous revascularization of ischemic limbs in immunodeficient
NOD/SCID/β2microglobulin null and NOD/SCID/MPSVII mice with acute unilateral
hind limb ischemia induced by femoral artery ligation compared to vehicle control treated
mice at 21 days after treatment (0.3±0.1)134. Even without permanent engraftment at the
site of ischemia, a low dose of ALDHhi cells were more effective at inducing
revascularization than transplantation of unsorted BM nucleated cells containing the
equivalent of fourfold more ALDHhi cells. Recent work by Sondergaard et al. has shown
that intravenously transplanted UCB ALDHhi cells recruited specifically to the ischemic
myocardium where they augmented vascular density in a murine model of myocardial
infarction204.
Although the detailed mechanisms by which ALDHhi cells induced endogenous
revascularization remains an active area of investigation in the Hess lab, our working
hypothesis describes that high ALDH activity simultaneously depletes for inflammatory
immune cells and enriches for multiple proangiogenic progenitor subtypes. After
transplantation, ALDHhi progenitor subtypes recruit transiently to areas of regional
hypoxic damage and contribute to the generation of a proangiogenic microenvironment
by potentially providing both structural and paracrine support.
Despite the paucity of mechanistic details regarding the vascular regenerative potential of
ALDHhi cells, clinical trials have been initiated to explore the safety and efficacy of the
use of autologous BM ALDHhi cells in many CVD conditions205,206. The FOCUS-Br trial
was undertaken to investigate intramyocardial injection of autologous ALDHhi cells for
therapeutic angiogenesis (www.clinicaltrials.gov trial no. NCT00314366). The results of
the trial showed evidence that transplantation intramyocardial transplantation of ALDHhi
cells is safe and supported possible functional benefits in the setting of chronic
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myocardial ischemia indicating need for further clinical testing in a larger cohort to fully
assess efficacy207.
BM ALDHhi cells have also been investigated in clinical trials for treatment of critical
limb ischemia (NCT00392509).

Intramuscular transplantation of autologous BM

ALDHhi cells were directly compared to unfractionated autologous BM MNC in PAD
patients with a Rutherford score of 4 (resting pain) or 5 (ulceration or necrosis)208.
Results of the study demonstrated safety and patients that received autologous BM
ALDHhi cells showed improved Rutherford category and reduced resting pain.
Furthermore patients in the ALDHhi treatment group showed improved ankle to brachial
index scores more rapidly than the MNC group indicating improved perfusion of the
lower limb. However, patients in both cohorts reported significantly improved quality of
life indices.208 More recently, a phase 2 placebo-controlled randomized clinical trial has
been initiated to investigate transplantation of BM ALDHhi cells to improve symptoms of
intermittent claudication (NCT01774097). Another phase 2 clinical trial is currently
underway to investigate intracarotid infusion of BM ALDHhi cells for patients after and
ischemic stroke (NCT01273337).

1.4.4 ALDH-purified cells stimulating islet revascularization and repair
The Hess laboratory focuses on the development of pre-clinical models to study the
potential utility of post-natal stem cells for the treatment of diabetes and its vascular
complications. Indeed, the successful induction of angiogenesis or revascularization is a
central process in tissue repair. In the context of regenerative therapies for diabetes, the
contributions of transplanted stem cells are not limited to the direct replacement of
damaged beta cells. As an alternative, the endogenous repair of damaged islets or the
generation of new islets in situ has also been proposed209. Hess and colleagues were the
first to show that transplantation of murine BM-derived MNC or further purified c-kit+
progenitor cells stimulate the recovery of streptozotocin (STZ)-damaged islets by
inducing proliferation of recipient beta cells and augmenting glycemic control via the
endogenous regeneration of beta cell function210. Donor cells with both hematopoietic and
EC phenotypes were recruited to ductal regions and surrounded damaged islets,
subsequently stimulating beta cell proliferation and insulin production in recipient-
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derived beta cells. Several groups have extended these findings to show that islet
recovery can be induced by the induction of hematopoietic chimerism in overtly diabetic
NOD mice211 and that simultaneous infusion of murine BM MNC with allogeneic MSC
optimize islet repair and protection against T-cell-mediated beta cell deletion

212

.

Although transplantation of murine BM-derived cells have shown proof of principle that
BM-derived progenitor can impact endogenous beta cell regeneration, further purification
and transplantation of human progenitor subtypes from multiple sources is underway in
our lab to study the actions of specific cellular populations relevant to islet regeneration.
Toward this end, Hess et al. have transplanted human ALDH-purified BM stem cells into
STZ-treated

hyperglycemic

NOD/SCID

mice

to

promote

islet

regeneration.

Transplantation of BM ALDHhi cells led to a significant reduction in blood glucose and
increased serum insulin due to an increase in endogenous beta cell proliferation resulting
in increased islet size and total beta cell mass213. Notably, transplanted BM ALDHhi cells
recruited to damaged islets and stimulated beta cell proliferation associated with
functional capillary formation in regenerating islets. Similar to hyperglycemic mice
transplanted with human BM cells, mice transplanted with human UCB ALDHhi cells
also demonstrated increased islet size and vascularization compared to controls.
However, blood glucose reductions were transient, returning to severe hyperglycemia
several weeks after transplantation. Furthermore, direct intra-pancreatic delivery of UCB
ALDHhi cells increased peri-islet engraftment and stimulated a permanent reduction in
hyperglycemia compare to ALDHlo cell controls via the induction of an islet proliferative
and revascularization program in recipient islets214. Unlike ALDH-purified BM
progenitor populations, ALDH-purified UCB drawn by venipuncture did not consistently
establish expandable MSC in culture, indicating a potential requirement for MSC to
maintain islet regeneration. Fortunately, adherent MSC can be liberated from UCB after
collagenase treatment215, and inclusion of these cells within the transplanted population
may further improve islet regeneration.
In the past, clinical applications of UCB-derived stem cells have been limited to
transplantation in the fields of hematology or oncology; however, an increasing number
of studies support the use of these cells for nonhematopoietic disorders, including
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diabetes216,217. UCB MNC transplantation into diabetic mice has shown delayed onset of
autoimmunity and insulitis in a model of type 1 diabetes and improved in hyperglycemia
and survival rates post-transplantation

218,219

. A clinical trial using autologous UCB cells

is currently underway in children with recently diagnosed type 1 diabetes
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. Delayed

loss of endogenous insulin production and enhanced glucose control have been reported
due to a highly functional population of regulatory T-cells within UCB220,221. However,
the functional mechanisms conferring beta cell protection and potential mechanisms for
the expansion of beta cell mass and vascularization after UCB transplantation require
further preclinical experimentation.

1.4.5 Roles of ALDH-Purified MSC in Islet Regeneration
MSC possess properties beneficial in the repair of tissues damaged by autoimmunity.
MSC have been shown to modulate the microenvironment after injury and stimulate a
shift from an inflammatory to a regenerative response222, and to aid in tissue repair by
exerting antifibrotic and neoangiogenic effects223. MSC have also been shown to migrate
toward areas of hypoxia and or tissue damage through their expression of a variety of
chemokine receptors and adhesion molecules. Islets attract MSC in vitro and in vivo by
CX3CL1-CX3CR1 and CXCL12-CXCR4 interactions224,225. MSC may also play an
important role in modulating the immune response, an important consideration in the
treatment of type 1 diabetes. In damaged tissues, MSC stimulate reduced T-cell226 and Bcell proliferation227, inhibit maturation as well as differentiation of dendritic cells228, and
decrease the production of inflammatory cytokines by immune cells229. MSC can exert
these effects by secreting immunosuppressive effectors such as TGF-β, IDO, or PGE2229.
Collectively, these characteristics make transplanted MSC an attractive target for the
development of cellular therapies for autoimmune diabetes230. As proof of principle, Lee
et al. have shown that multiple high-dose intracardiac infusion of human BM-derived
MSC into STZ-treated immune-deficient NOD/ SCID mice repaired islets and improved
hyperglycemia with only minimal engraftment in the pancreas231. Transplantation of
ALDH-purified MSC into the tail vein of STZ-treated hyperglycemic mice also stably
reduced blood glucose and increased serum insulin. Rather than stimulating increased
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islet size and vascularization, MSC transplantation stimulated an increase in the number
of small islets present in the pancreas. Newly formed beta cell clusters were small in size
with direct proximity to the ductal epithelium. These unique regenerative characteristics
suggested the induction of a islet neogenic mechanism, whereby transplanted ALDHpurified MSC stimulated new islet formation213. Similar to findings by Lee et al.,
transplanted ALDH-purified MSC showed low-level or transient recruitment to the
pancreas, but initially lodge in the liver and lung capillaries199, presumably exerting their
effects on islet regeneration via the release of unknown paracrine regenerative factors
into the bloodstream.

1.4.6 Future perspectives for use of ALDHhi cells in cell therapy
BM- or UCB-derived ALDH-purified mixed progenitor cells and ALDH-purified MSC
demonstrate a variety of regenerative functions that impact tissue repair and
revascularization. However, differences in progenitor frequencies and functions should
not be overlooked when considering the optimal progenitor cell populations for
regenerative therapies. In addition, the regenerative mechanisms induced by ALDHexpressing progenitors and the paracrine mediators that comprise the regenerative niche
require further elucidation. Provided with this foundation of critical information,
scientists will be able to design rational regenerative therapies using a combination of
regenerative small molecules or directed administration of multiple progenitor cell
subtypes to synergize endogenous blood vessel and subsequent tissue repair.

1.5 Thesis Overview and Hypotheses
Recently, our lab has shown that human BM ALDHhi mixed progenitor cells transiently
recruit to areas of ischemia and augment blood flow by stimulating the endogenous
revascularization of ischemic limbs in transplanted immune-deficient mice after
induction of unilateral hindlimb ischemia by femoral artery ligation/transection134.
However, in patients with CVD, pro-angiogenic cell content or function may be
compromised due to chronic diabetes or vascular disease-related pathologies rendering
autologous BM transplantation strategies less effective129,232-235. Readily available and
early in ontogeny, human umbilical cord blood (UCB) represents a promising allogeneic
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source of functional pro-angiogenic progenitor cells. During my thesis work I have
investigated the vascular regenerative potential of human UCB and BM-derived
hematopoietic and multipotent-stromal progenitor cells for the pre-clinical development
of rational allogeneic cell-based therapies for ischemic diseases focusing on PAD.
Furthermore, I have focused on global molecular approaches, and functional assays in
vitro (Figure 1.2) and in vivo (Figure 1.3) to determine the paracrine signals elaborated
from these pro-angiogenic cell sources that positively impact microvascular endothelial
cell activation and function Our working model for transplanted progenitor cell
involvement in vascular regeneration as investigated in this thesis is summarised in
Figure 1.4. The central hypothesis of my studies is that high ALDH activity identifies
populations of progenitor cells from blood or BM that will demonstrate augmented
support of vascular regeneration. Thus, the specific objectives of my studies were as
follows.
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Figure 1.2. in vitro models for determination of progenitor cell contribution to
endothelial cell function.
Co-culture assays to assess cell-mediated effects on survival, proliferation, and tube
forming capacity of endothelial cells. (A) Schematic overview of hanging transwell coculture and cell-conditioned medium assays to assess endothelial cell proliferation or
survival. (B) Representative photomicrograph of human endothelial cells cultured on
plastic. (C) Representative photomicrograph of human endothelial cells growing on a thin
layer of Matrigel to assess modulation of tube-like structure formation.
Adapted from: Putman DM, Hess DA. Isolation of human umbilical cord blood aldehyde
dehydrogenase-expressing progenitor cells that modulate vascular regenerative functions
in vitro and in vivo. Curr Protoc Stem Cell Biol. 2013;Chapter 2:Unit 2A.10
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Figure 1.3 Transplantation model of acute unilateral hindlimb ischemia.
(A) Diagram of the vasculature of the mouse hindlimb from the inguinal crease to the
bifurcation of the femoral artery into the saphenous and popliteal arteries that descend
into the calf and lower limb. Ligation sites for femoral artery ligation surgery are
indicated. Representative laser Doppler perfusion images of mouse hindquarters before
and after ligation and transection of femoral artery and vein. Regions of interest are
selected from ankle to toe to quantify relative perfusion in the surgical limb. (B) Outline
and timing for tracking recovery of perfusion in the ischemic limb after surgical
induction of acute ischemia. Number in lower left quadrant of each laser Doppler
perfusion image is the ratio of perfusion in the ischemic limb to the perfusion in the
control limb.
Adapted from: Putman DM, Hess DA. Isolation of human umbilical cord blood aldehyde
dehydrogenase-expressing progenitor cells that modulate vascular regenerative functions
in vitro and in vivo. Curr Protoc Stem Cell Biol. 2013;Chapter 2:Unit 2A.10
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Figure 1.4. Umbilical cord blood and bone marrow-derived stem and progenitor
cells support an angiogenic niche.
The ALDHhi subpopulation of cells in UCB and BM is enriched for progenitors from the
hematopoietic, endothelial, and mesenchymal lineages. Each of these progenitor cell
types recruit to and help co-ordinate a pro-angiogenic regenerative microenvironment in
ischemic tissues.
Adapted from: Putman, D. M., Bell, G. I. & Hess, D. A. Blood-Derived ALDHhi Cells in
Tissue Repair, in Regenerative Therapy Using Blood-Derived Stem Cells (Allan, D. S. S.
& Strunk, D.) 21–34 (Humana Press, 2012).

34

Figure 1.4.
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1.5.1 Aim 1
•

To characterise the capacity of umbilical cord blood-derived ALDH-purified cells
to modulate endothelial cell functions in vitro

•

To assess the effects on vascular regeneration after intra-venous transplantation of
UCB ALDHhi cells into immune-deficient mice with unilateral hindlimb ischemia
induced by femoral artery ligation surgery.

In Aim 1, I hypothesized that selection of UCB cells based on high ALDH activity will
select a population of cells with augmented capacity to promote recovery from ischemic
injury.

1.5.2 Aim 2
Due to the relative rarity of ALDHhi cells from UCB or BM, in Aim 2 I sought to
determine if it was possible to expand UCB-derived ALDHhi cells ex vivo to generate
more cells for therapeutic applications without losing beneficial vascular regenerative
effect. Therefore the objectives of Aim 2 were two-fold:
•

To optimize the ex vivo expansion of UCB ALDHhi hematopoietic cells under
clinically relevant serum-free conditions and to characterize vascular regenerative
functions of the expanded progenitor cells in vitro.

•

To investigate the paracrine mechanisms by which expanded hematopoietic
progenitor cells derived from UCB ALDHhi contribute to revascularization after
direct intramuscular injection into the ischemic limb.

In Aim 2, I hypothesized that ex vivo expansion of UCB ALDHhi cells would increase the
number of pro-angiogenic hematopoietic progenitor cells for application in vascular
regeneration without decreasing EC-supportive functions.

1.5.3 Aim 3
BM MSC are a population of progenitor cells that expand readily in ex vivo cultures with
underutilized potential for vascular regenerative cellular therapies. However, our lab has
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demonstrated in our beta cell regeneration model studies that different MSC lines from
different donors showed variable efficacy to promote regeneration213,236. Furthermore, it
has been previously shown that selection of high ALDH activity in BM cells selected for
cells with increased regenerative potential. Therefore the objective in Aim 3 was as
follows:
•

To characterize the differentiative and vascular regenerative functions of MSC
subpopulations selected after expansion for low versus high ALDH activity.

In Aim 3, I hypothesized that selection of MSC subpopulations with high ALDH activity
would identify a population of MSC with increased vascular regenerative potential.
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Chapter 2

2

Umbilical Cord Blood-Derived Aldehyde
Dehydrogenase-Expressing Progenitor Cells Promote
Recovery from Acute Ischemic Injuryii
This study focused on the characterization of UCB as a source of ALDHhi cells for
development of cell therapy for CVD. My objective was to characterize the capacity of
umbilical cord blood-derived ALDH-purified cells to modulate endothelial cell functions
in vitro and to augment revascularisation after intra-venous transplantation into immunedeficient mice with unilateral hindlimb ischemia induced by femoral artery ligation
surgery.

ii

A version of this chapter has been published: Putman, D. M., Liu, K. Y., Broughton, H. C., Bell, G. I. &
Hess, D. A. Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote
recovery from acute ischemic injury. Stem Cells 30, 2248–2260 (2012).
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2.1 Introduction
Ischemic disease is characterized by the reduction of blood flow to the heart or peripheral
tissues and encompasses life-threatening disorders such as ischemic heart disease and
critical limb ischemia. Despite advances in pharmacological and surgical management,
ischemic disease remains one of the leading causes of morbidity and mortality
worldwide1,2. Thus, novel therapies to promote the regeneration of damaged vasculature
are under intense pre-clinical investigation3-5.
Angiogenesis, the sprouting of new blood vessels from pre-existing vessels, is a central
process for tissue repair, allowing the delivery of circulating pro-angiogenic cells that
form a vascular regenerative microenvironment5. Asahara et al. first described human
bone marrow (BM)-derived cells that promoted the recovery of blood flow, and colocalized with new vessels after transplantation in vivo6. Later studies have shown that
these rare cells, termed endothelial precursor cells (EPC), express the cell markers CD34,
CD133, and VEGFR27. Because these markers were also expressed on clonally distinct
cell types of both hematopoietic and non-hematopoietic lineages, there has been
considerable controversy over which cell subtypes best promote vascular regeneration.
Endothelial colony forming cells (ECFC) are rare blood-derived cells that form lateoutgrowth adherent colonies of proliferative cells when propagated under strict
endothelial cell growth conditions, and can be isolated at increasing frequency from
human peripheral blood, BM, and umbilical cord blood (UCB). ECFC are distinguished
from pro-angiogenic hematopoietic cell types in human blood as they are exclusively
CD45–, and can integrate directly into perfused vessels in vivo. Recently, it has been
demonstrated that many of the cell types previously referred to as EPC are not endothelial
cell precursors per se, but represent myeloid/macrophage lineage cells that promote
vascular repair through proposed paracrine signaling to vessel-derived EC8,9,10-12. In
mouse models, circulating CXCR4+/VEGFR1+ hematopoietic cells are recruited to
sprouting vessels by secretion of stromal-derived factor (SDF-1) or vascular endothelial
growth factor-A (VEGF-A) produced by damaged vasculature4,13. Studies examining
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tumor metastasis have demonstrated that even small numbers of these hematopoietic cells
play a major role in establishing a permissive niche for tumor vascularization14-16.
Numerous studies have established that a decreased frequency or impaired function of
circulating CD133+ or CD34+ cells is associated with increased cardiovascular risk in
patients with ischemic heart disease and diabetes2,9,17-20. This, in addition to preclinical
data showing the pro-angiogenic potential of BM-derived cells, has led to a number of
clinical trials investigating treatment of cardiac21-23 and limb ischemia24,25 by
transplantation of heterogeneous human BM MNC. Although these studies have
demonstrated safety in the autologous setting, they have shown only modest
improvements in clinical endpoints compared to other approved therapies26. Thus,
purification of specific pro-angiogenic cellular sub-types from non-autologous sources,
and further characterization of specific sub-type contribution during the coordination of
vascular repair is warranted to improve current cell-based therapies for ischemic diseases.
Cord blood represents a promising source of regenerative progenitor cells. Early in
ontogeny, UCB has been shown to contain a higher frequency of ECFC28, and UCBderived ECFC have more robust vessel forming capacity than ECFC from adult blood9,29.
Due to recent widespread initiatives to HLA-phenotype and cryopreserve this material,
UCB now represents a readily available source of progenitor cells for cell therapy
applications. In addition, allogeneic UCB progenitor cell transplantation may have
distinct advantages over autologous BM in patients with obesity, chronic diabetes, or
vascular disease-related pathologies due to compromised progenitor cell content and
function30-33.
Using high aldehyde dehydrogenase (ALDHhi) activity, a cytosolic enzyme involved in
retinoic acid metabolism and cellular self-protection from oxidative damage34-39,
fluorescence activated cell sorting strategies to simultaneously enrich for progenitor cells
from hematopoietic, endothelial, mesenchymal lineages40. It has been demonstrated that
transplanted ALDHhi progenitors reconstitute hematopoiesis34,35, exhibit widespread tissue
distribution41, and recruit to areas of ischemia after transplantation40. Furthermore, BMderived ALDHhi cells can augment revascularization and blood flow of ischemic limbs in
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transplanted mice with acute ischemic injury40. Recently, we proposed a model of
coordinated neovascularization after human progenitor cell transplantation wherein
hematopoietic and non-hematopoietic progenitors act in concert to formulate a proangiogenic niche for vascular regeneration (Appendix 1)27.
Here we show that selection of human UCB cells with high ALDH activity
simultaneously purifies a mixed population of primitive hematopoietic and endothelial
colony-forming cells with potent pro-angiogenic functions. UCB ALDHhi progenitors
demonstrated a pro-angiogenic transcription profile and supported endothelial cell (EC)
survival in liquid culture and tube-like cord formation in growth factor–reduced matrigel.
Transplanted ALDHhi cells improved recovery of blood flow after femoral artery ligation
in NOD/SCID mice. Thus, UCB progenitors purified by high ALDH-activity represents
an allogeneic population of pro-angiogenic cells for the revascularization of ischemic
tissues.

2.2 Methods
2.2.1 Progenitor cell isolation from human umbilical cord blood
UCB was collected after informed consent by venipuncture at the London Health
Sciences Birthing Centre. The human research ethics committee at the University of
Western Ontario approved all studies. After hypaque-ficoll centrifugation, mononuclear
cells (MNC) were depleted of erythrocytes by ammonium chloride lysis and assayed for
ALDH activity using Aldefluor™ reagent (Stemcell Technologies, Vancouver, BC) as
previously described40. FACS was performed to isolate cells with low side scatter, and
high (ALDHhi) vs. low (ALDHlo) ALDH activity to >99% purity. Sorted cells were
washed in PBS to allow efflux of Aldefluor™ substrate via reactivation of inhibited
ABC-transporters.

2.2.2 Cell surface phenotype analysis
UCB MNC, ALDHhi or ALDHlo cells were labeled with anti-human antibodies against
pan-leukocyte marker CD45, and co-labeled with CD4 and CD8 (T cells), or CD19 and
CD20 (B cells), or CD33 (myeloid) and CD14 (monocytes), or CD31 (PECAM-1) and
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CD144 (VE-cadherin, GeneTex, Irvine, CA), or CD34 and CD38, or CD117 (c-kit) and
CD133 (Miltenyi Biotec, Auburn, CA), or CXCR4 and VEGFR2. All antibodies were
from BD Biosciences unless otherwise indicated. Cell surface marker expression was
measured using a FACSCalibur cytometer (BD Biosciences), and analyzed using FlowJo
software.

2.2.3 Colony forming cell assays
UCB MNC, ALDHhi or ALDHlo cells were cultured in methylcellulose (Methocult®
H4434, Stemcell Technologies) for 14 days and hematopoietic colony formation was
enumerated based on cell morphology identifying burst-forming units of erythrocytes
(BFU-E), colony-forming units of granulocytes (CFU-G), macrophages (CFU-M),
granulocytes and macrophages (CFU-GM), or multilineage mixed colonies (CFU-Mixed)
containing cells of all 3 types. ECFC were enumerated after adherent culture for 14 days
in complete endothelial growth media (EGM-2 + 2%FBS + EGF, VEGF-A, FGF, IGF-1,
Lonza) counting colonies of cells with cobblestone morphology as previously described9.

2.2.4 mRNA isolation and microarray analyses
mRNA was isolated from three sample-matched UCB ALDHhi and ALDHlo cell cohorts
using mRNeasy Mini kits (Qiagen, Mississauga, ON). Microarrays were performed in
triplicate using 18 human gene array chips (Affymetrix, Santa Clara, CA) at the London
Regional Genomics Facility. Transcripts differentially expressed by UCB ALDHhi versus
ALDHlo cells were analyzed using Partek Genomics Suite (Partek Inc., St Louis, MO).

2.2.5 Co-culture assays with human umbilical vein endothelial cells
(HUVEC)
To assess paracrine functions of UCB cells on human umbilical vein endothelial cell
(HUVEC) survival and proliferation during co-culture in vitro, 40x103 HUVEC were
cultured in endothelial basal media (EBM2, Lonza) with or without growth factors (EGF,
VEGF-A, FGF, IGF-1) and serum (2%) supplementation. Under each condition, 105
ALDHhi or 105 ALDHlo cells were seeded into porous (5µm pore size) hanging transwells
suspended above the HUVEC. The number of trypan blue excluding HUVEC present
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after 72 hours co-culture was enumerated by blinded hemocytometer counts. For tubelike cord formation assays, 50x103 HUVEC, or HUVEC supplemented with 20x103
ALDHhi or ALDHlo cells were seeded on growth factor reduced Matrigel (BD
Biosciences) and cultured for 72 hours. The number of complete branch points in the
cord structures formed by HUVEC was enumerated on an inverted microscope by
blinded manual counts of four fields of view at 24, 48, and 72 hours after plating. All coculture experiments were performed in triplicate.

2.2.6 Murine femoral artery ligation surgery and transplantation of
human UCB cells
Right femoral and saphenous artery and vein ligation with complete excision of the
femoral artery and vein was performed on anesthetised NOD/SCID (Jackson Laboratory,
Bar Harbor, ME) or NOD/SCID/MPSVII mice as previously described40. Within 24 hours
of surgery, non-irradiated or sublethally irradiated (300cGy) mice were transplanted by
tail-vein injection with PBS, 2x105 ALDHhi cells, 10x106 ALDHlo cells, or 20x106 MNC.
Cell doses were chosen based on the relative frequency of each cell type within UCB
MNC. NOD/SCID mice were used for functional studies to monitor the recovery of
perfusion and to quantify blood vessel density as described below. NOD/SCID/MPSVII
mice were used to detect human cell engraftment kinetics and localization in muscle
sections from ischemic limbs using β-glucuronidase (GUSB) staining as described below.

2.2.7 Quantification of hindlimb perfusion using laser Doppler
perfusion imaging
For laser Doppler perfusion imaging (LDPI; MoorLDI-2; Moor Instruments, Devon,
UK), anesthetized NOD/SCID mice were placed at 37°C for 5 minutes following shaving
of the hindquarters to remove hair. Blood flow was quantified within the hindquarters of
live mice after surgery, and at 3, 7, 14, 21, and 28 days post-transplantation. Perfusion
ratios (PR) comparing blood flow in the ischemic versus non-ischemic limb were
quantified by averaged units of flux from the ankle to toe in each limb using Moorflow
software.
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2.2.8 Quantification of blood vessel density
Adductor muscles from transplanted mice were embedded and frozen in optimum cutting
temperature medium (Sakura Finetek, Torrance, CA), cryosectioned, fixed in 10%
formalin (Sigma), and blocked with mouse-on-mouse reagent (Vector Labs, Burlingame,
CA). Murine blood vessel density in ischemic and non-ischemic limbs was quantified at
day 28 by counting mouse CD31+ capillaries and mouse von Willebrand factor (vWF+)
blood vessels using rat-anti mouse CD31 (1:100, BD Biosciences) or rabbit anti-mouse
vWF antibody (1:200, Millipore, Temecula, CA) and peroxidase-labelled anti-rat or antirabbit immunoglobulin G (IgG) secondary antibodies (Vector) visualised using 3, 3'diaminobenzidine (DAB) substrate, and counterstained with hematoxylin. Blood vessel
density was counted in a blinded fashion from 9 photomicrographic fields using light
microscopy.

2.2.9 Quantification of human cell engraftment by flow cytometry
BM and adductor muscles from the ischemic and non-ischemic limbs were analyzed for
human cell engraftment at 3, 7, and 28 days after transplantation by flow cytometric
detection of human CD45 and HLA-A,B,C in combination with 7-aminoactinomycin D
(7-AAD) viability dye (BD Biosciences). Muscle samples were digested with type II
collagenase (Worthington Biomedical, Lakewood, NJ) prior to antibody labelling.

2.2.10 Detection of human cells by GUSB-activity
Transplanted NOD/SCID/MPSVII mice with unilateral hindlimb ischemia were
sacrificed at 3, 7 and 28 days after transplantation to allow histochemical detection of
single human cell engraftment in ischemic muscle sections (GUSB-deficient) based on
the detection of ubiquitous GUSB activity in human cells as previously described42.
Muscle sections were co-stained with vWF to assess the distribution of engrafted human
cells with respect to murine vasculature, and with human CD45 to assess the lineage of
engrafted cells.
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2.2.11 Statistics
Analysis of significance was performed by one-way ANOVA for cell-surface marker and
progenitor frequency assays, and by two-way ANOVA with Bonferroni post-hoc tests for
all other assays using Graphpad Prism software.

2.3 Results
2.3.1 UCB ALDHhi cells were enriched for myeloid progenitor cell
surface phenotypes
Human UCB MNC were collected without prior lineage depletion34, and purified based
on cells with low side scatter (non-granular) and with low (ALDHlo, 41.36±3.6%) vs.
high

(ALDHhi,

0.4±0.1%)

ALDH

activity

compared

to

ALDH-inhibited

(diethylaminobenzaldehyde, DEAB) controls (n=10, Figure 2.1A,B). Compared to
unpurified UCB MNC (97.7±0.8% CD45+) or ALDHlo cells (99.1±0.5% CD45+), ALDHhi
cells showed lower expression of the pan-leukocyte marker CD45 (93.3±1.9% CD45+,
*p<0.05, n=4). Thus, sorted cell populations were gated into hematopoietic (CD45+) and
non-hematopoietic (CD45-) subsets, and further analyzed for primitive vs. mature
hematopoietic or endothelial cell surface marker expression.
CD45+ ALDHhi cells showed reduced expression lineage-specific markers for T- (CD4
and CD8, Figure 2.1C) and B-lymphocytes (CD19 and CD20, Figure 2.1D) compared to
unsorted MNC or ALDHlo cells (**p<0.01, Table 2.1). Over 90% of CD45+ ALDHhi cells
expressed CD33, an early myeloid lineage marker, but co-expression of the mature
monocyte marker CD14 was low (3.3±1.0%, Figure 2.1E; Table 2.1). Similarly, ALDHhi
cells showed near homogeneous expression of CD31 or PECAM-1 (96.7±2.9%) but low
co-expression of CD144/VE-cadherin (3.2±1.0%, Figure 2.1F; Table 2.1). Notably, the
CD45+ ALDHhi cells were highly enriched for the co-expression of the progenitor
markers CD34 (89.6±5.9%, Figure 2.1G), CD117 (80.2±4.9%), and CD133 (61.5±2.3%,
Figure 2.1H) compared to unsorted UCB MNC or ALDHlo cells (*p<0.05, Table 2.1).
CD45+ ALDHhi cells were enriched for SCID repopulating progenitor phenotype
(CD34+CD38–, Figure 2.1G)43, and ALDHhiCD34+ cells showed co-expression of the
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homing marker CXCR4 (14.2±2.9%, Figure 2.1I), but low expression of VEGFR2
(0.5±0.1%, Figure 2.1J).
CD45– cells, representing approximately 7% of the ALDHhi population, also showed
enriched expression of CD34 (65.0±14.8%), CD117 (64.9±12.4%), and CD133
(22.5±3.9%) progenitor markers (*p<0.05), but did not show increased expression of the
mature EC-associated adhesion molecules (CD31 and CD144) compared to UCB MNC
or ALDHlo cells (Table 2.2). Collectively these data indicate that the hematopoietic
fraction of ALDHhi cells was depleted of mature lymphocytes and monocytes yet
enriched for primitive myeloid progenitor phenotype, and the CD45– portion of the
ALDHhi cells similarly retained a primitive non-hematopoietic cell phenotype.

2.3.2 UCB ALDHhi cells demonstrated hematopoietic and endothelial
colony formation
UCB MNC, ALDHlo or ALDHhi cells were plated under lineage-specific growth
conditions for 14 days to assess hematopoietic and endothelial CFC frequency. After
culture in methylcellulose, ALDHhi cells were highly enriched for myeloid-lineage
colony forming cells (1 HCFC in 3.6 cells) compared to ALDHlo cells (1 HCFC in
6.6x103 cells, **p<0.01, n=4). ALDHhi HCFC demonstrated multipotent lineage
differentiation with increased production of erythroid, macrophage, granulocyte and
mixed morphologies (***p<0.001, Figure 2.1K). To assess ECFC function in vitro,
ALDH-purified UCB cells were cultured under stringent conditions established by Yoder
and colleagues9. Colony enumeration revealed increased ECFC content in ALDHhi cells
(1 ECFC in 4.6x104 cells) compared to ALDHlo cells (1 ECFC in 2.2x105 cells, *p<0.05,
Figure 2.1L). ECFC progeny were highly proliferative, did not express hematopoietic
markers (CD45, CD14), and expressed EC markers (CD31, CD105, CD144). Unlike
human BM40, MNC or ALDH-sorted cohorts from UCB did not establish plastic adherent
multipotent stromal cell colonies in vitro (n=10). Thus, UCB ALDHhi cells represented a
mixture of cells with enriched HCFC and ECFC function.

62

Figure 2.1 Purification of UCB ALDHhi cells enriches for hematopoietic and
endothelial colony forming cells.
(A,B) Human UCB MNC were sorted for low side scatter (SSC) and low
(ALDHlo=41.2±3.6%) versus high (ALDHhi=0.4±0.1%) ALDH activity with or without
DEAB inhibitor. Representative flow cytometry plots show that UCB ALDHhi cells were
depleted of cells expressing mature (C) T-lymphocyte (CD4, CD8), (D) B-lymphocyte
(CD19, CD20), (E) monocyte (CD14), and (F) endothelial (VE-cadherin, CD144) cell
surface markers, were enriched for cells expressing (E) early myeloid (CD33), (F)
adhesion (PECAM-1, CD31), and (G,H) primitive progenitor (CD34, CD1117, CD133)
markers. (I,J) CD34+ALDHhi cells showed low co-expression of chemokine receptors
(CXCR4, VEGFR2). (K) After culture for 14 days in Methylcellulose media (n=7), UCB
ALDHhi cells were highly enriched for multipotent HCFC. (L) After culture for 14 days
in complete endothelial growth media (EGM-2 + IGF, EGF, bFGF, VEGF-A + 2%
serum, n=5), UCB ALDHhi were also enriched for ECFC. Scale bar = 200μm. Data are
expressed as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001.
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Table 2.1 Cell surface marker expression for the hematopoietic (gated CD45+)
component of human UCB MNC, ALDHhi cells, and ALDHlo cells.
Markers (%)

MNC

ALDHhi

ALDHlo

CD4

47.6±3.2a

3.5±0.6**b

47.8±2.1a

CD8

24.9±0.9a

2.5±0.3**b

26.1±3.5a

CD19

20.3±1.8a

0.6±0.1**b

21.1±1.4a

CD20

23.6±1.8a

1.8±0.9**b

21.1±1.7a

Myeloid/

CD33

20.9±0.9a

90.4±4.8**b

1.4±0.3**c

Monocyte

CD14

17.7±1.2a

3.3±1.1**b

0.6±0.2**b

CD31

86.5±1.2a

96.7±2.9*b

81.0±3.5a

CD144

21.5±2.0a

3.2±1.0**b

4.9±2.9**b

CD34

5.1±1.9a

89.6±5.9**b

0.3±0.1a

CD117/c-kit

15.9±2.8a

80.2±4.9**b

12.5±5.3a

CD133

0.7±0.3a

61.5±2.3**b

0.2±0.1a

CXCR4

47.3±6.1a

17.7±2.5*b

37.8±5.8a

0.9±0.3a

0.3±0.1a

Lineage

T-Lymphocyte

B-Lymphocyte

Adhesion

Progenitor

Homing
KDR/VEGFR2 0.6±0.3a

Data represents mean ± SEM (n=4), different letters denote different expression patterns
at *p<0.05, **p<0.01 compared to unpurified MNC.
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Table 2.2. Cell surface marker expression for the non-hematopoietic (gated CD45-)
component of human UCB MNC, ALDHhi cells, and ALDHlo cells.
Lineage

Markers (%)

MNC

ALDHhi

ALDHlo

CD31

50.8±24.9a

38.7±16.6a

20.3±13.2a

CD144

20.0±12.5a

17.8±11.3a

6.5±3.8a

CD34

17.9±9.2a

65.0±14.8*b

1.3±0.6**c

CD117/c-kit

22.1±9.8a

64.9±12.4*b

12.8±3.5a

CD133

6.9±1.5a

22.5±3.9*b

0.4±0.3a

CXCR4

33.9±10.1a

8.8±3.4*b

7.4±1.1*b

1.9±1.0a

1.4±1.1a

Adhesion

Progenitor

Homing
KDR/VEGFR2 1.8±0.8a

Data represents mean ± SEM (n=4), different letters denote different expression patterns
at *p<0.05, **p<0.01 compared to unpurified MNC.
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2.3.3 UCB ALDHhi cells demonstrated a pro-angiogenic transcription
profile
Affymetrix microarray identified 1253 transcripts with significantly increased (*p<0.05)
expression in 3 UCB ALDHhi cell samples compared to sample-matched ALDHlo cells.
These transcripts were first filtered to include unique genes translating to plasma
membrane bound (196 hits) or extracellular (108 hits) locations, and subsequently filtered
for documented angiogenic biological functions (Tables 2.3 and 2.4). As a control for the
selection of cells with high ALDH-activity, ALDH1A1 mRNA expression was increased
42-fold in ALDHhi vs ALDHlo cells (p=2.08x10-5). Furthermore, significantly increased
CD34, PROM1, and KIT mRNA expression in ALDHhi cells (Table 2.3) correlated with
increased CD34, CD133, and c-kit/CD117 cell surface protein expression previously
observed by FACS (Figure 2.1, Table 2.1). Transcripts associated with early myeloid
progenitor differentiation (FLT3, CSF3R, CD33), integrin-mediated cell adhesion
(ITGA9, ITGAV, ITGA2B), and vascular cell signaling (TIE1, TIE2, FGFR1, endoglin)
were also highly expressed by UCB ALDHhi cells (Table 2.3). Interestingly, transcripts
for secreted cytokines associated with vascular functions (ANGPT1, FGF16, VEGFA),
immune cell migration (IL-18, IL-1b, IL-8, CSF1, CXCL2), and modulators of EGF and
IGF signaling (EREG, AREG, HBEGF, IGFBP7) were also increased in UCB ALDHhi
cells (Table 2.4). Collectively, these data suggested that UCB ALDHhi cells possessed a
pro-angiogenic transcription profile compared to ALDHlo cells.
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Table 2.3 Angiogenesis-associated transcripts encoding cell surface proteins with
increased expression in UCB ALDHhi versus ALDHlo cells.
Gene
Symbol

Common
Names

PROM1
CD34

prominin 1, CD133
transmembrane
sialomucin

KIT

c-kit, CD117

FLT3
IRAK3
ITGA9

FLT3 receptor tyrosine
kinase, CD135
IL-1 receptor
associated kinase 3

TIE1

integrin, alpha 9
colony stimulating
factor receptor, CD114
TGF-beta-1-binding
protein
type 1 transmembrane
C-type lectin receptor
EGF-module receptor 2
CD312
myeloid cell surface
antigen
tyrosine kinase with
immunoglobulin-like
and EGF-like domain 1

ITGAV

integrin, alpha V

ENG

endoglin, CD105

FGFR1

fibroblast growth factor
receptor 1, CD331

CSF3R
CD109
CD302
EMR2
CD33

ITGA2B

TMEFF1

TEK/TIE2

integrin, alpha 2b
transmembrane protein
with EGF-like and
follistatin-like domains
tyrosine kinase with
immunoglobulin-like
and EGF-like domain 2

Biological
Function
hematopoiesis, vascular
development / remodeling
hematopoiesis, vascular
development / remodeling
HPC survival, maintenance
and migration, HPC marker
myeloid progenitor
proliferation / differentiation
stimulates EC proliferation
and angiogenesis
cell-cell and cell-matrix
adhesion
granulocyte and neutrophil
survival / differentiation
cell division, differentiation,
motility, adhesion
phagocytosis, cell adhesion
and migration
mucin-like cell adhesion
adhesion molecule on
monomyelocytic cells
regulation of angiogenesis and
vasculogenesis
cell-cell, cell-matrix adhesion
vascular system development
and remodeling, EC migration
angiogenesis, embryonic
development, cell
proliferation, differentiation
cell-cell and cell-matrix
adhesion
unknown function during
embryonic development
angiogenesis, EC survival,
proliferation, migration,
adhesion

Molecular
Function
MAPK and Akt
signaling
adherence to BM
matrix and cells
tyrosine-protein
kinase signaling
fms-related
tyrosine kinase
signaling
regulates IL-1
receptor signaling
α9/β1 dimer
binds VCAM1
GCSF receptor
signaling
heterodimer with
TGFB1 receptor
carbohydrate
binding / adhesion
G-protein coupled
receptor signaling
tyrosine kinase,
binds sialic acid
modulates TEK /
TIE2 binding to
angiopoietins
αV/β3 binds
vitronectin
complexes with
TGF-beta, activin,
BMP molecules
tyrosine kinase
activity, binds
FGF molecules
α2B/β3 binds
fibronectin
modulates
Nodal and BMP
signaling
tyrosine kinase
activity, binds
angiopoietins

FC
vs Alo

p-value
vs Alo

109.8

1.9x10-6

89.7

3.7x10-5

67.9

7.1x10-6

27.4

3.1x10-5

27.0

1.5x10-6

26.8

2.8x10-6

20.0

3.4x10-3

17.6

9.9x10-6

17.0

4.1x10-4

9.2

1.4x10-5

7.3

3.7x10-5

4.9

3.6x10-3

4.6

3.0x10-3

2.8

1.8x10-3

2.8

2.1x10-3

2.2

5.9x10-4

2.1

2.4x10-3

2.0

1.8x10-3

FC, fold change; BMP, bone morphogenic protein; EC, endothelial cell, EGF, epidermal
growth factor; GCSF, granulocyte colony stimulating factor, HPC, hematopoietic
progenitor cell; IL-1, interleukin 1; MCSF, macrophage colony stimulating factor; TGF,
transforming growth factor; VCAM, vascular cell adhesion molecule
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Table 2.4 Angiogenesis-associated transcripts encoding secreted cytokines with
increased expression in UCB ALDHhi versus ALDHlo cells.
Gene
Symbol

Common
Name

ANGPT1
IL18

angiopoietin-1
interleukin 18 (IFNγinducing molecule)

IL1β

interleukin-1 beta

EREG
IL 8
(CXCL8)

epiregulin

AREG

amphiregulin
insulin-like growth
factor binding protein 7
bone morphogenic
protein 6
colony stimulating
factor 1, M-CSF
fibroblast growth factor
16

IGFBP7
BMP6
CSF1
FGF16
FBLN5
CXCL2
HBEGF
VEGFA

interleukin 8

fibrulin 5
chemokine (C-X-C
motif) ligand 2
heparin-binding EGFlike growth factor
vascular endothelial
growth factor A

Biological
Function
vascular development /
remodeling, angiogenesis
inflammation, EC migration,
angiogenesis
inflammation, EC
differentiation / proliferation
EC proliferation, angiogenesis
chemoattraction of angiogenic
and inflammatory cells
EC proliferation, angiogenesis
implicated in tumor
angiogenesis
EC development,
proliferation, angiogenesis
macrophage differentiation,
migration and function
angiogenic factor during
development
EC adhesion during vascular
development / remodeling
chemoattraction of angiogenic
and inflammatory cells
endothelial cell proliferation,
angiogenesis
regulation of angiogenesis and
vasculogenesis

FC, fold change; EC, endothelial cell

Molecular
Function
TIE2 receptor
activation
IL 18 receptor
activation
IL-1β receptor
activation
EGF receptor
activation
CXCR1 and
CXCR2 activation
EGF receptor
activation
binds IGF1 and
IGF2
BMP receptor
activation
M-CSF receptor
activation
FGFR1 and
FGFR2 activation
vascular ligand
for integrins

FC
vs Alo

p-value
vs Alo

17.3

3.6x10-5

16.7

7.7x10-6

16.5

3.8x10-4

12.1

2.6x10-4

8.5

3.1x10-5

5.9

1.4x10-4

4.7

1.5x10-4

3.9

3.4x10-3

3.4

3.4x10-4

2.9

3.4x10-3

2.5

5.8x10-3

CXCR2 activation
EGF receptor
activation
VEGFR1 and R2
activation

2.2

2.4x10-3

2.1

8.0x10-3

1.7

4.8x10-3
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2.3.4 UCB ALDHhi cells augment the survival of HUVEC in vitro
To assess the paracrine functions of ALDH-purified UCB cells on endothelial cell
survival and proliferation in vitro, 40x103 HUVEC were seeded into transwell co-cultures
for 72 hours using a 5μm pore hanging insert containing 105 UCB ALDHhi or ALDHlo
cells (or basal media control) suspended above HUVEC. Under optimal conditions
containing growth factors (GF+) and serum, non-contact co-culture with ALDHlo or
ALDHhi cells did not impact the 5-fold expansion of HUVEC observed over 72h (Figure
2.2A,E). Conversely, in GF-/serum-free conditions with or without ALDHlo cell
supplementation, HUVEC invariably died within 72 hours (Figure 2.2B,E). In contrast,
co-culture with ALDHhi cells under GF-/serum-free conditions promoted HUVEC
viability for 72 hours (*p<0.05, Figure 2.2B,E). Under GF+/serum-free conditions,
ALDHhi cell co-culture promoted a modest expansion (1.7-fold) of HUVEC
(67.4±7.1x103 cells), compared to >3-fold HUVEC loss with basal media (12.4±2.6x103
cells) or ALDHlo cell supplementation (14.4±2.8x103 cells, *p<0.05, Figure 2.2C,E).
Under GF-/serum+ conditions, ALDHlo or ALDHhi co-culture did not significantly alter
HUVEC numbers (Figure 2.2D,E). Thus, non-contact co-culture with human ALDHhi
cells promoted HUVEC survival under GF-/serum-free conditions. These effects were
consistent with the pro-survival stimulus in HUVEC provided by VEGF-A treatment44, a
central pro-angiogenic cytokine with increased mRNA-expression in UCB ALDHhi cells
(Table 2.4).
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Figure 2.2 UCB ALDHhi cells promote endothelial cell survival under growth factor
and serum-free conditions.
(A-D) Representative photomicrographs of HUVEC density after 72h co-culture with
UCB ALDHlo or ALDHhi cells in hanging transwells with or without growth factor or
serum supplementation. Scale bar = 200μm. (E) Non-contact co-culture with human UCB
ALDHhi cells promoted the survival of HUVEC under growth factor-free, serum-free
conditions (n=5). Data are expressed as mean ± SEM, *p<0.05.
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2.3.5 UCB ALDHhi cells augment tube-like cord formation by HUVEC
in vitro
HUVEC were cultured alone at 50x103 per well, or co-cultured with 20x103 ALDHhi or
ALDHlo cells on growth factor reduced Matrigel. HUVEC established partially completed
cord networks within 24 hours (Figure 2.3A). Although co-culture of HUVEC with UCB
ALDHlo cells did not significantly alter cord formation, supplementation with ALDHhi
cells increased the number of HUVEC tube-like cord formed at 24 hours after plating
(Figure 2.3B and C). Although UCB ALDHhi cells established ECFC in liquid culture
(Figure 2.1L, inset), UCB ALDHlo or ALDHhi cells seeded alone on growth factor
reduced Matrigel did not spontaneously align to form cord networks (Figure 2.3D), and
tube-like cord stability of HUVEC was not enhanced by co-culture with UCB ALDHlo or
ALDHhi at 72 hours (Figure 2.3E-H). Enumeration of completed branch points at 24 and
48 hours revealed that co-culture with UCB ALDHhi cells augmented cord formation by
HUVEC compared to media controls (n=6, *p<0.05, Figure 2.3H). Therefore, co-culture
with UCB ALDHhi cells promoted the cord-forming function of HUVEC in vitro.

73

Figure 2.3 UCB ALDHhi cells augmented tube-like cord formation by HUVEC.
Representative photomicrographs of tubule formation by HUVEC after 24 (A-C) and 72
lo

hi

(E-G) hours co-culture with ALDH or ALDH cells or media control. Scale bar =
500μm. (D) ALDHhi cells plated without HUVEC did not form cord structures. (H) Cohi

culture with ALDH cells augmented the formation of complete tubule networks formed
by HUVEC at 24 and 48 hours, but did not augment tubule stability after 72 hours coculture. Data are expressed as mean ± SEM, *p<0.05.
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2.3.6 Transplanted UCB ALDHhi cells enhanced the recovery of
hindlimb perfusion
To determine whether ALDH-purified human UCB cells could support blood vessel
regeneration after intravenous transplantation in vivo, we induced acute unilateral
hindlimb ischemia in NOD/SCID mice by right femoral artery ligation with complete
excision of a 0.5cm section of the femoral artery and vein. Blood flow was assessed by
LDPI and the perfusion ratio (PR) in the ischemic versus control limb was decreased
>10-fold (PR=0.08±0.02) post-surgery confirming consistent induction of unilateral
hindlimb ischemia (Figure 2.4). Within 24 hours of surgery mice were tail vein injected
with PBS vehicle control, unsorted UCB MNC, ALDHhi cells, or ALDHlo cells. The
representative LDPI shown in Figure 2.4 documents the recovery of limb perfusion after
transplantation. PBS-injected control mice showed recovery of PR from 0.07±0.01 after
surgery to 0.36±0.05 by day 7 post-surgery without subsequent improvement at later time
points (Figure 2.4A,E). This baseline recovery of perfusion was sufficient to prevent
excess morbidity or limb loss in PBS transplanted mice. Mice transplanted with 20x106
MNC or 10x106 ALDHlo cells showed equivalent recovery of limb perfusion similar
compared to PBS controls (Figure 2.4B,D-E). In contrast, mice transplanted with 50-100fold fewer ALDHhi cells (2x105) showed increased perfusion by day 14 posttransplantation (PR=0.58±0.07) compared to all other treatments and augmented
perfusion was maintained for 28 days post-transplantation (PR=0.64±0.06, **p<0.01,
Figure 2.4C,E). Thus, intravenous-transplantation of human UCB ALDHhi cells improved
the limb perfusion in mice with acute unilateral hindlimb ischemia.
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Figure 2.4 Transplanted UCB ALDHhi cells augmented perfusion in ischemic
hindlimbs.
Representative LDPI following right femoral artery ligation and tail vein injection of (A)
PBS vehicle control (n=7), (B) 20x106 unsorted UCB MNC (n=7), (C) 2x105 ALDHhi
cells (n=7), or (D) 10x106 ALDHlo cells (n=7). Numbers in lower left of each image
indicate perfusion ratio of the ischemic versus the non-ischemic hindlimb. (E) Compared
to all other treatments, transplantation of UCB ALDHhi cells promoted improved
recovery of perfusion in ischemic mouse hindlimbs by day 14 and augmented perfusion
was maintained to day 28. Data are expressed as mean ± SEM, **p<0.01.
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2.3.7 Transplanted UCB ALDHhi cells increased capillary density in
the ischemic limb
To address the recovery of blood vessels in the ischemic hindlimb, sections from the
adductor muscle at the site of artery ligation were stained for both murine CD31+
capillary (Figure 2.5A-C) and vWF+ blood vessel (Figure 2.5D-F) density. Compared to
the non-ischemic limb at day 28 (65.3±6.1 CD31+/mm2, 8.1±1.2 vWF+/mm2), PBSinjected mice showed significant reduction (*p<0.05) of both CD31+ capillaries
(53.5±4.8/mm2, Figure 2.5G) and vWF+ blood vessels (5.5±1.4/mm2, Figure 2.5F) within
the ischemic hindlimb. However, mice transplanted with UCB ALDHhi cells
(73.7±10.5/mm2) had significantly more CD31+ capillaries compared to mice transplanted
with ALDHlo cells (61.1±12.4/mm2, *p<0.05) or PBS (65.3±6.1/mm2,**p<0.01, Figure
2.5G). Similarly, mice transplanted with ALDHhi cells (8.8±1.8/mm2) showed higher
vWF+ blood vessel density than mice injected with ALDHlo cells (5.8±1.2/mm2, *p<0.05),
or MNC (5.8±0.9/mm2, *p<0.05), or PBS-injected controls (8.1±1.2 vWF+/mm2,
***p<0.001, Figure 2.5H). Despite only partial recovery of perfusion, CD31+ and vWF+
vessel density in the ischemic limbs of ALDHhi cell-treated mice was equivalent to the
vessel density of the non-ischemic control limb at day 28 (Figure 2.5G,H). Thus, UCB
ALDHhi cell transplantation increased both CD31+ capillary and vWF+ blood vessel
density in the ischemic hindlimb after femoral artery ligation.

79

hi

Figure 2.5. Transplanted UCB ALDH cells augmented blood vessel density within
ischemic hindlimbs.
Representative photomicrographs of adductor muscle sections from the ischemic and
non-ischemic limbs of mice injected with PBS or UCB ALDHhi cells stained for (A-C)
CD31+ capillaries or (D-F) vWF+ blood vessels at day 28 post-transplantation. Scale bar =
100μm. Compared to all other treatments, (G) CD31+ capillary density, and (H) vWF+
blood vessel density was increased in the ischemic limb of mice transplanted with human
hi

UCB ALDH cells. Data are expressed as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001
as determined by two way ANOVA and Bonferroni post-tests to compare multiple
means.
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2.3.8 Transplanted UCB ALDHhi cells recruited to the ischemic
muscle at low frequency
In order to correlate the recovery of perfusion with human cell engraftment, murine BM
and adductor muscle were collected at 3, 7, and 28 days after transplantation, and
analyzed for the presence of human CD45+ or HLA-A,B,C+ cells by flow cytometry.
Despite consistent human cell hematopoietic chimerism in the BM of mice transplanted
with ALDHhi cells (Figure 2.6A,C) or MNC (Figure 2.6C), human cells were not
significantly detected in the adductor muscle of ischemic limbs by flow cytometry
(Figure 2.6B,D) at day 28. In addition, mice processed for engraftment at earlier time
points showed no evidence of human cells in the ischemic limb at 3 (n=3) or 7 days (n=3)
post-transplantation by FACS. Therefore, we repeated engraftment experiments using
identical cell doses in the GUSB-deficient NOD/SCID/MPSVII recipient to permit the
detection of transplanted human cells at single cell resolution. At 3 and 7 days posttransplantation, the detection of GUSB expressing cells confirmed the recruitment of
human cells to the ischemic hindlimbs of mice that received MNC (n=4, Figure 2.6E-F)
or ALDHhi cells (n=4, Figure 2.6H-I). However, human cells were not detected in the
ischemic limbs of mice that received ALDHlo cells (n=4). Although transplanted cells
were never detected in the non-ischemic limb, engrafted MNC and ALDHhi cells were
observed in ischemic muscle sections surviving out to 28 days (Figure 2.6G, J). Staining
for GUSB-activity combined with murine vWF showed engraftment of single human
cells between muscle fibres (Figure 2.6K) and in association with the connective tissue
surrounding blood vessels (Figure 2.6L). Also, the majority of GUSB+ human cells
surviving at day 28 co-stained for CD45 (Figure 2.6M). Despite low frequency
engraftment in the ischemic region, early recruitment of ALDHhi progenitor cells to the
site of ischemic injury was sufficient to augment blood vessel density and improve limb
perfusion.
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Figure 2.6 Transplanted human UCB ALDHhi cells recruited to the ischemic
hindlimb.
Representative flow cytometry plots illustrating the detection of human cells
(CD45+/HLA-A,B,C+) cells within (A) the bone marrow and (B) ischemic hindlimbs of
mice transplanted with UCB ALDHhi cells. (C,D) Despite engraftment of human cells in
the mouse bone marrow, human cells were rarely detected in the ischemic hindlimb by
flow cytometry. Representative photomicrographs showing the detection of transplanted
human cells (red) in the adductor muscle of the ischemic hindlimb of mice transplanted
with (E-G) UCB MNC or (H-J) UCB ALDHhi cells at 3, 7 and 28 days posttransplantation. GUSB+ human cells (arrows) were detected in the ischemic limb of mice
injected with UCB MNC or ALDHhi cells, but not in mice injected with UCB ALDHlo
cells. Co-staining for GUSB-activity with murine vWF at day 28 showed (K) engraftment
of single GUSB+ cells between muscle fibres, and (L) associated with vWF+ blood
vessels. (M) GUSB+ human cells surviving at day 28 co-stained for CD45. Scale bars =
100μm.
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2.3.9 Sublethal irradiation did not improve perfusion in the ischemic
hindlimb
The requirement for preparative irradiation is an important consideration in the design of
clinically applicable cell therapies for ischemic diseases. In an attempt to improve human
cell engraftment in the ischemic limb, transplantation experiments were repeated after
sublethal irradiation (300cGy) administered as a means to reduce xenorejection by
residual innate immunity or NK-cell activity in the NOD/SCID model. Surprisingly, in
mice receiving UCB ALDHhi cells, perfusion at early time points (days 3, 7, and 14) was
similar for all transplanted groups (Figure 2.7A-E). Although perfusion improved in the
ALDHhi cell transplanted cohort at day 21, perfusion was reduced to baseline by day 28
(Figure 2.7E), indicating that only a transient improvement in limb perfusion was
observed. Compared to mice transplanted without preparative irradiation (Figure 2.4),
irradiated mice receiving an equal dose of UCB ALDHhi cells actually showed delayed
recovery of perfusion at day 14 (PR300cGy = 0.40±0.05 vs PR0cGy = 0.58±0.07).
Nonetheless, at day 28, irradiated mice injected with ALDHhi cells still showed improved
vWF+ blood vessel density (Figure 2.8) similar to non-irradiated mice.
Irradiated mice also showed enhanced recruitment of ALDHhi cells to the BM at day 7
(1.3±0.2%, Figure 2.9A,C), resulting in extensive hematopoietic repopulation by day 28
(44.7±2.0%, Figure 2.9A,C). Unexpectedly, human cells in the ischemic limb were not
detected by FACS or GUSB staining at day 7 (Figure 2.9B,D,E), and were only rarely
detected at day 28 (Figure 2.9F). Thus, irradiation prior to ALDHhi cells transplantation
did not augment engraftment or the recovery of perfusion in the ischemic limb.
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Figure 2.7 Transplanted UCB ALDHhi cells induced transient recovery of perfusion
in the ischemic limbs of mice that received preparative irradiation.
Representative LDPI following right femoral artery ligation, 300 cGy sublethal
preparative irradiation to suppress immune rejection, and tail vein injection with (A) PBS
vehicle control (n=6), (B) 20x106 unsorted UCB MNC (n=7), (C) 2x105 UCB ALDHhi
cells (n=8), or (D) 10x106 ALDHlo cells (n=8), and monitored for 28 days. Numbers in
lower left of each LDPI image indicate perfusion ratio of the ischemic versus the nonischemic hindlimb from ankle to toe. (E) Summary of mean perfusion ratios in all
transplanted mice as described above. Compared to all other treatments, transplantation
of UCB ALDHhi cells promoted a transient recovery of perfusion in ischemic mouse
hindlimbs at day 21 post-transplantation. Data are expressed as mean ± SEM, **p<0.01.
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Figure 2.8 Transplanted UCB ALDHhi cells augmented blood vessel density in the
ischemic hindlimb of irradiated mice.
Representative photomicrographs of adductor muscle sections from the non-ischemic and
ischemic hindlimbs of mice injected with (A, B) PBS or (C) UCB ALDHhi cells or (D)
UCB ALDHlo cells stained for vWF+ blood vessels at day 28 post-transplantation. Scale
bar = 100µm. (E) Summary of vWF+ blood vessel density for each transplanted cohort at
28 days post-transplantation. Compared to all other treatments, blood vessel density was
increased in the ischemic limb of mice transplanted with human UCB ALDHhi cells. Data
are expressed as mean ± SEM, ***p<0.001.
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Figure 2.9 Transplanted UCB ALDHhi cell showed reduced engraftment in the
ischemic limb and increased engraftment in the bone marrow of irradiated mice.
(A,B) Representative flow cytometric detection of human cells in (A) bone marrow or
(B) ischemic muscle (B) of mice transplanted with UCB ALDHhi cells after sublethal
(300cGy) preparative irradiation. (C-D) Summary of human cell (CD45+/HLA-A,B,C+)
engraftment in (C) the bone marrow or (D) ischemic muscle of all transplanted mice at 7
and 28 days–post transplantation. (E, F) Representative photomicrographs showing the
detection of transplanted human cells (red) in the adductor muscle of the ischemic
hindlimb of mice transplanted with UCB ALDHhi cells at 7 and 28 days posttransplantation. GUSB+ human cells (arrows) were detected in the ischemic limb of mice
at 28 days post-transplantation, Scale bar = 100μm.
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2.4 Discussion
In the present study we demonstrate that ALDH-expressing cells from human UCB,
representing <0.5% of total UCB cells and primarily comprised of primitive myeloid
progenitor cells, demonstrated increased expression of mRNA transcripts for several
angiogenic cytokines, and stimulated the survival and tubule forming functions of EC
during co-culture in vitro. Intravenous transplantation of UCB ALDHhi cells also
augmented recovery of limb perfusion induced by femoral artery ligation and transection.
Although the engraftment of human cells within ischemic muscle was infrequent, UCB
ALDHhi cells specifically recruited to the ischemic limb within 3 days of transplantation,
and stimulated the recovery of blood vessel and capillary density. Furthermore, ALDHhi
cells function within the pancreas to promote islet revascularization after transplantation
into streptozotocin-treated mice45,46. Collectively, these data suggest that UCB ALDHhi
progenitor cells represent a readily available population of pro-angiogenic cells for the
development of cellular therapies to promote endogenous revascularization.
The UCB ALDHhi population was significantly enriched for human hematopoietic
progenitor function. Approximately 1 in 4 ALDHhi cells demonstrated multipotent CFU
capacity in methylcellulose cultures. UCB ALDHhi cells also showed increased
expression of primitive cell surface markers (CD34, c-kit/CD117, and CD133), and
>90% of UCB ALDHhi cells expressed the early myeloid marker CD33, indicating a
substantial enrichment of early myeloid progenitors. At the same time, UCB ALDHhi
cells were depleted of mature T- and B-lymphocytes as well as CD14 expressing
monocytes. This is notable as CD14+ monocytes have been specifically implicated in the
paracrine support of angiogenesis47. However, transplantation of UCB ALDHhi cells,
containing only 3% CD14+ monocytic cells significantly improved perfusion and blood
vessel density in the ischemic limb, whereas transplantation of mice with 100-fold higher
doses of unsorted MNC, containing over 17% CD14+ monocytes, failed to promote
recovery from hindlimb ischemia. Recent studies have demonstrated that murine
common myeloid progenitors preferentially differentiate into pro-angiogenic monocytes
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that support neovessel formation in vivo48. Although UCB ALDHhi cells may be capable
of differentiating into monocytes in vivo, our data indicates that primitive UCB ALDHhi
myeloid progenitors play a significant role in support of angiogenesis in vivo.
UCB ALDHhi cells also possessed enriched ECFC capacity in vitro. In contrast to the
dominant myeloid progenitor composition, ECFC were infrequent at approximately 1
ECFC in 50,000 ALDHhi cells. Although this represents a significant ECFC enrichment
from unpurified UCB MNC9, it is unlikely that the few ECFC within 40x103 ALDHhi
cells make a major contribution towards the maintenance of HUVEC survival and the
induction of tubule forming function that we observed under growth factor and serum
starved conditions in vitro. However, paracrine contributions of the non-hematopoietic
component of the ALDHhi population should not be overlooked in vivo. Approximately
7% of the UCB ALDHhi population were CD45-, and these cells demonstrated high coexpression of primitive endothelial precursor markers (CD34 and CD133). Therefore, we
propose that UCB ALDHhi cells represents a heterogeneous mixture of primitive
hematopoietic and non-hematopoietic progenitors that may act in synergy to generate a
supportive microenvironment to promote EC survival and revascularization function.
After intravenous transplantation, UCB ALDHhi cells induced stable recovery from acute
ischemic injury within 2 weeks of transplantation into mice with unilateral hindlimb
ischemia. However, permanent engraftment of ALDHhi cells within the ischemic muscle
was below the threshold of detection by flow cytometry. Notably, transplantation of 50100-fold greater cell doses of unpurified UCB MNC or ALDHlo cells also showed little
engraftment by FACS. Using NOD/SCID/MPSVII mice, a unique cell tracking model
capable of detecting GUSB-expressing human cell at the single cell level, we
demonstrate that intravenous-injected UCB ALDHhi cells specifically recruited into the
ischemic limb at 3 and 7 days after transplantation, and these cells survived in ischemic
muscle tissue, albeit at low frequencies, for up to 28 days. Nonetheless, this low
frequency engraftment of ALDHhi cells in the ischemic region at early time points was
sufficient to augment the revascularization of ischemic muscle indicating a vascular
stabilization was mediated by the ALDHhi cells.
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Recent models have proposed a transient role for pro-angiogenic hematopoietic cells in
the stabilization of injured vasculature, and in the activation and recruitment of vessel
resident endothelial precursors to the sprouting vessel branch8. In support of this concept
we show that sublethal irradiation prior to transplantation of ALDHhi cells reduced
recruitment of human cells to the ischemic region, increased engraftment of ALDHhi cells
in the murine BM, and delayed the functional recovery of perfusion. Therefore, we
propose that early recruitment of ALDHhi cells to the ischemic region is critical for
vascular recovery, allowing ALDHhi cells to release pro-angiogenic stimuli that activate
an endogenous program for collateral vessel formation resulting in improved limb
perfusion. Thus, strategies to improve the efficiency ALDHhi progenitor cell delivery, or
to prolong survival at or near the site of ischemic injury, is expected to further augment
vascular regeneration via paracrine or contact dependent mechanisms.

2.4.1 Conclusion and Summary
Strategies that purify pro-angiogenic cell subtypes from alternate human sources are
required to improve the efficacy of human cell therapy trials26. Our studies outline several
important caveats relevant to the development of cellular therapies to treat ischemic
diseases. First, we have identified a mixed population of hematopoietic/myeloid and nonhematopoietic/endothelial ALDHhi progenitor cells from human UCB as a readilyavailable and clinically applicable cell population with potent pro-angiogenic function.
Second, the potential use of allogeneic UCB cells will open new avenues towards clinical
cell based therapies for ischemic disease, as mounting evidence indicates the potential for
progenitor deletion and dysfunction of autologous BM cells in patients with severe
diabetes and cardiovascular disease2,18-20. Third, we have shown that neither high-level
nor permanent engraftment of human cells were necessary to mediate augmentation of
perfusion and improved vessel density in vivo. In an allogeneic context, such as
intramuscular delivery of UCB ALDHhi cells in patients with ischemic heart disease or
critical limb ischemia49,50, future clinical transplantation strategies employing UCB may
require only short-term immune suppression to initiate potent revascularization. Future
studies will increase our understanding of the cellular constituents and paracrine
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pathways that modulate regenerative angiogenesis, and will lead to novel therapies to
improve tissue vascularization during ischemic diseases.
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Chapter 3

3 Ex Vivo Expanded Hematopoietic Progenitor Cells Promote
Endothelial Cell Survival and Ischemic Limb Revascularization
Due to the relative rarity of ALDHhi cells from UCB or BM, I aimed in Chapter 3 to
determine if it was possible to expand UCB-derived ALDHhi cells ex vivo to generate
more cells for therapeutic applications without losing beneficial vascular regenerative
effect. Therefore the objectives of this chapter 3 were two-fold:
•

To optimize the ex vivo expansion of UCB ALDHhi hematopoietic cells under
clinically relevant serum-free conditions and to characterize vascular regenerative
functions of the expanded progenitor cells in vitro.

•

To investigate the paracrine mechanisms by which expanded hematopoietic
progenitor cells derived from UCB ALDHhi contribute to revascularization after
direct intramuscular injection into the ischemic limb.

The studies presented in this chapter used HMVEC as the EC source as minor adjustment
compared to the HUVEC used in Chapter 2 to more closely model the phenotype of the
EC thought be involved in angiogenesis and vascular regeneration. Vascular regeneration
tends to affect the capillary microcirculation more so than a large vessel venous EC like
HUVEC. The work presented in this chapter build directly upon the findings presented
in Chapter 2. Specifically, it demonstrates that UCB ALDHhi cells can be efficiently
expanded ex vivo without loss of vascular regenerative phenotype. Moreover, it
introduces further refinement of the in vivo and in vitro models of vascular regeneration
from those used in Chapter 2. The in vitro model used in this chapter introduces further
mechanistic characterizing of the effects of HPC on cultured EC in terms of cell survival
and death as measured by flow cytometry. Building on the in vivo murine hindlimb
ischemia model from the previous chapter, here I present techniques to measure limb
usage in addition to blood perfusion data. Quantitation of limb usage in addition to
simple measurement of perfusion indicates that mice regain functional usage of the limb
in addition to recovery of simple blood flow, strengthening the model. Furthermore, the
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transplantation method was changed to intramuscular injection to more closely model the
transplantation strategy from most PVD and CLI trials as well as to decrease delays in
therapeutic benefit due to delayed and inefficient recruitment of cells transplanted
intravenously.

3.1 Introduction
Ischemia, caused by insufficient blood flow to a given tissue, represents a widespread
burden on human health. Cardiovascular disease (CVD) is the leading cause of death in
North America, and accounts for roughly one third of all deaths and related healthcare
costs for patients with CVD and stroke is now estimated to be in excess of $300 billion in
the US alone1,2. Since Asahara et al. first described a role for circulating bone marrowderived cells in vascular regeneration, cell therapy has emerged as an important strategy
to treat ischemic diseases3-7. Thus, the development of novel cellular therapies for the
management of acute cardiovascular diseases such as myocardial infarction and stroke, as
well as chronic ischemic disease such as coronary and peripheral arterial disease, remain
the focus of intense preclinical research.
Early clinical trials building upon the preclinical promise shown by bone marrow and
umbilical cord blood-derived endothelial and hematopoietic progenitor cells showed that
transplantation in humans was well-tolerated and safe6-8. Unfortunately, many of these
therapies showed mixed results in improving cardiovascular disease outcomes, leading
researchers to refocus on better understanding of the role of circulating progenitor cells in
vascular repair9. As such, several cell types have been implicated in vascular regeneration
including multiple cell types from the hematopoietic lineage10-13.
Recent cell-based approaches for vascular regeneration have focused on better functional
characterization of purified cellular subpopulations and the mechanisms by which
transplanted progenitor cells mediate vascular regeneration. Several groups have
demonstrated that cells of the myeloid lineage recruit to areas of ischemia and support
vessel regeneration though paracrine signaling to vessel-resident endothelial cells14-17.
Our lab has demonstrated that transplantation of primitive hematopoietic progenitor cells
with high aldehyde dehydrogenase (ALDH) activity, derived from human bone marrow
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or umbilical cord blood, promote recovery from acute ischemic injury in immune
deficient mice with hindlimb ischemia more effectively than unpurified, more
heterogeneous populations (Chapter 2)18,19. However, implementation of a cell-based
therapy using UCB or BM-derived ALDHhi cells is hindered by the rarity of the ALDHhi
cell population as it accounts for less than 1% of total MNC in BM or UCB samples.
However, interest in developing strategies to increase the number of hematopoietic stem
and progenitor cells for transplantation into patients with hematological disorders has led
to identification of clinically-applicable culture strategies for hematopoietic progenitor
expansion using defined, xeno-free conditions supplemented with stem cell factor (SCF),
thrombopoietin (TPO) and fms-related tyrosine kinase 3 ligand (FLT3L) 20-22.
In this study we characterize serum-free ex vivo expansion of UCB-derived ALDHhi
hematopoietic progenitor cells as a transplantable cell population for vascular
regenerative cell therapies. We demonstrate that intramuscular transplantation of
expanded ALDHhi cells can accelerate the recovery of perfusion and limb use after
femoral artery ligation-induced ischemic injury. Even after a 20-fold increase in the total
number of myeloid cell progeny available for transplantation, expanded HPC prevented
capillary loss as effectively as freshly isolated UCB ALDHhi cells. In addition, the
secretion of pro-angiogenic and pro-inflammatory effectors from expanded ALDHhi cells
correlated with improved survival and tube formation by human microvascular
endothelial cells (HMVEC) during co-culture in vitro. We propose that ex vivo-expanded
myeloid progeny derived from the ALDHhi subset of UCB represent a readily available,
clinically applicable population for future development of cell therapies to prevent limb
loss in patients with severe peripheral artery disease.

3.2 Methods
3.2.1 Purification of human umbilical cord blood cells based on
aldehyde dehydrogenase activity
Human umbilical cord blood samples were collected with informed consent immediately
after scheduled, full-term Cesarean sections by venipuncture at the London Health
Sciences Birthing Centre. The Human Research Ethics Committee at the University of
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Western Ontario approved all studies. Cord blood samples were labeled with RosetteSep
human cord blood progenitor cell enrichment tetrameric antibody complexes to
prospectively deplete cells expressing lineage specific (Lin-) markers CD2, CD3, CD14,
CD16, CD19, CD24, CD56, CD66b and glycophorin. After hypaque-ficoll centrifugation
(Stem Cell Technologies, Vancouver, Canada) Lin– MNC were further depleted of
erythrocytes by ammonium chloride lysis and assayed for ALDH activity using Aldefluor
reagent (Stem Cell Technologies) as previously described (Appendix 1, Chapter
2)18,19,23,24. Fluorescence activated cell sorting was performed to isolate cells with low side
scatter and high (ALDHhi) versus low (ALDHlo) ALDH activity. Before use in
experiments, sorted cell population of >98% purity were washed in phosphate-buffered
saline (PBS) to allow the efflux of Aldefluor substrate via ATP-binding cassettetransporters, leaving the cells unmodified for subsequent functional characterization and
transplantation experiments.

3.2.2 Ex vivo expansion of hematopoietic progenitors from UCB
ALDHhi cells
After fluorescence activated cell sorting, UCB ALDHhi cells were plated on recombinant
human fibronectin coated (1 hour coating with 0.0125 mg/mL fibronectin in PBS
followed by sterile water rinse) dishes in X-vivo 15 (Lonza, Basel, Switzerland)
supplemented with stem cell factor (SCF, 10ng/mL), Fms-related tyrosine kinase 3 ligand
(FLT3LG, 10ng/mL), and thrombopoietin (TPO, 10ng/mL). All growth factors were from
Life Technologies, Burlington, ON. Growth media was changed every 3 days and
conditioned media was collected after 3 and 6 days of expansion. Ex vivo expanded
hematopoietic progenitors (HPC) were harvested and enumerated by Trypan blue
viability at day 6.

3.2.3 Assessment of ALDH-activity and cell surface marker
expression after ex vivo expansion
After 6 days ex vivo expansion, HPC were first assayed for the retention of high ALDH
activity using Aldefluor reagent by flow cytometry to compare fluorescence levels to
DEAB-inhibited control samples. Freshly isolated UCB ALDHhi cells and day 6 ex vivoexpanded HPC progeny were labeled with anti-human antibodies for lineage-specific
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markers for T lymphocytes (CD3, Biolegend, San Diego, CA), macrophages (CD11b, BD
Biosciences), monocytes (CD14, BD Bioscience), B lymphocytes (CD19, BD
Bioscience), myeloid cells (CD33, BD Bioscience), and with antibodies for primitive
progenitor-specific markers CD34 (Biolegend), CD38 (BD Biosciences), CD133
(Miltenyi Biotech, Auburn CA) and CD117 (BD Bioscience). Viable, 7-aminoactinomycin D (7AAD, BD Bioscience)-excluding cells were assessed for ALDH-activity
and cell surface marker expression using an LSRII flow cytometer at the London
Regional Flow Cytometry Facility and analyzed using FlowJo software (Treestar,
Ashland, OR).

3.2.4 Quantitation of hematopoietic colony forming capacity in vitro
Freshly isolated UCB ALDHhi or 6-day ex vivo-expanded HPC were cultured in semisolid methylcellulose media (Methocult® H4434, SCT) at limiting dilution.
Hematopoietic colony formation at 14 days was enumerated by manual counting under
bright field light microscopy, based on cell morphology identifying burst-forming units
of erythrocytes (BFU-E), colony-forming units of granulocytes (CFU-G), macrophages
(CFU-M), granulocytes and macrophages (CFU-GM), or multilineage mixed colonies
(CFU-Mixed) containing cells of all 3 myeloid cell types listed above.

3.2.5 Microarray assessment of gene transcription after ex vivo
expansion
mRNA was isolated from 6 day culture expanded HPC or freshly-isolated (uncultured)
UCB ALDHhi cells using the mRNeasy Mini kits (n=3, Qiagen, Mississauga, ON).
Microarray analysis was performed in triplicate using human array chips (Affymetrix,
Santa Carla, CA) at the London Regional Genomics Centre (London, ON). Genes
differentially expressed by uncultured UCB ALDHhi cells versus ex vivo-expanded HPC
were analyzed using the Partek Genomic Suite and angiogenesis associated-transcripts
coding for secreted proteins were identified (Partek, Inc., St. Louis, MO).
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3.2.6 HMVEC survival when exposed to HPC-secreted factors
For endothelial cell growth and survival assays, 4x104 HMVEC (adult, dermal source)
were cultured in endothelial basal media (EBM2-MV, Lonza) with or without growth
factors (EGF, VEGF-A, FGF, IGF-1) and serum (5%) supplementation. To assess
whether co-culture with expanded HPC could support HMVEC survival under serumstarved, growth factor depleted conditions, 8x104 HPC were seeded into porous (1µm)
hanging transwells suspended above the HMVEC. The number of trypan blue excluding
HMVEC present after 72 hours co-culture was enumerated by blinded hemocytometer
counts. To assess HPC-conditioned media could support endothelial cell survival, 3x103
HMVEC were plated in endothelial basal media with or without growth factors, or in
serum-free HPC-conditioned media collected after 3 or 6 days of expansion. The number
of HMVEC present after 72 hours of culture was quantified using the CyQUANT cell
proliferation assay (Life Technologies) performed as described by the manufacturers
protocol. Briefly, total lysed-cell DNA content was quantified by a fluorescence plate
reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) and cell number was
interpolated by a standard curve. To quantify HMVEC apoptosis rates during co-culture
or after exposure to HPC-conditioned media, HMVEC were also harvested after 24 hours
and labelled with viability dye 7AAD and co-stained with anti-human annexin V and
assayed using flow cytometry. Annexin V is expressed on the external cell membrane
early during the apoptotic cascade and identified apoptotic cells and 7AAD staining was
used to identify live versus dead cells. The frequency of live (7AAD−/annexin V−),
apoptotic (7AAD−/annexin V+), and dead HMVEC (7AAD+) was quantified using FlowJo
analysis software.

3.2.7 HMVEC tubule network formation when exposed to HPCsecreted factors
To assess endothelial cell tubule formation, 1.4x104 HMVEC were cultured on growth
factor-reduced Matrigel (BD Biosciences) for up to 48 hours. HMVEC Matrigel cultures
were bathed with either endothelial basal media (EBM) without growth factors or serum,
complete EGM2-MV (EBM + growth factors, +5% serum), or serum-free HPC
expansion media, or serum-free HPC-conditioned media collected after 3 or 6 days of
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expansion. To assess whether direct cell contact could augment endothelial cell function,
HMVEC were also co-cultured on growth factor reduced Matrigel in direct co-culture
with 1x105 ex vivo-expanded HPC in EBM. The number of complete branch points in the
tubule networks formed by HMVEC was enumerated on an inverted microscope by
blinded manual counts of complete branch points using four fields of view in triplicate
wells at 6, 24 and 48 hours.

3.2.8 Identification of secreted angiogenic proteins during HPCHMVEC co-culture
Conditioned EBM (without serum or growth factors) was harvested after 72h of culture
of 4x104 HMVEC or 8x104 HPC to assess cytokines secreted by each cell type under
basal culture conditions. To identify angiogenic proteins differentially secreted when
cross-talk between EC and HPC was permitted, HMVEC and HPC were co-cultured
together to generate EBM media conditioned by both cell types in direct co-culture
simultaneously. Angiogenesis-associated proteins were detected in EC-, HPC-, and
EC/HPC co-culture-conditioned media samples using a human angiogenesis antibody
array C1000 kit and chemiluminescence imaging of the membranes as per manufacturer
instructions (Human Angiogenesis Antibody Array C1000, RayBiotech, Norcross, GA,
USA). Mean signal intensities for each protein detected was normalized to signal
intensity of negative and positive control spots to adjust for differences in exposures
between arrays and between samples as outlined in manufacturer guidelines. Relative
fold-changes in protein levels in conditioned media were calculated by densitometry
comparing array signal density between 3 different biological samples using Image J
software.

3.2.9 Murine femoral artery ligation and intramuscular transplantation
of expanded HPC
To induce unilateral hindlimb ischemia, surgical ligation and complete resection of the
right femoral artery and vein was performed on anesthetised NOD/SCID (Jackson
Laboratory, Bar Harbor, ME) or NOD/SCID/MPSVII mice as previously described in
detail in Putman et al. in Appendix 1 and elsewhere (Chapter 2, Appendix 1)19,24. Within
24 hours of surgery, mice were transplanted by intramuscular injection at three sites into
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the right (surgical/ischemic) adductor muscle with 50μL saline as vehicle control, 20x106
unsorted UCB MNC, 1x105 UCB ALDHhi cells, 1x105 ALDHlo cells, or 5x105 ex vivoexpanded HPC. Total cell doses injected were selected based on frequency of ALDHhi
cells in unpurified UCB MNC and based on the frequency of cells that retained high
ALDH-activity after 6 days of culture.

3.2.10 Quantification of hindlimb perfusion using laser Doppler
perfusion imaging
Anesthetized mice were stabilized at 37°C for 5 minutes on a heat pad before blood flow
in the lower hindlimbs (ankle to toe) was quantified using laser Doppler perfusion
imaging (LDPI, Moor Instruments, Devon, UK). The perfusion ratio of the
ischemic/surgical limb compared to the uninjured/control limb was assessed after surgery
to confirm induction of acute ischemic injury with a perfusion ratio (PR<0.1) <10%
compared to the normal limb. Subsequent LDPI measurements were taken in each mouse
at 3, 7,14, 21, and 28 days after transplantation to track recovery of perfusion temporally.

3.2.11 Gait analysis to assess recovery of limb use after injury
Noldus CatWalk software and equipment (CatWalk 7.1, Noldus, Wageningen,
Netherlands) was used to quantify usage of the hindlimb after femoral artery ligationinduced injury. Baseline limb usage was determined by relative print intensity in the right
versus left hindlimb, before and after surgery. PBS or expanded HPC-transplanted mice
mice were reassessed for limb usage at 3, 7, 14, 21, and 28 days after transplantation by
running on the CatWalk system. Relative usage of the injured right hindlimb was
quantified by normalizing print intensity of the right hindlimb compared to the
contralateral uninjured leg at each time point.

3.2.12 Assessment of hindlimb muscle vascularization
Adductor muscles from transplanted mice were were harvested, embedded in optimum
cutting temperature medium (Tissue Tek, Sakura Finetek, Tokyo, Japan), frozen, and
cryosectioned. Muscle sections were fixed in 10% formalin (Sigma), and blocked with
mouse-on-mouse reagent (Vector Labs, Burlingame, CA). Adductor muscle blood vessel
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density in ischemic and nonischemic limbs was quantified at 7 and 28 days after
transplantation by quantifying mouse CD31+ blood vessels using rat anti-mouse CD31
(1:100; BD Biosciences) and peroxidase-labeled anti-rat secondary antibodies (Vector
Labs) visualized using 3,3'–diaminobenzidine substrate

(Vector), and counterstained

with hematoxylin. Blood vessel density was counted in a blinded fashion from nine
photomicrographic fields per sample using light microscopy.

3.2.13 Statistics
Analysis of significance was performed by one-way ANOVA with Tukey’s multiple
comparison tests for progenitor frequency assays, EC survival/proliferation assays,
cytokine array screens, and vessel density histology. Two-way repeated measures
ANOVA with Bonferroni post-hoc tests were used for LDPI and Matrigel tube forming
time courses. Catwalk limb usage data were analysed using an unpaired Student’s t-test.
All statistical analyses were performed using Graphpad Prism software.

3.3 Results
3.3.1 Ex vivo expansion of UCB ALDHhi cells
Lineage-depleted (Lin–) human UCB MNC with low side scatter and high (ALDHhi,
2.4±0.4% of Lin– cells) or low (ALDHlo, 16.2±3.6% of Lin– cells) aldehyde
dehydrogenase activity were selected based on diamniobenzaldehyde (DEAB) inhibition
gating controls (n=18, Figure 3.1). Next, the FACS-purified UCB ALDHhi cells were
plated on fibronectin-coated dishes in serum-free X-vivo-15 media supplemented with
10ng/ml of each recombinant human TPO, SCF, and FLT3L. After 6 days in culture,
there was a 20.0±5.6 fold increase in total cell number. 13.2±2.4% of expanded cells
(Table 3.1, n=4) maintained high ALDH activity amounting to a 2.6-fold expansion of
total ALDHhi cells over 6 days ex vivo expansion.
After 6 days culture under expansion conditions, resulting hematopoietic cells were
assessed for changes in cell surface marker expression compared to freshly isolated UCB
ALDHhi cells. Expanded progeny showed a decreased frequency of cells expressing the
hematopoietic progenitor marker CD34 (29.5±2.7%) compared to freshly isolated

108

ALDHhi cells (92.5±2.7%, Table 3.1 n=4). Similarly, expanded cells showed a
diminished frequency of cells expressing prominin 1 (CD133) from 73.0±1.2% to
10.2±1.8%, and the receptor tyrosine kinase for SCF (c-kit/CD117) from 33.5±8.1% to
2.9±0.6% (Table 3.1, n=4). However, taking into account the 20-fold expansion in total
cell number, the total number of CD34+ cells was increased 6.4-fold, the total number of
CD133+ cells was increased 2.8-fold, and the total number of CD117+ cells was increased
1.7-fold after 6 days expansion. Culture expanded cells maintained high expression of the
early myeloid progenitor marker Siglec-3 (CD33, 96.2±0.07%) compared to parental
UCB ALDHhi cells (96.1±0.8%, Table 3.1, n=4). Finally, after 6 days ex vivo culture
there was no increase in the expression of mature lineage-specific markers for monocytes
(0.3±0.1% CD14+, Table 3.1, n=4), macrophages (0.4±0.2% Mac-1/CD11b+), B cells
(0.0±0.0% CD19+, Table 3.1 n=4), or T cells (0.1±0.1% CD3+, Table 3.1 n=4).
Collectively, these data indicate that ex vivo culture of UCB ALDHhi cells results in the
expansion of the total number of primitive cells that retained early myeloid phenotype
without increasing cell surface marker expression associated with mature monocyte or
macrophage lineages.
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Figure 3.1. Ex vivo expansion of hematopoietic progenitor cells from lineage
depleted UCB ALDHhi cells.
Following ficoll-paque centrifugation and bead-labeled antibody negative selection of
mature lineage markers (A) human UCB mononuclear cells were selected according to
size (forward scatter) and granularity (side scatter). Inhibition of ALDH activity by
DEAB prevents accumulation of Aldefluor fluorescence. Cells with low side scatter
selected based on low (ALDHlo) or high (ALDHhi) Aldefluor™ fluorescence (n=18). (B)
Schematic overview of ex vivo expansion of hematopoietic progenitor cells (HPC). (C)
Representative FACS plots of measures of retention of high ALDH activity in ex vivoexpanded HPC (n=4).
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Table 3.1. Cell surface marker phenotype
changes after ex vivo expansion of HPC.
UCB
hi
Lineage Marker ALDH
cells (%)
Hematopoietic
Progenitor
ALDH
100
CD34
92.5±2.7
CD38
75.9±4.9
CD133
73.0±1.2
CD117
33.5±8.1
Myeloid
CD33
96.1±0.8
Monocyte
CD14
2.8±0.9
B cell
CD19
0.8±0.2
T cell
CD3
3.0±1.5

ex vivo
expanded
HPC (%)

13.2±2.4
29.5±4.4
43.9±7.5
10.2±1.8
2.9±0.6
96.2±0.7
0.3±0.1
0.0±0.0
0.1±0.1
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3.3.2 Ex vivo expansion of ALDHhi UCB cells increases the total
number of hematopoietic progenitor cells.
Fresh UCB ALDHhi cells and 6 day expanded progeny were plated at limiting dilution in
semi solid methylcellulose media with hematopoietic growth factors to enumerate
clonogenic hematopoietic colony formation before and after 6 days ex vivo expansion.
Notably, the ex vivo-expanded HPC retained significant multipotent myeloid colony
forming capacity (Figure 3.2A). In freshly isolated UCB ALDH cells, approximately 1 in
3 cells showed hematopoietic colony forming function in methylcellulose. After ex vivo
culture, HPC progeny displayed a reduced frequency of colony forming units at
approximately 1 in 8 cells. At 20.0±5.6-fold total cell expansion this amounts to a 7.5fold increase in total hematopoietic colony forming cells after 6 days ex vivo culture. Ex
vivo-expanded HPC also showed a significant decrease in the overall frequency of
erythroid blast forming units (BFU-E, macrophage (CFU-M) and granulocyte (CFU-G)
colony forming units (Figure 3.2A, n=4, p<0.05). Furthermore, ex vivo expansion caused
a shift in myeloid lineage specification away from granulocytic differentiation towards
erythroid differentiation (Figure 3.2B,C). Taken together, these data illustrate that ex vivo
culture of UCB ALDHhi cells effectively increases the total number of hematopoietic
progenitor cells (HPC) available for further application.
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Figure 3.2. Ex vivo expanded HPC retain myeloid multipotency.
(A) Following 6 days of serum free culture expanded HPC retain diminished progenitor
cell marker phenotype. (C) HPC plated in semi-solid methylcellulose media show
myeloid multipotency at diminished levels compared to (B) freshly isolated ALDHhi
cells. (*p<0.05, n=5).
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3.3.3 Expanded HPC retain a vascular regenerative transcription
profile
Affymetrix microarray identified multiple transcripts with significantly changed
expression levels (>1.5 fold increase, p<0.01) in 3 ex vivo-expanded HPC samples
compared to 3 parental, uncultured UCB ALDHhi cell samples. Confirming cell surface
phenotype as measured by flow cytometry, ex vivo-expanded HPC expressed
significantly less KIT (CD117, p=8.31x10-6) and PROM1 (CD133, p= 6.88x10-4)
compared to UCB ALDHhi cells. Interestingly, despite significant reduction in CD34
expression at the cell surface there was no significant reduction in CD34 transcript levels
in HPC compared to UCB ALDHhi cells. The raw data was next filtered to focus on
transcripts coding for secreted proteins with documented biological functions that
potentially modulate endothelial cell survival and pro-angiogenic processes that were
significantly upregulated after ex vivo expansion (n=3, Table 3.2). Ex vivo-expanded HPC
showed upregulation of several transcripts which code for secreted growth factors known
to modulate vascular regeneration including epidermal growth factor (EGF), vascular
endothelial growth factor A and B (VEGF-A, VEGF-B), and angiopoietin 1 (ANGPT1,
Table 3.2). Furthermore, HPC expressed significantly higher levels of transcripts for
proteins

that

modulate

vascular

growth

factor

signaling

including

ribonuclease/angiogenin inhibitor-1 (RNH1, angiogenin regulator) and insulin-like
growth factor binding protein 3 (IGFBP3, insulin-like growth factor modulator, Table
3.2). Ex vivo expansion of HPC from UCB ALDHhi cells also increased expression of
transcripts associated with matrix modifying proteins, including tissue inhibitor of
metalloproteinases 1 and 3 (TIMP-1, TIMP-3, Table 3.2). Collectively, these data suggest
that ex vivo-expanded HPC retain a vascular regenerative transcription profile.
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Table 3.2. Transcripts for secreted proteins associated with vascular regeneration
upregulated in ex vivo-expanded HPC
FoldChange p-value
vs. UCB vs. UCB

Gene
Symbol

Common Name

Biological Function

Molecular Function

ALDHhi ALDH

hi

promotes endothelial cell
epidermal growth proliferation, survival, differentiation, EGF receptor
EGF

factor

and migration

activation

6.5

4.6x10

2.9

1.2x10

2.5

7.7x10

2.5

1.1x10

2.0

2.4x10

1.9

5.6x10

1.5

2.3x10

1.5

4.8x10

-4

tissue inhibitor of

TIMP3

metalloproteinases prevents matrix remodeling,

inhibition of MMP

3

activity

stabilizing preexisting vasculature

ribonuclease/

RNH1

modulates cellular

angiogenin

promotes cell survival under stress

localization, regulatory

inhibitor 1

conditions, decreases apoptosis

activity of angiogenin

vascular

primary regulator and activator of

endothelial growth angiogenesis, autocrine signaling
VEGFA factor A

-5

promotes vascular homeostasis

-7

VEGFR2 receptor
activation

-3

stabilizes the blood vasculature by

ANGPT1 angiopoietin 1

suppressing EC responses during

TIE2 receptor

vascular stress

activation

-3

tissue inhibitor of MMP-independent functions include inhibition of MMP

TIMP1

metalloproteinases inhibition of apoptosis, induction of

activity; stimulating the

1

angiogenesis and cell proliferation

Akt survival pathway

vascular

critical for blood vessel survival under

-4

endothelial growth pathological conditions, non-essential VEGFR1 receptor
VEGFB factor B

role in vessel formation

activation

-4

insulin-like
growth factor
IGFBP3 binding protein 3 inhibits endothelial cell apoptosis,

modulates IGF
signaling

-4
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3.3.4 Expanded HPC support endothelial cell tubule formation in
vitro.
To assess whether these expanded HPC supported EC tubule forming function via
paracrine actions, human microvascular endothelial cells (HMVEC) were plated on a thin
gel of growth factor reduced matrigel bathed in growth factor+/serum+ endothelial
growth medium (EGM2-MV, Figure 3.3A), or growth factor-/serum– endothelial basal
media (EBM, Figure 3.3B), to serve as positive and negative controls for tubule
formation respectively. In addition, HMVEC were exposed to basal HPC expansion
media (X-vivo 15 + cytokines) or day 3 or day 6 HPC conditioned media (Figure 3.3D).
Finally, HMVEC were co-cultured directly with expanded HPC in EBM (Figure 3.3C).
Interestingly, HPC-conditioned media showed no effect on tubule formation compared to
basal media controls (n=8). However, after 6 hours of direct co-culture with ex vivoexpanded HPC, HMVEC formed significantly more branch points compared to HMVEC
grown in EBM or X-vivo 15 vehicle controls (p<0.01, Figure 3.3D, n=4). Furthermore,
direct co-culture with HPC supported tubule formation equivalent to HMVEC grown in
positive control conditions containing EGM fully supplemented with growth factors and
serum. Importantly, HPC plated alone on growth factor reduced matrigel did not result in
tubule formation. Together, this data shows that direct co-culture with HPC promotes EC
tubule formation under growth factor-free and serum-free conditions.
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Figure 3.3. Ex vivo-expanded HPC support tubule formation by HMVEC in serumfree, growth factor reduced conditions.
EC were seeded onto growth factor-reduced Matrigel supplemented with endothelial
basal media with (A) 5% serum and EC growth factors, (B) basal EC media, (C) 5x103
expanded HPC in direct co-culture, xvivo15 basal, or day 3 or day 6 HPC conditioned
media. Photomicrographs were taken at 6h (A-C), 24h, and 48h and branch points were
enumerated by blinded counts (Scale bar = 500 μm). (D) Summary of complete branch
points counts per well. (**p<0.01).
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3.3.5 Expanded HPC support HMVEC survival under growth factorfree, serum-free conditions
HMVEC were grown on plastic in EGM2 media fully supplemented with serum and
growth factors (EGM2-MV, Figure 3.4A), or in basal endothelial cell media (EBM)
without serum or growth factors (Figure 3.4B) or in non-contact transwells containing ex
vivo-expanded HPC in EBM (Figure 3.4C). Under fully supplemented conditions (EGM2
+ serum + cytokines) HMVEC demonstrated a 4-fold increase in cell number in 72 hours,
whereas culture in serum and growth factor depleted basal conditions resulted in a 2-fold
reduction in cell number. HPC co-culture prevented HMVEC cell loss after 72 hours
under basal growth factor-free, serum-free conditions (Figure 3.4D, n=5-8, p<0.05).
To further address the paracrine support of endothelial cell survival under growth factorfree, serum-free conditions, HMVEC were plated in HPC conditioned media and cells
were enumerated after 72 hours using the CyQuant system. Similar to the transwell coculture results, HMVEC grown in day 3 or day 6 conditioned media showed the
prevention of cell loss associated under growth factor-free, and serum-free conditions
(Figure 3.4E, n=6-7, p<0.05).
Due to the pro-survival responses elicited in HMVEC when exposed to HPC secreted
factors, HMVEC were also harvested after 24 hours culture in EGM2-MV, EBM, or in
non-contact transwell co-culture with HPC and assessed for apoptosis using 7aminoactinomycin D (7AAD) combined with annexin V-staining measured by flow
cytometry (Figure 3.4F, n=4-6). HPC co-culture significantly reduced the frequency of
dead cells (% 7AAD+ cells) compared to EBM-cultured controls (Figure 3.4G, n=4-6,
p<0.05). However, HPC co-culture only modestly reduced the frequency of early
apoptotic cells (% 7AAD-/Annexin V+). In contrast, HPC conditioned media did not
alter total cell death or apoptosis rates compared to EBM or X-vivo 15 vehicle controls
(Figure 3.4G). Collectively, these data indicate that HPC co-culture supported the
survival of EC in serum-free, growth factor-free conditions.
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Figure 3.4. Ex vivo-expanded UCB HPC and conditioned media support the survival
of endothelial cells under serum-starved conditions.
(A-C) 4x104 HMVEC were cultured for 72 hours in basal media (EBM2) with or without
growth factors (EGF, VEGF, FGF, IGF-1) and serum (5%) supplementation. Into each
culture a hanging 1μm pore transwell was suspended above the EC and filled with 8x104
day 6 expanded HPC or basal media (Scale bar = 200μm). (D) Non-contact co-culture
with D6 expanded HPC promoted the survival of EC under growth factor-free, serumstarved conditions (*p<0.05, n=5-8, in duplicate). (E) 3x103 EC were cultured in HPC
expansion basal media (Xvivo 15) with or without EC growth factors (EGF, VEGF, FGF,
IGF-1) and serum (5%) supplementation. Day 3 or Day 6 conditioned medium (X vivo
15 base) collected during HPC expansion supported survival of EC under serum and
growth factor-free conditions (n=6-7 in triplicate, *p<0.05). (F) Representative plots
showing flow cytometric detection of Annexin V/7AAD survival status of endothelial
cells 24 hours after culture. (G) Summary statistics for cell survival status at 24 hours.
(different letter denotes *p<0.05).
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3.3.6 HMVEC co-culture with HPC increased the secretion of prosurvival signals
HMVEC and HPC were grown in basal endothelial cell media (EBM) alone, or in direct
co-culture with both cell types in basal EBM. After 72 hours, the conditioned media from
each culture condition was collected and screened for secreted protein content using
antibody array. When grown in basal endothelial media without serum or growth factors
both HMVEC and ex vivo-expanded HPC secreted growth factors, chemokines, matrix
modifying proteins and secreted receptor proteins associated with endothelial cell
function during angiogenesis (Figures 3.5, 3.6, n=3). Notably, co-culture of HPC with EC
significantly increased levels of several growth factors associated with vascular
regeneration including epidermal growth factor (EGF, Figure 3.5, n=3, p<0.05) and
angiopoietin-2 (Figure 3.6, n=3, p<0.05). Moreover, HPC co-culture increased the
amount of angiopoietin-2 secreted into the media significantly more than the additive
signals of HMVEC or HPC cultured alone, indicating a potential cellular crosstalk
regulating increased angiopoietin 2 secretion (n=3, p<0.05). Many chemokines which
have been implicated in the recruitment of inflammatory cell types to areas of ischemia
were

also

significantly

increased

during

HPC

co-culture

including

GROα,β,γ/CXCL1,2,3, IL8/CXCL8, and RANTES/CCL5 (Figure 3.5, n=3, p<0.05).
Several matrix modifying proteins were significantly upregulated during HPC co-culture
including tissue inhibitor of metalloproteinases 1 and 2 (TIMP-1, TIMP-2, Figure 3.5,
n=3, p<0.05) and matrix metalloproteinase-9 (MMP-9, Figure 3.6, n=3, p<0.05). TIMP-2
was significantly upregulated in co-culture compared to the additive signals of HMVEC
and HPC alone (n=3, p<0.05). Overall, HPC co-culture with HMVEC in unsupplemented
media increased the paracrine and autocrine secretion of several angiogenesis-associated
growth factors, chemokines and matrix modifying proteins.
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Figure 3.5. HMVEC co-culture with HPC increases secretion of pro-survival
signals: Part 1.
(A) Chemiluminescent imaging of RayBio® Membrane-Based Antibody Human
Angiogenesis Array C1000 was used to screen and compare expression levels of
angiogenesis-associated cytokines, growth factors, proteases, and soluble receptors
secreted in basal endothelial media after 72 in culture. (B) HMVEC grown in basal
unsupplemented media co-cultured with ex vivo-expanded HPC are exposed to higher
levels of pro-survival signals (n=3, *p<0.05).
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Figure 3.6. HMVEC co-culture with HPC increases secretion of pro-survival
signals: Part 2.
(A) Chemiluminescent imaging of RayBio® Membrane-Based Antibody Human
Angiogenesis Array C1000 was used to screen and compare expression levels of
angiogenesis-associated cytokines, growth factors, proteases, and soluble receptors
secreted in basal endothelial media after 72 in culture. (B) HMVEC grown in basal
unsupplemented media co-cultured with ex vivo-expanded HPC are exposed to higher
levels of pro-survival signals (n=3, *p<0.05).
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3.3.7 Expanded HPC enhance recovery of limb perfusion after
transplantation into ischemic limbs
Previously in Chapter 2, I demonstrated that freshly isolated UCB ALDHhi cells support
recovery of perfusion and revascularization in the ischemic hindlimb of mice after
intravenous transplantation into mice with unilateral hindlimb ischemia (Chapter 2)19. To
confirm these findings with UCB ALDHhi cells and to assess whether expanded HPC
could impact the recovery of perfusion in vivo, freshly isolated UCB ALDHhi cells and ex
vivo-expanded HPC were transplanted intramuscularly into immune deficient NOD/SCID
mice with acute unilateral hindlimb ischemia after femoral artery ligation surgery.
Hindlimb perfusion was assessed by laser Doppler perfusion imaging (LDPI) and the
perfusion ratio of the ischemic limb versus the contralateral control limb was determined
weekly for up to 28 days. After femoral artery ligation surgery, the perfusion ratio (PR)
of the treatment leg was less than 10% of the control leg in all transplanted mice
(PR≤0.1). Mice treated with intramuscular phosphate buffered saline (PBS, Figure 3.7A)
vehicle control established the baseline recovery of perfusion (PR=0.49±0.03 at 28 days
after treatment). Mice with ischemic adductor muscle transplanted intramuscularly with
freshly isolated 20x106 UCB MNC or 1x105 purified UCB ALDHlo cells showed no
significant changes in recovery of perfusion compared to PBS controls (Figure 3.7D). In
contrast, mice that were treated by intramuscular transplantation of 1x105 purified UCB
ALDHhi cells (Figure 3.7B, Day 7 PR=0.45±0.09) or 5x105 ex vivo-expanded HPC
(Figure 3.7C, Day 7 PR=0.40±0.02) showed significantly accelerated recovery of
perfusion of the ischemic limb compared to PBS vehicle controls (Figure 3.7A, Day 7
PR=0.25±0.02) within 7 days after transplant (Figure 3.7D). At a frequency of 13.2% of
expanded HPC retaining high ALDH activity, mice transplanted with 5x105 HPC receive
an equivalent dose of 6.6x104 ALDHhi cells, a lower effective dose of ALDHhi cells.
Importantly, improved perfusion at day 7 translated to a significant increase in perfusion
at later time points (days 14-28) compared to PBS injected controls. Collectively, these
data confirm that transplantation of UCB ALDHhi cells promote recovery or perfusion in
the ischemic hindlimb of mice after femoral artery ligation. Furthermore, the data
indicates that ex vivo expansion of HPC from UCB ALDHhi cells does not diminish
vascular regenerative function.
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To further assess recovery from acute ischemic injury, limb use by gait analysis of
transplanted mice was assessed using Noldus™ Catwalk 7.1 software. Mice treated by
intramuscular injection of ex vivo-expanded HPC showed significantly increased usage of
the ischemic limb at 7 days after transplant compared to PBS treated control mice (Figure
3.7E). These findings demonstrate that the recovery of perfusion in mice transplanted
with UCB ALDHhi cells or ex vivo-expanded HPC is accompanied by augmented
recovery of limb usage in the injured limb.
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Figure 3.7. Direct intramuscular injection of UCB ALDHhi cells augment perfusion
of ischemic limbs.
(A-C) Representative LDPI following right femoral artery ligation and tail vein injection
of PBS vehicle control, 20x106 unsorted UCB MNC, 1x105 ALDHhi cells, 1x105 ALDHlo
cells, or 5x105 ex vivo-expanded HPC monitored for 28 days (n=7-15). Numbers in
bottom left of each LDPI image indicate perfusion ratio of the ischemic versus the nonischemic hindlimb from ankle to toe. (D) Summary of mean perfusion ratio ± SEM as
above. Transplantation of UCB ALDHhi cells promoted robust, maintained recovery of
perfusion in ischemic mouse hindlimbs by day 7 post-transplantation as compared to
saline injected controls (*p<0.05,**p<0.01). (E) Noldus™ catwalk paw print intensity at
day 7 post transplantation showed that mice transplanted with HPC regained use of their
ischemic leg faster than saline vehicle controls (n=6).
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3.3.8 Intramuscular transplantation of HPC prevents loss of
endogenous blood vessels after acute ischemic injury
Ischemic and control adductor muscle were cryosectioned and stained for CD31
expression to enumerate the blood vessels present at 7 and 28 days after injury. Within 7
days of femoral artery ligation, saline-treated control mice showed a significant loss of
the CD31+ positive vessels in the ischemic limb (61.9±2.1 CD31+ vessels/mm2) compared
to the contralateral control limb (69.9±0.8 CD31+ vessels/mm2, p<0.05, n=7, Figure
3.8C). This loss of vascularization in the ischemic limb (62.5±1.6 CD31+ vessels/mm2,
Figure 3.8D) of saline treated mice was consistent at 28 days after induction of ischemic
injury compared to normal limb (69.4±0.6 CD31+ vessels/mm2, Figure 3.8D). Mice
treated by intramuscular injection of UCB MNC or ALDHlo cells showed no difference in
ischemic limb vascularization compared to PBS controls (Figure 3.7). Mice transplanted
with ex vivo-expanded HPC showed prevention of CD31+ cell loss at 7 (72.3±0.6 CD31+
vessels/mm2, Figure 3.8C) and 28 days after treatment (68.1±1.8 CD31+ vessels/mm2,
Figure 3.8D). Purified ALDHhi cells from fresh UCB similarly showed a reduction in the
loss of vascularization in the ischemic muscle at 28 days after treatment (71.8±2.3 CD31+
vessels/mm2, Figure 3.8D). These findings suggested that UCB ALDHhi cells and ex vivoexpanded HPC prevent the loss of CD31+ vessels in the ischemic hindlimb of mice after
ischemic injury.
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Figure 3.8. Intramuscular transplantation of ex vivo-expanded cord blood
hematopoietic progenitor cells prevents loss of vascularization of ischemic hindlimb
muscle after acute ischemic injury.
(A, B) Representative photomicrographs of CD31 staining in ischemic adductor muscle
sections taken 28 days after right femoral artery ligation and intramuscular injection of
PBS, ALDHhi cells, or HPC. (C, D) Summary of mean vessel density ± SEM in the
ischemic or non-ischemic limb at (C) 7 days, or (D) 28 days after transplantation. Mice
that were transplanted with fresh UCB ALDHhi cells or ex vivo-expanded HPC
demonstrated increased vascularization of the surgical limb. (*p<0.05).
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3.4 Discussion
In this study I demonstrate that human UCB-derived cells with high ALDH activity can
be readily expanded in serum free conditions without diminishing vascular regenerative
function after direct intramuscular transplantation in vivo. After 6 days ex vivo culture in
clinically relevant serum free conditions, 20-fold expansion of total hematopoietic cell
number was obtained with substantial expansion of total myeloid progenitor cell number.
Our findings show that ex vivo-expanded HPC maintained an angiogenic vascular
regenerative phenotype by mRNA transcriptional profile. Furthermore, we demonstrate
the HPC responded to EC cell signals in culture and increase secretion of angiogenic
growth factors, matrix-modifying proteins and chemokines that recruit support cells to
the site of injury, inflammation and hypoxia.
This vascular regenerative phenotype of HPC was confirmed by demonstration that HPC
supported endothelial cell survival and tubule formation in growth factor-free, serum-free
co-culture culture conditions. Importantly, transplantation of ex vivo-expanded HPC into
immune-deficient mice with femoral artery ligation–induced hindlimb ischemia promoted
recovery of perfusion and prevented loss of vascularization in the hindlimb similar to
previously characterized UCB ALDHhi cells (Chapter 2)19. Thus, we propose that ex vivo
expansion of UCB ALDHhi cells represents a clinically applicable means of effectively
increasing the number myeloid progenitor cells for cardiovascular disease therapy
without reducing vascular regenerative function.
After 6 days of serum free expansion culture UCB ALDHhi cells expanded 20-fold in
total cell number. Of these expanded HPC, only 13.2±2.4% retained high ALDH activity,
amounting to a total 2.6 fold expansion of ALDHhi cells over 6 days ex vivo expansion.
Based on other progenitor cell surface marker expression our 6-day expansion protocol
also produced a 6.4-fold expansion of CD34+ cells, a 2.8-fold expansion of CD133+ cells
and a 1.7-fold expansion in the number of total CD117+ cells, despite a decrease in the
relative frequency of cells expressing progenitor markers. The general decrease in
progenitor marker expression frequency despite total progenitor cell number is consistent
with other published hematopoietic cell expansion protocols20,25,26. Furthermore, it is
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possible that the number of CD117 expressing cells is higher than detected by flow
cytometry as after prolonged culture in high concentrations of SCF, the ligand for
CD117/c-Kit, leads to receptor internalization and recycling as is the case with many
receptor tyrosine kinases27. Relative decreases in hematopoietic progenitor marker
expression were confirmed by microarray results showing significantly lower expression
of both CD117/c-Kit (KIT) and CD133 (PROM1) transcripts. Thus, we demonstrate here
that ex vivo expansion of UCB ALDHhi cells effectively increases the number of
angiogenic myeloid ALDHhi/CD34+/CD133+/CD117+ progenitors cells available for cell
therapy applications.
It has recently been shown that decreasing autocrine inhibitory signaling during HPC
expansion by use of a batch-fed system, it is possible to significantly increase the
expansion of hematopoietic stem and progenitor cells28,29. It is plausible that by applying
new, more efficient methods of ex vivo HPC expansion, and by the use of novel
molecules to prevent progenitor differentiation, it will be possible to further increase the
number of hematopoietic cells that retain vascular regenerative function for cell therapy
applications outside of transplantation for haematological disorders. This is an important
area of development for applications employing UCB-derived cells in an allogeneic
setting, because available cell number currently prohibits clinical application.
We also demonstrated that co-culture of HPC with endothelial cells in growth factor-free,
serum-free, basal endothelial cell media led to increased survival of endothelial cells as
measured by cell counts and by viability dye measures in vitro. Furthermore,
intramuscular transplantation of HPC into the ischemic hindlimb of mice augmented
recovery of perfusion and prevented loss of capillary density within the ischemic muscle
tissue. As such, HPC conditioned media contained secreted EGF and co-culture with EC
increased the concentrations of EGF significantly compared to EC cultured alone.
Moreover, EGF transcript levels were increased 6.5-fold in ex vivo-expanded HPC
compared to fresh UCB ALDHhi cells. The observed pro-survival effect on endothelial
cells in both in vitro and in vivo contexts is consistent with potential paracrine stimulatory
effects by secreted EGF on endothelial cells. Endothelial cells express epidermal growth
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factor receptor (EGFR)30-32 and EGFR activation has been shown to activate the PI3K/Akt
pathway thereby regulating endothelial cell survival33.
Furthermore, we show that ex vivo-expanded HPC retain a vascular regenerative,
angiogenic transcriptional and secretory profile beyond EGF expression. After culture,
HPC showed upregulation of important regulators of endothelial cell function including
angiopoietin 1 (ANGPT1) and vascular endothelial growth factors A and B (VEGF-A,
VEGF-B). During homeostasis in vivo EC-EC contacts are stabilized and cell survival is
promoted by perivascular cells who secrete angiopoietin 1 and activate theTie2 receptor
on endothelial cells34,35. Vascular endothelial growth factor A (VEGF-A) is the primary
regulator of the angiogenic cascade by which endothelial cells become activated to
proliferate and migrate in response to hypoxia or injury36. Furthermore, VEGF-A
signaling has been shown to be necessary for EC survival signaling in homeostatic
quiescence and in hypoxic conditions36,37. Additionally, VEGF-B signaling has been
demonstrated to be critical for blood vessel survival under pathological conditions
promoting not only EC survival but increasing survival of mural smooth muscle cells or
pericytes38. ANG2 is expressed by EC and its expression is increased under hypoxic
conditions34,39. ANG2 is stored in endothelial Weibel–Palade bodies which are secreted in
response to inflammation and mediate endothelial cell activation34,40,41. However, in the
absence of VEGF, angiopoietin 2 induces destabilization and regression of the
vasculature. During hypoxia, which promoted both ANG2 and VEGF secretion,
neovascularization is induced by a VEGF mediated pro-angiogenic program referred to
as the “angiogenic switch”34,39. HPC co-culture increased secreted ANG2 levels in
conditioned media significantly indicating a potential role for HPC in increasing
activation of endothelial cells during inflammation and hypoxia. Taken together, these
data indicate that ex vivo-expanded HPC maintain the transcriptional prolife and
secretory functions necessary to support vascular stabilization after ischemic injury
pushing the EC cell program from regression to survival and stabilization.
HPC co-culture with HMVEC also increased the secretion of TIMP-1 and TIMP-2 in
vitro. Moreover, TIMP1 transcript was upregulated in HPC after ex vivo expansion from
UCB ALDHhi cells. Increased TIMP expression been shown in hematopoietic progenitor
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cells and myeloid cells previously, and play a role in modifying the extracellular matrix
in response to vascular injury or hypoxia42. Broadly, TIMPs inhibit MMP-mediated
remodelling of the extracellular matrix and basement membrane, an important step in
both vascular regression and angiogenesis. TIMPs promote the stability of blood vessels
by preventing breakdown of the supportive extracellular matrix and promoting basement
membrane deposition36,43. Beyond the normal activity of TIMPs regulating MMP activity,
TIMP-1 has been shown to have MMP-independent functions which include inhibition of
apoptosis, induction of angiogenesis and cell proliferation44. In particular, TIMP-1 has
specifically been shown to prevent TNF-α mediated apoptosis in EC though the Akt
pathway45. Both the MMP-independent and MMP-mediated effects of TIMP-1 on EC
and the vasculature promote endothelial cell survival by supressing cell death are
consistent with our in vitro and in vivo findings showing less cell death in HPC-EC coculture conditions.
Ex vivo HPC expansion led to increases in transcripts associated with modulating
vascular growth factor signaling ribonuclease/angiogenin inhibitor 1 (RNH1) and insulinlike growth factor binding protein 3 (IGFBP3). RNH1 has been shown to promote cell
survival in stress conditions by decreasing apoptosis and modulating the cellular
localization and activity of angiogenin which is promoter of angiogenesis46. IGFBP3 has
been demonstrated to inhibit endothelial cell apoptosis by an IGF-independent
mechanism47. Thus, angiogenin and IGFBP3 may represent important regulators EC
function and the effects of these two regulators may also contribute to the pro-survival
mechanism consistent with our findings.
Co-culture of HPC with EC increased secreted levels of several chemokines including
members of the CXC and CC families, GRO/CXCL1-3, IL-8/CXCL8, and
RANTES/CCL5. GRO and CXCL8 are known to play a role in chemokine-mediated
regulation of angiogenesis and regulate recruitment of neutrophils, macrophages and
lymphocytes to the site of injury48-52. Interestingly, MMP-9 was also secreted by ex vivoexpanded HPC. MMP-9 is thought to be important in activating the angiogenic switch,
playing a role in increasing VEGF bioavailability by freeing it from deposits within the
extracellular matrix53. MMP-9 has been further implicated in vascular regeneration by
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playing a role in promoting vasculogenesis54. Notably, MMP-9 has been implicated in the
mobilization of circulating angiogenic cells that also modulate a pro-angiogenic niche in
areas of hypoxia. Collectively, the cumulative effects of these molecular mediators all act
to increase the potential recruitment of circulating cells from the host, which can help
mediate a vascular regenerative program at the site of injury. These proposed
mechanisms could play a plausible role in vivo in vascular regeneration seen after
transplantation of HPC into ischemic tissues.
Our lab has previously described a subset of hematopoietic progenitor cells with from
human BM high ALDH activity that play a role in paracrine support of vascular
regeneration (Chapter 2)18,24,55. Perin et al. have recently reported phase I/II clinical trials
using autologous BM-derived ALDHhi cells for the treatment of critical limb ischemia
secondary to peripheral artery disease and ischemic heart failure56,57. Both studies
demonstrated the safety of ALDHhi cells in patients with cardiovascular disease.
Importantly, in patients with critical limb ischemia, intramuscular injection of autologous
BM ALDHhi promoted improved Rutherford category scores and reduced resting pain.
Furthermore patients treated by ALDHhi cell transplant showed modest but significantly
improved ankle to brachial index scores indicating improved perfusion of the lower limb.
Finally, patients who were treated with BM ALDHhi cells reported significantly improved
quality of life after treatment56. These data demonstrate that ALDHhi cells are a viable
clinical cell population for the treatment of ischemic disease, and our data further
suggests that this population may be expanded using clinically applicable conditions to
increase the number of pro-vascular progenitor cells available for transplantation.
Notably however, there is emerging evidence that application of autologous bone marrow
progenitor cells in patients with diabetes or cardiovascular disease might be problematic.
There exists convincing evidence for decreased frequency and reduced regenerative
function for circulating and bone marrow progenitor cells in patients with chronic
diabetes, cardiovascular disease and increasing age58-61. Unfortunately, the patients who
would most benefit from vascular regenerative therapy are generally of increasing age
and overwhelming affected by diabetes and cardiovascular disease1, making the
development of allogeneic transplantation strategies desirable. As such, human umbilical
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cord blood represents an allogeneic source is readily available and may possess distinct
advantages over autologous bone marrow as source of cells for vascular regenerative
therapy. Most notably, umbilical cord blood is early in ontogeny and free of chronic
disease and age related dysfunctions. We have also shown here that ex vivo culture of
UCB derived ALDHhi cells permits expansion of the number of cells available for
therapy. However, it is possible that similar ex vivo expansion strategies could be applied
to autologous bone marrow transplants in patients as an alternative in order bypass the
need for immune suppression in the allogeneic setting. Nonetheless, we propose that
UCB ALDHhi cells represent a readily available, and expandable HPC population with
robust vascular regenerative properties. Therefore, expanded UCB-derived ALDHhi cells
represent an excellent candidate population for the development of allogeneic cell
therapy for ischemic disease.
Our current work demonstrates that is possible to increase the number of hematopoietic
progenitor cells available from UCB ALDHhi cells for applications in vascular
regeneration without losing regenerative function. We propose that purification of BM or
UCB based on high aldehyde dehydrogenase activity followed by ex vivo expansion to
increase the progenitor pool poses a promising clinical approach to developing cell
therapy for vascular regeneration and the treatment of ischemic disease.
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Chapter 4

4

High Aldehyde Dehydrogenase Activity Identifies a
Subpopulation of Multipotent Stromal Cells with Increased
Vascular Regenerative Function
BM MSC are a population of progenitor cells that expand readily in ex vivo cultures with
promising potential for vascular regenerative cellular therapies. However, our lab has
demonstrated that different MSC lines from different donors showed variable efficacy to
promote regeneration. Furthermore, the Hess lab had previously shown that re-selection
of MSC that retained high ALDH activity after culture increased islet regenerative
capacity. Therefore the objective of the studies presented in this chapter was as follows:
•

To characterize the differentiative and vascular regenerative functions of MSC
subpopulations selected after expansion for low versus high ALDH activity.

The studies presented in Chapter 4 use some of the general findings from Chapters 2 and
3 and other work by the Hess laboratory, specifically that selection of cells with high
ALDH activity isolates a population of cells with increased vascular regenerative
potential, as the basis for an approach to prospectively identify a subset of MSC that
might be superior candidates for future development of cellular therapy for CVD. It uses
the in vitro models established in Chapters 2 and 3 to establish proof of concept for
proposed future in vivo studies with populations of MSC purified by ALDH activity
level.
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4.1 Introduction
Despite significant progress and advances to improve clinical management,
cardiovascular disease (CVD) remains the leading cause of premature death worldwide
and represents a huge burden on the health care systems in North America1-5. Ischemia is
characterized by insufficient blood flow to a given tissue or organ and includes both acute
conditions like myocardial infarction and stroke and chronic ischemic conditions like
atherosclerotic arterial disease. Direct and indirect costs of medical management and
treatment of CVD is a growing burden on global health care systems, estimated to now
cost in excess of $310 billion annually in the United States alone3,4,6-8.
Multipotent stromal cells (MSC) also referred to as mesenchymal stromal stem cells can
be isolated from bone marrow (BM) and other tissues. MSC are defined by their ex vivo
culture method; they must be plastic adherent, express the markers CD73 (ecto 5’
nucleotidase), CD90 (Thy-1), and CD105 (endoglin) after culture and must not express
hematopoietic markers like CD45 or CD141,2,7-10. Additionally, MSC must demonstrate
definitive multipotency, by ability to differentiate into osteocytes, adipocytes and
chondrocytes1-5.
Broadly, MSC are considered as good candidates for allogeneic cell therapy applications
because of their low immunogenicity; they do not express MHC class II (HLA-DR) nor
co-stimulatory molecules like CD40, CD80 and CD863,4,6-8. Furthermore, MSC have
been shown to demonstrate multi-tissue engraftment and little proliferative capacity after
transplantation, reducing risk of transplantation related malignancies1,2,7-10. In general,
MSC contributions towards regenerative therapy is primarily through the modulation of
the tissue microenvironment as opposed to cell replacement6,8,11. Indeed MSC have been
demonstrated to readily support many repair processes including vascular regeneration1,810

. MSC have also been shown to augment cardiomyocyte1,10-14 and EC1,10,15,16 survival,

and secrete VEGF-A, FGF-2, ANG-1, and MCP-11,10,12-14,17. MSC have also been recently
identified as a component of vascular pericytes that express CD146 in multiple human
organs in situ and help stabilize newly formed vessels when co-transplanted with ECs in
vivo15,16,18-20. MSC have furthermore been shown to play an important role in
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immunomodulation presenting interesting potential paracrine applications in autoimmune disease and inflammatory conditions17,18,21-23. Taken together these unique
properties underscore the considerable promise of MSC from human BM or UCB as a
potential source for vascular regenerative cell therapies.
BM MSC represent a readily available population of progenitor cells that expand
efficiently in ex vivo cultures with promising potential for vascular regenerative cellular
therapies. However, an outstanding limitation to the successful implementation of MSCmediated regeneration in various clinical therapeutic settings is major inter-donor
variability in MSC function.

The Hess laboratory have previously shown that

transplanted BM MSC populations show substantial donor variation in ability to support
regeneration of pancreatic islets in a streptozotocin-induced beta cell deletion model of
diabetes19,20.

Other groups have demonstrated donor variation in MSC in terms of

osteogenic differentiative capacity21,23,24. Furthermore, MSC have been shown to undergo
replicative senescence under differentiative growth conditions and subsequent reduction
in regenerative function over prolonged culture in several systems19,25. This decline in
MSC function over extended ex vivo culture also demonstrates notable inter-donor
variability24. To improve cell therapy using MSC, it is desirable to identify prospective
markers to identify subpopulation with increased regenerative capacity.
Our laboratory has previously demonstrated that aldehyde dehydrogenase (ALDH), a
cytosolic enzyme involved in retinoic acid synthesis and in cellular self-protection
against oxidative stress is a useful marker of primitive progenitor cells associated with
increased vascular regenerative function (Chapter 2)26,27. Indeed the Hess laboratory have
shown that selection of BM mononuclear cells with high ALDH activity isolates an
enriched starting population of mixed hematopoietic, endothelial and mesenchymal
progenitor cells that supported robust recovery of perfusion and increased vascularization
after femoral artery ligation-induced ischemic injury in an immunodeficient mouse
model26. Furthermore, the Hess laboratory has demonstrated the MSC derived from BM
cells with high ALDH activity support increased regeneration in the diabetic pancreas19.
Thus, we hypothesized that MSC subpopulations with increased ALDH activity will
improve vascular regenerative function via the paracrine support of endothelial cell
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activation and neo-vessel forming function. In this chapter, we present preliminary
characterization of the differentiation and vascular regenerative properties of MSC
subpopulations with high versus low ALDH activity sorted after expansion.

4.2 Methods
4.2.1 BM MSC derivation and culture
BM aspirates were acquired with informed consent during routine pre-screening for BM
donation by Dr. Anargyros Xenocostas at the London Health Sciences Centre in London,
Ontario, Canada. The mononuclear cell fraction was isolated using ficoll centrifugation.
BM mononuclear cells were then depleted of residual red blood cells by lysis in
ammonium chloride. Mononuclear cells were plated at 2.7x105 cells/cm2 on tissue culture
treated plastic dishes in fully-supplemented Amniomax C-100 media (Gibco, Grand
Island, NY). Culture media was changed 48 hours after plating to allow adherent stromal
cells to adhere to plastic. Thereafter, growth media was changed 3 times per week for
maintenance and cell expansion. Adherent MSC colonies were detectable by light
microscopy within 2 weeks of plating. MSC were harvested by trypsin and subsequently
passaged at 4.7x103 cells/cm2 for expansion culture. After passage 2-3, MSC were
harvested using trypsin and suspended in FBS + 10% DMSO for cryopreservation.
Thawed MSC were seeded at 4.7x103 cells/cm2 in Amniomax to reestablish MSC culture
and subsequently passaged prior to reaching 80% confluence until sufficient cell numbers
were accrued for experiments.

4.2.2 Isolation of MSC subpopulations based on ALDH activity
To assay BM MSC for relative ALDH activity, growth media was aspirated, cells were
washed with PBS and cells were collected after trypsin-mediated detatchment. After cell
counting, MSC were assayed for ALDH activity using Aldefluor reagent at 10x106
cells/mL as per manufacturer instructions (Stemcell Technologies, Vancouver, BC).
Fluorescence activated cell sorting (FACS) was performed to isolate cells with high
(ALDHhi) or low (ALDHlo) ALDH activity to >99% purity. ALDHlo gating was set by
using DEAB inhibition of ALDH activity in control samples. Sorted cells were
subsequently washed in PBS to allow efflux of Aldefluor substrate via reactivation of
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inhibited ABC-transporters prior to plating at 2.7x105 cells/cm2 on tissue culture treated
plastic dishes in fully supplemented Amniomax C-100 media as described above.

4.2.3 Cell surface marker phenotype analysis
BM MSC were harvested with trypsin, collected in PBS+5%FBS and assayed for ALDH
activity level by labeling with Aldefluor as above. Subsequently, cells were stained with
anti-human antibodies for MSC marker expression CD73, CD90, CD105. To confirm that
MSC populations are negative for hematopoietic markers MSC were also labelled with
antibodies raised against monocyte marker CD14, and pan-leukocyte marker CD45.
Finally, to further characterise MSC sub populations Aldefluor labelled MSC were
labelled with antibodies for pericyte marker CD146 and LNGFR (CD271, Miltenyi
Biotech, Auburn CA).

All other antibodies were obtained from BD Biosciences

(Missisauga, ON). Viable, 7-amino-actinomycin D (7AAD, BD Bioscience)-excluding
cells were assessed for ALDH-activity and cell surface marker expression using an LSRII
flow cytometer at the London Regional Flow Cytometry Facility and analyzed using
FlowJo software (Treestar, Ashland, OR). All gating was performed based on
fluorescence minus-one controls (FMO.)

4.2.4 in vitro adipogenesis assay
To test differentiation of MSC into the adipose lineage, active ALDHhi or ALDHlo MSC
cultures were harvested using trypsin and reseeded in 12 well plates at 1x104 cells/cm2
and grown for 2-4 days to near confluency in Amniomax media. Amniomax media was
aspirated and cells were washed with PBS before replacement with adipogenesis
differentiation media (Gibco). Adipogenesis media was changed every 3-4 days for 14
days. After 14 days of adipocyte induction, cultures were fixed in formalin and subjected
to Oil Red O staining to label intracellular lipid stores. Cells were counterstained with
hematoxylin to visualise cell nuclei. Relative induction of adipogenesis was quantified by
percentage red pixels of total in photomicrographs measured using ImageJ software.
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4.2.5 in vitro osteogenesis assay
To assess differentiation of MSC into osteocytes, active ALDHhi or ALDHlo MSC
cultures were harvested using trypsin and reseeded in 12 well plates at 5x103 cells/cm2
and grown for 2-4 days to near confluency in Amniomax. Amniomax media was
aspirated and cells were washed with PBS before replacement with osteogenesis
differentiation media (Gibco). Osteogenesis media was changed every 3-4 days for 21
days. After 21 days of osteocyte induction, cultures were fixed in formalin and processed
for Alizarin Red S staining to detect calcification of osteocytes.

4.2.6 in vitro chondrogenesis assay
To assess differentiation of MSC into chondrocytes, active ALDHhi or ALDHlo MSC
cultures were harvested using trypsin, counted, pelleted and resuspended at 1.6x107
cells/mL of Amniomax. To create MSC micromass cultures 5μL aliquots of the
concentrated cell solution were carefully seeded in multiwall plates. After establishment
and 2 hours of incubation in high humidity conditions at 37°C, chondrogenesis
differentiation media (Gibco) was added to the micromass cultures. Chondrogenesis
media was changed every 2-3 days for 21 days. After 21 days of chondrocyte induction
micromasses were collected and embedded in optimum cutting temperature medium and
frozen. Cryosections were prepared at 8μm and fixed in formalin prior to Alcian Blue
staining to detect proteoglycans produced by chondrocytes. Cryosections were
counterstained with Nuclear Fast Red to identify nuclei in chondrocyte micromasses.

4.2.7 Generation of BM ALDHlo and ALDHhi MSC conditioned media
After FACS isolation, ALDHhi or ALDHlo MSC were seeded at 4.7x103 cells/cm2 and
grown in Amniomax for 3 days at 37°C to reestablish culture.

After 3 days the

Amniomax media was aspirated and replaced with serum-free, growth factor-free,
endothelial basal media (EBM, Lonza, Basel, Switzerland). After an additional 48 hours
in EBM culture without supplement, ALDHhi MSC- or ALDHlo MSC-conditioned media
was collected and filtered at 0.2μm and frozen for later use.
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4.2.8 HMVEC Culture
Human dermal microvascular endothelial cells (HMVEC) were grown in endothelial
basal medium-2 (EBM2, Lonza) supplemented with single-quots to make endothelial
growth medium (EGM2-MV, Lonza) containing fetal bovine serum (5% FBS), epidermal
growth factor (EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth
factor (FGF-B), insulin-like growth factor-1 (IGF-1), and ascorbic acid. Cells were
seeded at 4.7x103 cells/cm2. For maintenance culture, EGM2-MV was changed every 23 days when required

4.2.9 CyQUANT endothelial cell proliferation assays
HMVEC were seeded at 3x103 cells/well in 96 well plates using 100μL of fetal bovine
serum and growth factor supplemented endothelial growth media (EGM2-MV,
GF+/Serum+, Lonza), basal endothelial media with or without growth factors and serum,
(GF+/Serum-, GF-/serum+, or GF-/serum-), or in ALDHhi MSC- or ALDHlo MSCconditioned basal endothelial media. Cultures were maintained for 72 hours at 37°C
before each well carefully inverted and blotted to remove media from each well.

The

whole 96-well microplate was then frozen at -70°C for later use. To quantitate increased
DNA content representative of increased cell division, adherent cells were lysed by
addition of lysis buffer with CyQUANT GR dye in each well for 2-5 minutes at room
temperature, and protected from light as per manufacturer instructions (Molecular Probes,
Eugene, OR, USA).

Fluorescent signal in each well was assessed by fluorescence

microplate reader at 480nm excitation and 520nm emission maxima. Cell number in
each well was interpolated from a standard curve generated with known number of
HMVEC per well.

4.2.10

Fluorescent cell labeling for co-culture studies

HMVEC were labeled using CellTracker Green CMFDA

(Molecular Probes), at a

hi

concentration of 2μM in PBS+ PBS+5%FBS. ALDH or ALDHlo MSC tagged using
CellTracker Red CMPTX (Molecular Probes) at a concentration of 3μM in PBS+5%FBS.
Growth medium was aspirated from cell culture flasks and washed with PBS. After
washing, cells were incubated in appropriate dye solution for 15-45 min, at 37°C. The
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dye solution was then aspirated and replaced with normal growth medium, followed by
incubation at 37°C for at least 30 min prior to harvest for co-culture experiments.

4.2.11
HMVEC and MSC co-culture tubule formation assays on
Geltrex basement membrane extract
Geltrex reduced growth factor basement membrane extract (Gibco) was coated as a thin
gel on a 24-well plate at a volume of 100μL per well, followed by incubation at 37°C for
1-2 hours to allow the gel to set. The appropriate conditioned medium from ALDHhi
versus ALDHlo MSC, or from EGM-2 or EBM controls was then added at a volume of
400μL per well. EBM was added to negative control and experimental wells and EGM2MV was added to positive control wells. CellTracker Green CMFDA tagged HMVEC,
with previously established cells under EGM2-MV conditions, were harvested for
secondary culture and 4.5x104 cells were added to each well. CellTracker Red CMPTXdyed MSC were harvested and labeled with Aldefluor and sorted into ALDHlo and
ALDHhi MSC as described above.

CMPTX-tagged ALDHhi and ALDHlo MSC

populations and were added to experimental wells, at 9x103 ALDHhi MSC or ALDHlo
MSC per well. Endothelial cell tubule formation was assessed at 6 hours and 24 hours
after plating by phase contrast and fluorescent micrographs. Tubule branch points were
enumerated using 4 different fields of view by a blinded observer. All co-culture assays
were performed in duplicate.

4.2.12
Murine femoral artery ligation and intramuscular
transplantation of expanded MSC
To assess the effects of MSC in vascular regeneration in vivo we induced acute unilateral
hindlimb ischemia by surgical ligation and complete resection of the right femoral artery
and vein on anesthetised NOD/SCID (Jackson Laboratory, Bar Harbor, ME) mice as
previously described (Chapter 2, Appendix 1)27,28. Within 24 hours of surgery, mice were
transplanted by intramuscular injection at three sites into the right (surgical/ischemic)
adductor muscle with 50μL saline as vehicle control or 5x105 BM MSC.
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4.2.13
Quantification of hindlimb perfusion using laser Doppler
perfusion imaging
Anesthetized mice were stabilized at 37°C for 5 minutes on a heating pad before blood
flow in the lower hindlimbs (ankle to toe) was quantified using laser Doppler perfusion
imaging (LDPI, Moor Instruments, Devon, UK). The perfusion ratio of the
ischemic/surgical limb compared to the uninjured/control limb was assessed after surgery
to confirm induction of acute ischemic injury with a perfusion ratio (PR<0.1) of <10%
compared to the normal limb. Subsequent LDPI measurements were taken in each mouse
at 3, 7,14, 21,and 28 days after transplantation to track recovery of perfusion temporally.

4.2.14

Statistics

Data and results are reported as mean values ± SEM. Statistical comparisons were made
using a Student’s t-test for adipogenesis induction and one-way ANOVA test followed by
Tukey’s Post-Hoc tests for all other assays.

4.3 Results
4.3.1 BM MSC phenotype by ALDH activity level
Human BM-derived MSC cultures were established and assayed for ALDH activity using
Aldefluor and FACS. Sorted MSC subpopulations with high (37.4±3.2% ALDHhi, Figure
4.1) and low (45±4.2% ALDHlo, Figure 4.1) ALDH activity were isolated based upon
DEAB-inhibited controls. Both ALDHhi and ALDHlo MSC displayed robust expression
of characteristic stromal markers CD73, CD90, CD105 (Figure 4.2, Table 4.1) but did not
express hematopoietic marker CD45 (Figure 4.2D, Table 4.1) or monocyte marker CD14
as detected by flow cytometry (Table 4.1). Furthermore, both ALDHhi and ALDHlo MSC
highly expressed pericyte marker CD146 and LNGFR/CD271 (Figure 4.2E, Table 4.1).
Taken together, these data indicated that both subpopulations BM MSC express MSC
cell surface markers, fulfilling an important determinant in the minimal criteria for MSC
as set by the International Society for Cellular Therapy2.
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Figure 4.1. Bone marrow MSC purified according to high and low levels of ALDH
activity using Fluorescence Activated Cell Sorting.
(A) DEAB inhibits ALDH activity and establishes a negative gate to mark the ALDHlo
MSC subset. ALDHlo and ALDHhi MSC subsets sorted by FACS. (B) Representative
photomicrographs of MSC FACS sorted in to (B) ALDHhi and (C) ALDHlo populations
and plated in Amniomax media and grown by plastic adherence (n=14).
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Figure 4.2. Bone marrow MSC with high and low levels of ALDH activity display
MSC markers.
Bone Marrow subpopulations with high and low ALDH activity were isolated by FACS
and analyzed for cell surface marker expression associated with MSC phenotype. Both
ALDHhi and ALDHlo MSC showed high levels of (A) CD73, (B) CD90, and (C) CD105
expression. Both populations were negative for hematopoietic marker (D) CD45. Both
ALDH populations expressed pericyte marker (E) CD146. All gates were set by
fluorescence-minus-one controls (FMO).
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Table 4.1. Bone marrow MSC with high and low
levels of ALDH activity display MSC markers.
hi

lo

ALDH
MSC (+%)

ALDH
MSC (+%)

CD45
CD14

0.2±0.2
0.3±0.3

0.3±0.3
2.0±1.8

CD73
CD90

97.9±0.9
82.0±11.4

92.4±5.0
80.3±12.1

CD105

64.2±10.2

50.6±15.0

76.5±7.3

67.4±13.4

73.3±20.4

69.5±8.5

Lineage Marker
Hematopoietic

MSC

Pericyte
CD146
Other
CD271
(n=3-6)
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4.3.2 Both BM MSC ALDHhi and ALDHlo subpopulations
demonstrate multipotent stromal cell differentiation
Human BM-derived MSC were separated into subpopulations by level of ALDH activity
by FACS and were subjected to in vitro differentiation conditions to characterize
mesenchymal multipotency. Both ALDHhi and ALDHlo MSC formed Oil Red O positivestaining adipocytes after 14 days culture in adipogenesis induction media (Figure 4.3).
Notably, ALDHhi MSC (Figure 4.3A,C) demonstrated significantly increased frequency
of adipocyte induction compared to ALDHlo MSC (Figure 4.3B,D) as measured by
percent Oil Red O positive staining by culture area (Figure 4.3E, p<0.05, n=4). Both
ALDHhi (Figure 4.4A,C) and ALDHlo MSC (Figure 4.4A,C) also demonstrated induction
of osteocyte formation as assayed by Alizarin Red S detection of calcium deposition after
21 days in osteogenesis media for 21 days (Figure 4.4).

Furthermore, both ALDHhi

(Figure 4.5A) and ALDHlo MSC (Figure 4.5B) demonstrated induction of chondrocyte
differentiation in micromass culture in chondrogenesis media for 21 as measured by
detection of proteoglycan deposition by chondrocytes using Alcian Blue staining in
cryosections (Figure 4.5). Taken together, these data indicate that subpopulations of BM
MSC with both high and low levels of ALDH activity demonstrate mesenchymal
multipotency consistent with the defining minimal criteria2.
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Figure 4.3. Bone marrow-derived ALDHhi MSC show increased adipogenesis.
(A,C) ALDHlo MSC and (B,D) ALDHhi MSC were grown for 14 days in adipogenesis
differentiation media prior to Oil Red O staining. Representative (A,B) bright field and
(C,D) phase contrast photomicrographs of cell cultures stained with Oil Red O and
hematoxylin. (E) ALDHhi MSC show greater induction of adipocyte formation as
measured by % red pixels indicating positive Oil Red O staining after 14 days in
adipogenesis medium compared to ALDHlo MSC (n=4, p<0.05).
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Figure 4.4. Bone marrow-derived ALDHhi and ALDHlo MSC differentiate into
osteocytes.
(A,C) ALDHlo MSC and (B,D) ALDHhi MSC were grown for 21 days in osteogenesis
differentiation media prior to Alizarin Red S staining. Representative (A,B) bright field
and (C,D) phase contrast photomicrographs of cell cultures stained with Alizarin Red S.
Both ALDHhi and ALDHlo MSC induction of osteocyte formation as measured by % red
pixels indicating calcium deposition in osteocytes (n=4).
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Figure 4.5 ALDH activity level does not affect chondrocyte differentiation by MSC.
Both bone marrow-derived (A) ALDHlo and (B) ALDHhi MSC showed robust formation
of chondrocytes after 21 days micromass culture in chondrogenesis medium. Induction of
chondrogenesis in micromass cryosections was confirmed by Alcian blue staining
indicating proteoglycan deposition. Nuclear Fast Red counterstaining labels nuclei.
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4.3.3 ALDHhi MSC demonstrated increased support of endothelial cell
proliferation
To test differences in paracrine support of support of endothelial cell proliferation
ALDH-purified ALDHhi or ALDHlo MSC subpopulations were cultured in GF-free
serum-free endothelial basal media to generate MSC-conditioned media used for
HMVEC growth studies.

Dermal-origin HMVEC were cultured on plastic in basal

endothelial media with or without GFs (EGF, VEGF-A, FGF, IGF-1) and 5%FBS, or in
ALDHhi MSC-conditioned or ALDHlo MSC-conditioned media generated without serum
or growth factor supplementation. Conversely, HMVEC grown without either or both
serum and growth factors showed no proliferation over 72hours. HMVEC cultured in
GF+/FBS+ endothelial growth media demonstrated approximately 3.5 fold increase in
cell number over 72 hours as measured by CyQuant quantification. Notably, ALDHhi
MSC-conditioned media significantly increased proliferation of HMVEC compared to
ALDHlo MSC-conditioned media and basal endothelial media (p<0.01, n=5).
Interestingly, there was notable variation in HMVEC proliferative responses between BM
donor source. Pairwise comparisons of ALDHhi vs. ALDHlo MSC-conditioned media
within all other donor samples showed significant increases in EC proliferation in
ALDHhi–treated cultures (p<0.05, n=5). Intriguingly, BM45 MSC conditioned media
was most effective at promoting proliferation in both ALDHhi and ALDHlo
subpopulations further illustrating inter-donor variability in the induction of HMVEC
growth.

Taken together these data demonstrate the purification of BM MSC based on

high ALDH activity isolated a subpopulation of MSC with increased paracrine secretory
support of EC expansion.
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Figure 4.6. ALDHhi MSC conditioned media supports proliferation of endothelial
cells.
Representative photo-micrographs of human micro-vascular endothelial cells (HMVEC)
grown in (A) growth factor+/serum+ EGM2 media, (B) basal growth factor-free/serumfree, (C) ALDHhi MSC-conditioned media or (D) ALDHlo MSC-conditioned media. (E)
Compared to ALDHlo MSC-conditioned basal media, and basal media, ALDHHi MSC
conditioned media increased HMVEC proliferation. (F) Induction of HMVEC
proliferation varies according to the individual donor bone marrow source from which the
MSC were derived. (E) Different letters denote significant differences in mean (p<0.01,
n=5).
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4.3.4 ALDHhi and ALDHlo MSC augmented HMVEC tubule stability
To assess the potential for MSC-mediated support of endothelial cell tube formation,
CellTracker Green CMFDA fluorescent-tagged HMVEC were plated on growth factor
reduced Geltrex in basal endothelial media without serum or growth factor
supplementation. ALDH sorted MSC subpopulations were fluorescently labelled with
CellTracker Red CMPTX and co-cultured with EC at a ratio of 1 MSC:5 EC. Within 6
hours of co-culture, red-labelled MSC were detected in association with newly formed
endothelial cell tubules, consistent with perivascular wrapping function of MSC (Figure
4.7G,H). Direct co-culture of HMVECs with either ALDHlo or ALDHhi MSC did not
significantly increase tubule branch point formation by HMVECs at 6 hours relative to
negative control basal endothelial cell media (Fig. 4.7A-H,Q, n=3). Moreover, the
number of branch points formed by HMVEC in MSC co-cultures was reduced compared
to the number of branch points formed by HMVEC alone in growth factor- and serumsupplemented media (Figure 4.7Q). However, after 24 hours of co-culture, only ALDHhi
MSC supported significantly increased endothelial cell tubule formation compared to
basal conditions (Figure 4.7R). Moreover, ALDHhi MSC co-culture promoted tube
formation at equivalent levels to HMVEC cultured alone in growth factor and serum
supplemented endothelial growth media. ALDHlo MSC co-culture did not significantly
alter HMVEC tubule formation compared to controls or ALDHhi MSC co-culture (Figure
4.7R, n=3). These data demonstrated that purification of MSC with high ALDH activity
isolates a population of cells with increased support of endothelial cell tubule
stabilization.
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Figure 4.7. Co-culture with bone marrow-derived ALDHhi and ALDHlo MSC
augments HMVEC tubule formation.
Representative photomicrographs of tubule and branch point formation by HMVECs
after (A-H) 6 hours or (I-P) 24 hours culture in basal media (EBM, A,E,I,M), positive
control media (EGM2-MV, B,F,J,N), EBM with ALDHlo MSC co-culture (C,G,K,O), or
EBM with ALDHhi MSC co-culture (D,H,L,P). Scale bar = 300μm. (Q) Co-culture with
ALDHhi and ALDHlo MSC significantly augmented tubule branch point formation
relative to basal media at 6 hours. (R) ALDHhi MSC-conditioned media supported
maintenance of significantly more branch points compared to ALDHlo at 24 hours. Data
are expressed as mean ± SEM. (Q,R) Different letters denote significant difference,
p<0.05, n=3.
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4.3.5 Intramuscular injection of BM MSC promotes accelerated
recovery of perfusion after acute ischemic injury.
To establish proof of concept in vivo and to assess the functional role of transplanted
MSC in vascular regeneration, NOD/SCID mice were subjected to unilateral femoral
artery ligation and transplanted by intramuscular injection of BM MSC (non-sorted) into
the injured leg adductor muscle. Mice were monitored for recovery of perfusion using
laser Doppler perfusion imaging for 28 days. Seven days after treatment of PBS vehicleinjected control mice had recovered a perfusion ratio (PR, ischemic limb/normal limb) of
0.25±0.03 (Figure 4.8A, n=7). However, mice treated with heterogeneous BM MSC
showed significantly augmented rate of recovery of perfusion (PR=0.52±0.07) within 7
days compared to PBS-treated mice (Figure 4.8A, p<0.01, n=6). Although perfusion was
increased in MSC transplanted mice at days 7 and 14, significantly improved perfusion
was not maintained at later time points (Days 21 and 28). Two different BM MSC donor
sources were used. At day 7 post-treatment mice injected with BM20 MSC (Figure 4.8B,
PR=0.67±0.06, n=3) showed significantly augmented recovery of perfusion compared to
both PBS (Figure 4.8B, PR=0.25±0.03, n=7, p<0.01) and BM18 MSC (Figure 4.8B,
PR=0.37±0.03, n=3, p<0.01) treated mice. Notably, mice treated with BM18 MSC
showed no significant differences in recovery of perfusion compared to PBS controls.
Taken together, these data indicate that BM MSC support the recovery of perfusion in the
ischemic hindlimb of immune deficient mice after acute injury. However, inter-donor
variability in the induction of recovered perfusion by different MSC lines was evident.
This in vivo model will form the basis for future investigations to determine the in vivo
vascular regenerative potential of ALDHlo or ALDHhi MSC sub-populations and to
further identify other phenotypes of BM MSC samples associated with increased
regenerative function.
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Figure 4.8. Bone marrow MSC show differential support of vascular regeneration
by donor source.
LDPI was used to quantify perfusion in the hind limb following right femoral artery
ligation and intramuscular injection PBS vehicle control (n=7), or 5x105 BM MSC (n=6)
monitored for 28 days. (A) Perfusion ratio of the ischemic versus the non-ischemic
hindlimb from ankle to toe in all transplanted mice as described above. Compared to
saline controls, transplantation of BM MSC promotes recovery of perfusion in ischemic
mouse hindlimbs by day 7 post-transplantation. (B) Data presented in (A) sub-divided by
MSC donor, MSC from BM20 showed increased support of perfusion recovery compared
to donor BM18 MSC. Data are expressed as mean ± SEM, *p<0.01 v PBS, #p<0.01 v
BM18 MSC.
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4.4 Discussion
In this chapter, we demonstrate that BM MSC can be sub-fractionated into populations
based upon the level of ALDH enzyme activity. Both ALDHhi and ALDHlo MSC display
the characteristic cell surface marker phenotype typical of mesenchymal stromal cells
devoid of hematopoietic cell contamination. Moreover, both ALDHhi and ALDHlo
subpopulations display robust mesenchymal multipotency, demonstrating differentiation
capacity to adipocytes, osteocytes and chondrocytes under lineage specific differentiation
conditions. We show that the MSC subpopulation with high ALDH activity after culture
expansion demonstrates increased paracrine support of endothelial cell proliferation in
vitro, under serum-free, growth factor free conditions. Furthermore, we demonstrated
that ALDHhi MSC also augmented endothelial cell tubule formation, stabilizing tube-like
structures possibly through perivascular wrapping. We propose that high ALDH activity
provides a clinically relevant, FACS-selectable, and prospective marker to identify MSC
subpopulations with increased vessel supportive functions for the development of
improved cell therapies for ischemic disease.
The Hess laboratory and others have previously identified cells high levels of ALDH
activity as a marker which selects hematopoietic (Chapter 2)26,27,29-35, endothelial (Chapter
2)26,27,36-38, neural39,40, and mesenchymal19,26 cells with primitive, stem/progenitor cell
phenotype and function. Our lab has previously demonstrated that initial selection of
ALDHhi mixed progenitor cells from BM26 or UCB (Chapter 2)27 demonstrate increased
support of endothelial cell function in vitro and enhanced vascular regeneration in vivo.
The Hess laboratory have shown that while MSC-like cells can be derived from the
ALDHlo BM cells, these cells do not demonstrate full multi-lineage differentiation, and
are restricted primarily to the adipocytes lineage26. In contrast, MSC grown from ALDHhi
BM mononuclear cells represent true MSC, which expand efficiently in ex vivo culture
and demonstrate full multipotecy forming fat, bone and cartilage26. Furthermore, the
frequency of mesenchymal colony forming cells is significantly higher in the ALDHhi
population of human BM compared to ALDHlo BM26. Together these findings led us to
hypothesize that high ALDH activity might be a good prospective marker to further
purify an ALDHhi MSC subset with increased capacity for vascular regeneration after
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expansion ex vivo. Importantly, both the ALDHlo and ALDHhi subsets of expanded MSC
demonstrated extensive expression of CD146, a cell surface marker previously associated
with perivascular wrapping function for MSC isolated from multiple human tissues in
situ16.
The findings that BM ALDHhi cell promote recovery of hindlimb ischemia in mice was
used as preclinical justification for initiating clinical trials in patients with critical limb
ischemia, the most severe form of peripheral arterial disease (PAD)(NCT00392509)41.
Intramuscular transplantation of freshly isolated (uncultured) autologous BM ALDHhi
cells at multiple sites in the ischemic limb was compared directly compared to unpurified
autologous BM MNC in PAD patients with a Rutherford score of 4 (resting pain without
significant ulceration) or 5 (resting pain with unresolved ulceration or necrosis)41.
Results of this pioneering study demonstrated safety and patients that received
autologous BM ALDHhi cells showed improved Rutherford category and reduced resting
pain. Furthermore patients in the ALDHhi treatment group showed improved ankle to
brachial index scores more rapidly than the MNC group indicating improved perfusion of
the lower limb.

However, patients in both cohorts reported significantly improved

quality of life indices.41 More recently, a phase 2 placebo-controlled randomized clinical
study has been initiated to investigate transplantation of BM ALDHhi cells to improve
symptoms of intermittent claudication (NCT01774097).

The Hess laboratory have

previously shown that the BM ALDHhi progenitor cells are primarily (>90%) comprised
of hematopoietic precursor cells that efficiently form myeloid colonies in vitro, and are
also highly enriched in CD45- progenitor cells that generate multipotent fibroblast
colonies (1 CFU-F in 1500 BM ALDHhi cells) that expand efficiently and adherent to
plastic. Furthermore, MSC have been widely investigated in clinical trials for
cardiovascular disease. As a readily ex vivo expandable population of cells from BM,
MSC have been proposed as excellent candidates for cell therapy due to their robust
paracrine activities and perivascular wrapping functions. Indeed in diabetic rat models,
BM MSC have been demonstrated to promote vascular repair and wound healing42-44.
Moreover, a randomized controlled clinical trial was undertaken to compare BM MNC
and BM MSC therapy in diabetic patients with critical limb ischemia45. This study
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showed that both BM MNC and MSC were safely administered by intramuscular
administration and both BM MNC or BM MSC promoted improvements in perfusion,
tissue oxygenation, and pain free walking time at 24 weeks post treatment45.

Notably,

greater cell numbers could be generated during the ex vivo expansion of BM MSC
compared to the fresh BM MNC, indicating the appeal of ex vivo expansion to increase
cell numbers for transplantation.
However, a number of preclinical models have shown that BM MNC and MSC from
patients with diabetes or cardiovascular disease show diminished function for vascular
regeneration46-49. For this reason, cell therapy approaches using BM MSC combined with
ex vivo expansion are appealing as ex vivo expansion and targeted intra-muscular
transplantation may restore MSC vascular regenerative function, or alternatively, you
could potentially source BM from healthy donors for use in an allogeneic context. In
addition, the establishment of national registries to cryopreserve and HLA-phenotype
UCB samples may provide a renewable source of vascular regenerative MSC from early
ontogeny and devoid of chronic cardiovascular disease co-morbidities. Moving forward
towards essential experiments that will establish proof-of-concept, I propose that ALDH
activity presents a useful functional marker to identify MSC subpopulations with
increased vascular regenerative potential. Furthermore, selection of ALDHhi MSC might
also be helpful in screening cell lines to identify sample with increased or diminished
vascular regenerative potential. Taken together I propose that BM-derived MSC with
high ALDH activity represent a promising candidate for further development of cell
therapy for cardiovascular disease broadly and for critical limb ischemia and peripheral
arterial disease specifically.
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Chapter 5

5

Summary and Discussion

5.1 Summary of Major Findings
The overall objective of this thesis was to expand our understanding of the role of human
progenitor cells in vascular regeneration as a means to improve the outcome of potential
cell therapy applications in ischemic cardiovascular disease. Towards this end, I have
characterized a population of umbilical cord blood derived progenitors purified by
selection of cells with high ALDH activity, a mixed stem and progenitor cell population
with enhanced regenerative functions. Using complementary in vitro and in vivo models,
I have demonstrated the vascular regenerative effects of UCB ALDHhi cells. Furthermore,
I have demonstrated that it is feasible to increase the number of these useful, proangiogenic hematopoietic cells for vascular regenerative therapy by clinically applicable,
serum-free ex vivo expansion without diminishing vascular regenerative activity.
Building upon the abundant pre-clinical promise of MSC for vascular regenerative
therapies and the concept of high ALDH activity as a marker of cells with increased
progenitor cell and vascular regenerative phenotypes, I further demonstrated that MSC
with high ALDH activity demonstrate the support of endothelial cell function in vitro,
further reinforcing the use of ALDH as a prospective marker of multiple progenitor cell
lineages with enhanced vascular regenerative functions. Taken together, my studies have
demonstrated the viability of high ALDH activity as a useful marker for the isolation and
purification of blood and BM-derived cell types with increased efficacy in treatment of
ischemic disease (Figure 5.1).
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Figure 5.1 Summary of thesis findings.
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5.1.1 Chapter 2 – UCB ALDHhi cells induce vascular regeneration
The aims of my studies in chapter 2 were to characterize the capacity of UCB ALDHhi
cells to support vascular function in vitro in models of endothelial cell co-culture and in
vivo in a murine model of acute unilateral hind limb ischemia. Our lab had previously
demonstrated that selection of BM cells with high ALDH activity isolates a
subpopulation of cells that reconstitute hematopoiesis1,2, show widespread tissue
distribution3, and recruit to areas of ischemia after intravenous transplantation4.
Furthermore, the Hess lab have demonstrated that BM ALDHhi cells augment revascularization of the ischemic limb in transplanted mice after acute ischemic injury4.
Numerous studies have demonstrated that patients affected by CVD and/or diabetes have
decreased numbers of circulating pro-angiogenic cells, and furthermore these few
circulating have diminished efficacy in supporting vascular regeneration5-11. For this
reason my studies focused on the investigation of UCB as an alternate source of ALDHhi
pro-angiogenic progenitor cells for allogeneic transplantation approaches to augment the
diminished efficacy and frequency of circulating cells for vascular regeneration in
patients with CVD where autologous transplantation may be of limited effectiveness.
At the onset of these studies, I hypothesized that transplantation of human UCB ALDHhi
HPC would promote vascular regeneration of ischemic limbs in immune-deficient mice
with unilateral hind limb ischemia via paracrine mechanisms. I demonstrated that
selection of UCB ALDHhi cells isolates a population with increased myeloid HPC
phenotype by cell surface marker expression and by colony forming cell capacity in vitro.
Furthermore, my studies demonstrated that isolation of cells with high ALDH activity
from UCB enriches and selects for rare CD45–ECFC within the more heterogenous MNC
population. I showed that the UCB ALDHhi population demonstrated a pro-angiogenic
transcription profile compared to UCB cells with low ALDH activity. Indeed,
transcription of several important vascular regeneration-associated cytokines including
ANG1 and VEGF-A were expressed at significantly higher levels in ALDHhi cells than in
UCB ALDHlo cells. In co-culture with EC, UCB ALDHhi cells promoted the survival of
EC under growth factor-free, serum-free conditions. Moreover, in co-culture with EC on
growth factor-reduced matrigel, UCB ALDHhi cells supported augmented EC tubule

186

formation. Importantly, intravenous transplantation of UCB ALDHhi cells in an immunedeficient mouse model of acute unilateral hind limb ischemia significantly augmented
recovery of perfusion and increased vascularization in the ischemic limb compared to
vehicle-transplanted controls. Notably, the value of purification of the ALDHhi progenitor
cell subset was shown by increased recovery of perfusion and vascularization compared
to transplantation of heterogeneous UCB MNC containing an equivalent dose of ALDHhi
cells. After intravenous transplantation of UCB ALDHhi cells mice showed low levels of
human cell engraftment specifically in the ischemic muscle. Preparative irradiation to
reduce human cell rejection did not enhance recovery of perfusion by enhancing
engraftment or hematopoietic reconstitution. Indeed, irradiated mice showed increased
recruitment of human cells to the BM consistent with previously demonstrated
hematopoietic reconstituting capacity1,2. Transplantation of UCB ALDHhi cells into
irradiated mice showed delayed, less robust recovery of perfusion or vascularization in
the ischemic hindlimb compared to non-irradiated mice consistent with decreased early
recruitment of transplanted ALDHhi cells to the ischemic muscle. Indeed, our lab has
previously shown that tail vein injected BM-derived ALDHhi cells recruit specifically to
the ischemic hind limb within 6-24 hours after femoral artery ligation surgery indicating
the chemotactic nature of ALDHhi cells in response to ischemic damage stimuli4. We
concluded that although increased engraftment and survival of ALDHhi cells in the
ischemic hindlimb was predicted to improve revascularization, permanent or long-term
residence in the ischemic limb was not required to achieve potent recovery of small
capillary function.
My work in chapter 2 demonstrated that purification of ALDHhi cells from UCB is a
viable, readily available and less invasive alterative source of ALDHhi cells to BM. Due
to the early ontogeny of UCB, it will not have any CVD or age-associated morbidities
that might impair the most effective applications of cell therapy. The evidence that
purified ALDHhi cells were more effective than transplantation of heterogeneous MNC
containing as many ALDHhi cells indicates the importance of prospective selection
strategies to isolate cell types with increase vascular regenerative function while
depleting cells with either no benefit or potentially inhibitory effects. Overall, these
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studies indicated that UCB ALDHhi cells are a promising candidate for future
development of cell therapies for the treatment of CVD and more specifically for PAD
and CLI.

5.1.2 Chapter 3 – ex vivo expanded UCB HPC retain pro-angiogenic
capacity
Building directly upon the findings of chapter 2, my second aim was to address a primary
shortcoming of the use of blood derived ALDHhi cells. Namely, selection of ALDHhi cells
for use in a human setting may be hindered by the number of cells available for transplant
because the ALDHhi population is very rare accounting for less than 0.5% of total MNC
in UCB and less than 1% in total BM MNC4,12. The first goal in chapter 3 was to develop
an ex vivo expansion protocol which could increase the number of cells available for
therapy without untoward differentiation that may decrease the effectiveness of the cells
for vascular regeneration. Thus my aim for the studies presented in chapter 3 was to
optimize the ex vivo expansion of UCB ALDHhi hematopoietic cells under clinically
relevant serum-free conditions and to characterize vascular regenerative functions of the
expanded progenitor cells in vitro. In addition, I wanted to investigate the paracrine
mechanisms by which expanded hematopoietic progenitor cells derived from UCB
ALDHhi contribute to revascularization after direct intramuscular injection into the
ischemic limb. The hypothesis for these studies was that ex vivo expansion of UCB
ALDHhi cells would increase the number of pro-angiogenic hematopoietic progenitor
cells for application in vascular regeneration without decreasing EC-supportive functions.
I demonstrated that ex vivo expansion of UCB ALDHhi cells in clinically relevant, serumfree media with recombinant human TPO, FLT3L, and SCF for 6 days imparted a 20-fold
expansion of early myeloid cells retaining hematopoietic progenitor phenotype without
increasing the number of mature monocytes or macrophages. Moreover, after ex vivo
expansion from UCB ALDHhi cells, the resultant progeny retained hematopoietic
progenitor colony forming function in vitro and maintained a pro-angiogenic
transcriptional profile similar to freshly isolated UCB ALDHhi parental cells. In fact, the
expanded HPC population showed upregulation of several important vascular
regeneration-associated transcripts including significant upregulation of EGF, VEGF-A
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and ANG1. In direct co-culture with HMVEC, ex vivo-expanded HPC augmented tubule
formation in serum-free growth factor reduced conditions. Furthermore, HPCconditioned media and co-culture of HPC with HMVEC promoted increased survival of
HMVEC in growth factor-free serum-starved conditions. I demonstrated that during coculture with HMVEC, in basal unsupplemented media, HPC increased secretion of the
vascular regenerative growth factors EGF and ANG2. Furthermore HPC co-culture
increased secretion of chemokines that have been shown to play a role in modulating
recruitment of other support cells that are implicated in vascular regeneration in response
to injury or hypoxia including GRO/CXCL1-3, IL-8/CXCL8, and RANTES/CCL5.
Finally, HPC co-culture also increased secretion levels of matrix modifying proteins,
MMP-9, TIMP-1 and TIMP-2. These pro-angiogenic and matrix-modifying proteins have
been implicated in the induction of angiogenic sprouting in vivo and in vascular
stabilization and extracellular matrix remodeling respectively.
Using our well established immune-deficient mouse model of acute hindlimb ischemia, I
demonstrated that intramuscular injection of ex vivo-expanded HPC augmented recovery
of perfusion and increases vascularization of the ischemic muscle. Furthermore, I showed
that this improved vascular repair after femoral artery ligation in mice treated with ex
vivo expanded UCB HPC also resulted in improved recovery of limb usage compared to
vehicle controls. This indicates the usefulness of cell therapy for vascular regeneration
reaches beyond improvements in blood flow to ischemic tissue and includes accelerated
limb usage during recovery. Adequate perfusion and limb usage in ischemic tissues is an
important factor in moderating quality of life improvements in patients afflicted with
peripheral artery disease and critical limb ischemia. Taken together, my work in Chapter
3 demonstrated that it is possible to increase the number of pro-angiogenic hematopoietic
cells using clinically relevant expansion conditions. Importantly, I demonstrated that this
expansion of cell number does not decrease the efficacy for vascular regeneration
compared to the parental UCB ALDHhi cell population. Collectively, the findings from
Chapters 2 and 3 demonstrated that UCB is a readily available, expandable source of
progenitor cells with vascular regenerative potential, presenting a promising candidate
cell population for development of cell therapies for ischemic PAD.

189

5.1.3 Chapter 4 – MSC with high ALDH activity
Multipotent stromal cells can be isolated from bone marrow (BM) and many other
tissues. Broadly, MSC are considered good candidates for allogeneic cell therapy
applications because of their established safety after infusion, low immunogenicity and
potential immunomodulatory effects. Moreover, MSC are considered to be excellent
cellular sources of regenerative cytokines for many tissue repair processes and
specifically they have been shown to secrete pro-angiogenic factors13-17. Implementation
of MSC therapy has been somewhat hindered by variability in MSC function between
donor source and by lack of prospective markers for selection of samples with the
optimal regenerative potential for a given application. Our laboratory has previously
demonstrated that selection of high ALDH activity isolates an increased frequency of
MSC from BM MNC4 and as MSC differentiate in prolonged ex vivo culture, ALDH
activity and regenerative capacity is reduced. Furthermore, my earlier studies from
Chapters 2 and 3 have shown that high ALDH activity identifies hematopoietic cells with
increased vascular regenerative potential. For these reasons I hypothesized that selection
of MSC subpopulations with high ALDH activity after expansion culture would identify
a population of MSC with enhanced vascular regenerative functions.
In Chapter 4, I demonstrated that after expansion ex vivo, both ALDHhi and ALDHlo MSC
subpopulations expressed the cell surface markers characteristic of MSC, CD73, CD90,
and CD105, and were devoid of contaminating hematopoietic cells and monocytes.
Moreover, I showed that both MSC sub-populations expressed the pericyte marker
CD14618 and the prospective MSC marker low affinity nerve growth factor receptor
(LNGFR) also called CD27119. Furthermore, I demonstrated that both ALDHhi and
ALDHlo subsets of expanded MSC demonstrate mesenchymal multipotency, showing
growth factor induced differentiation into bone, fat and cartilage. Thus, both ALDHhi and
ALDHlo MSC met the strict definition of MSC set forth by the International Society for
Cellular Therapy20.
Adapting the in vitro co-culture systems I developed in Chapters 2 and 3, I demonstrated
that ALDHhi MSC showed greater support of endothelial cell proliferation in basal
conditions compared to ALDHlo MSC. Moreover, using fluorescent tagging and co-
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culture with HMVEC, I demonstrated that ALDHhi MSC demonstrated increased vessel
integration/association and provided structural support for the stabilization of EC tubule
formation in vitro compared to ALDHlo MSC. Based on my findings in Chapter 4, I
propose that BM-derived MSC with high ALDH activity represent an excellent candidate
for further development of cellular therapies for cardiovascular disease. Moreover, after
intramuscular injection of unpurified, culture expanded MSC into immune deficient mice
with unilateral hindlimb ischemia I showed evidence for inter-donor sample variability in
the capacity of BM MSC to promote vascular regeneration. These findings confirmed the
need for further study to identify additional prospective markers to identify MSC with
effective vascular regenerative function.

5.2 Clinical Applications
The findings presented in this thesis provide substantial pre-clinical justification for
further investigations of potential application of purified UCB ALDHhi cells, ex vivoexpanded HPC derived from UCB ALDHhi cells, and MSC subpopulations with high
ALDH activity. Indeed, Phase I/II clinical trials headed by Perin and colleagues have
demonstrated the safety and efficacy of autologous BM ALDHhi cells by intramyocardial
injection in patients with heart failure and by intramuscular injection in patients with
critical limb ischemia21,22. My work demonstrates the potential application of UCBderived ALDHhi cells in allogeneic transplant strategies both by intravenous and
intramuscular injection. Specifically in patients with severe PAD, transplantation of BMderived ALDHhi cell has been demonstrated to support the recovery of perfusion and
improved disease outcome, decreasing Rutherford score and resting pain with
concomitant increases in self reported quality of life21. These promising findings
demonstrate the potential for application of ALDHhi cells broadly for CVD and
specifically for patients with PAD and CLI.
Purification by high ALDH activity does not represent the only subpopulation of BM
MNC that has been investigated at the clinical level; autologous BM CD34+ have been
previously assessed in patients with moderate to severe CLI23. These studies also
demonstrated safety and suggested a promising trend towards reduced amputation and
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improved clinical indices23. However, I postulate that ALDH may represent a superior
marker to isolate a subpopulations of cells as it isolates not only the hematopoietic
progenitor cell types as would CD34 selection, but also isolates increased frequency of
MSC and ECFC4,12. However, to date the majority of cell therapy trials for CVD have
investigated heterogenous BM MNC populations. Despite the mixed results in BM MNC
therapy for acute myocardial infarction, meta-analyses have shown small benefits in left
ventricle ejection fraction24. Furthermore, the clinical trials investigating application of
BM MNC for PAD and CLI have shown some promise despite the small sample size of
trials completed25-27. As larger trials are completed, higher-powered analyses will be
needed clarify disease outcome improvements, and our preclinical data suggests that
prospective purification of pro-angiogenic progenitors and concomitant removal of
potentially interfering inflammatory cells could potentially help improve trial outcomes.
Interestingly, it has been demonstrated that MSC derived from a type 2 model diabetic
(db/db) mice showed decreased frequency, recruitment and efficacy in the support of
wound healing in diabetic mice compared to wild type controls28. Furthermore, MSC
isolated from rats with STZ-induced diabetes showed diminished differentiation,
paracrine cytokine secretion, and anti-apoptotic activity compared to healthy controls29.
However, studies have shown that using ex vivo growth factor (IGF and FGF2) activation
of diabetic-derived MSC has been shown to abrogate disease associated dysfunction
suggesting possible rejuvenation strategies to augment autologous MSC for CVD patients
may be possible30. Moreover, pretreatment of MSC from type 2 (db/db) diabetic mice
with EGF has been shown to abrogate diabetes-related dysfunction and to support
recovery of perfusion in mouse model of hindlimb ischemia31. These finding point
towards the potential benefit of a combined cell therapy approach using HPC cotransplantation with HLA-matched MSC. Indeed, our pre-clinical characterization of proangiogenic effectors showed that HPC secrete EGF and EGF-family cytokines that are
expected improve MSC-mediated vascular regenerative effects in vivo. Using a similar
approach, clinical trials using co-administration of expanded BM MSC with BM MNC in
patients with moderate to severe PAD showed safety and suggested improvements in
both hemodynamic and clinical indices32.
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Broadly, most cell therapies investigated for ischemic disease at the clinical level
encompass autologous approaches, despite accumulating evidence of disease associated
progenitor cell dysfunction in the patients with CVD8,9,28,29,33,34. Thus, the preclinical work
presented in this thesis may represent important findings regarding possible alternative
allogeneic sources (namely UCB) of purified angiogenic supportive progenitor cell types
untouched by chronic CVD co-morbidities. In addition, despite demonstrating safety in
multiple applications, arguably many of the clinical trials completed to date have been
underpowered to properly assess efficacy in treatment of CVD25,26,35,36. While many have
shown promising trends improving disease outcomes, further study is required to
properly identify the best candidate and delivery techniques for future cell therapy for
CVD37. To date, there have been few significant clinical trials investigating application of
allogeneic BM MSC or UCB cells for PAD27. Notwithstanding, the findings presented in
this thesis and by other research groups demonstrate the abundant promise shown in preclinical experiments for possible allogeneic cell therapy with BM MSC14,38 or UCBderived cells12,39-42 for PAD and CVD broadly. As such, I propose that purified UCB
ALDHhi cells, their ex vivo-expanded HPC progeny, and the ALDHhi subset of expanded
BM MSC all represent promising candidates for future cell therapy applications.

5.2.1 Angiogenic Hematopoietic Cells
It is important to note that UCB ALDHhi cells represent a heterogeneous progenitor cell
population, that contained enriched frequency of both hematopoietic and endothelial
colony forming cells4,12. Throughout this thesis I have taken great care to delineate the
contributions of supportive hematopoietic progenitors from the potential contributions of
non-hematopoietic endothelial progenitor cells or EPC. Indeed, confusion in the field still
exists because many populations that have been termed “EPC” are in fact hematopoietic
cell types that do not give rise to mature EC. Yoder et al. have established the phenotype
of the true, non-hematopoietic progenitor cells which they termed ECFC, defined by
cobblestone morphology, late outgrowth after plating from blood and no expression of
hematopoietic markers CD45 or CD146. Others have called ECFC the late blood
outgrowth EPC in contrast to the early outgrowth cells which should be more properly
called circulating angiogenic cells (CAC) or colony forming unit-Hill cells (CFU-
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Hill)43,44. The population of cells that Asahara et al. termed EPC in the seminal 1997
manuscript45, and early outgrowth CAC in fact more closely resemble heterogeneous
populations of VEGF-activated monoctyes46-49. Nonetheless, culture-expanded CAC
populations derived primarily from CD14+ monocytes have been shown to be an
important circulating angiogenic cell type40,50,51. UCB ALDHhi cells and ex vivo-expanded
HPC do not contain notable CD14+ monocytes, an important distinction between UCB
ALDHhi cells and CAC broadly. In addition our ALDHhi cell-derived HPC are generated
using traditional hematopoietic expansion conditions whereas CAC are expanded using
angiogenic growth factors. Both CAC and CFU-Hill cells have been shown to play a role
in paracrine support of angiogenesis and vascular regeneration44,47,48. More generally,
ALDHhi cells are different from CAC or CFU-Hill cells in that ALDHhi selection depletes
mature macrophages and lymphocytes, which are known to be constituent cells types of
those other angiogenic cell populations. However, both CFU-Hill and CAC include
hematopoietic progenitor cells, which would have high ALDH activity, indicating some
overlap in these pro-angiogenic but non-vessel integrated cellular populations. Since
selection of high ALDH activity isolates cells with progenitor cell function, it remains
possible that ALDHhi cells or expanded HPC differentiate into mature effectors like
monocytes or macrophages in vivo which may contribute to improved revascularization
and perfusion after transplantation. However, whether the vascular regenerative effects of
UCB ALDHhi cells or expanded HPC is mediated directly by the transplanted cells or by
differentiated progeny after transplantation remains to be elucidated after future studies.

5.3 Future Directions
Our screening approach to identify secreted soluble factors that might modulate vascular
regeneration was limited by availability of panel candidate factors. To identify a more
global profile of blood-derived progenitor cell paracrine factors that modulate vascular
regeneration, I propose the development of a proteomic approach to identification of the
complete secretome of UCB ALDHhi cells, expanded HPC or ALDHhi MSC. Other
groups have done similar proteomic screening to identify the secretome of human
embryonic stem cells52, EPC46,53, and to identify stem cell-mediated cytokine deposition
in extracellular matrix54,55. Identification of a global secretory profile of angiogenic
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hematopoietic cells including UCB ALDHhi cells and ex vivo-expanded HPC will help
determine the mechanisms by which blood cell-mediated vascular regeneration can occur
and will help direct future development of rational cell, peptide or drug therapies for
CVD.
Beyond identification of the paracrine and juxtacrine factors that regulate angiogenic
blood cell-mediated vascular interactions in ischemic disease, I propose that future cell
therapy clinical trails should only be undertaken on cell types with better characterized
molecular mechanisms of action to prevent unnecessary expenditures on suboptimal
cellular populations. For this reason, gain and loss-of-function studies on critical
paracrine mediators should be performed on candidate cellular populations to develop a
more in depth understanding of cell-mediated vascular regeneration after acute and under
chronic ischemic conditions. Better understanding of the molecular mediators regulating
effective regeneration could also direct possible future applications of autologous cell
therapies with ex vivo or correction of CVD-associated angiogenic cell dysfunction.
A limitation of my mouse model for investigating potential cell therapy for CAD or PAD
is that femoral artery ligation induces an acute ischemic injury and does not recapitulate
the atherosclerotic chronic disease condition. The most common mouse models used to
assess atherosclerosis are the apolipoprotein E-deficient (ApoE-/-) and low density
lipoprotein receptor knockout (LDLR-/-)56-58. The ApoE knockout model is characterized
by spontaneous development of atheromatous lesions, the development of which is
accelerated on a Western diet57. More recently, investigations have combined the ApoE
knockout mice model of atheroscelosis with the acute injury model of femoral artery
ligation59. Moreover, one group demonstrated that transplantation of CD34+/M-cadherin+
BM-derived progenitor cells promoted increased arteriogenesis in the ischemic hindlimb
of ApoE-/- mice with surgically-induced unilateral hindlimb ischemia. These findings
indicate that a population of hematopoietic progenitor cells promotes vascular
regeneration in a chronic atheromatous model of hindlimb ischemia. I propose
investigating application of UCB ALDHhi cells, HPC, and ALDHhi MSC in similar
models of chronic ischemic disease to further confirm my findings.
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Recently, progress has been made in advancing the effectiveness of ex vivo expansion of
hematopoietic stem and progenitors cells. A notable example of these novel factors are
the aryl hydrocarbon receptor antagonists which have been shown to dramatically
increase the expansion of hematopoietic stem cells60. Moreover, the Sauvageau lab has
recently identified many new factors involved in HSC regulation61. Beyond new small
molecule and protein mediators of HSC/HPC expansion, novel ex vivo culture techniques
have augmented our ability to increase the number of progenitor cells available after
expansion. The Zandstra group demonstrated recently that using a batch-fed culture
system which reduces accumulation of autocrine inhibitory factors that dampen
expansion significantly increases expansion rates of HPC62,63. Use of these novel
expansion strategies will augment our ability in the future to increase the number of cells
available for cell therapy in disease conditions beyond simple HSC transplantation for
hematological disorders.
As the key cellular mediators of progenitor cell vascular regeneration are better
characterized and the molecular mechanisms are elucidated it will become increasingly
feasible to consider ex vivo bio-engineering approaches to develop de novo blood vessels
for clinical application. As new scaffolds are identified and characterized such as
decellularized blood vessel explants64, our increased understanding of the important cell
types in vascular regeneration will help advance possible autologous seeding with BM or
blood-derived cells before scaffold implantation. Moreover, it is important to recognize
that sufficient vascularization is necessary for long-term successful engraftment of many
tissue transplant strategies broadly65. Thus, it will be increasingly important to understand
possible autologous or allogeneic cell sources that may augment vascularization of tissue
grafts. Indeed, in the practice of reconstructive plastic surgery it is well recognized that
proper vascularization is a limiting factor in the implementation of many promising tissue
engineering applications66-68. This demonstrates the importance of a better understanding
of the cellular mediators of vascular regeneration beyond vascular disease as a key
component of regenerative medicine broadly. The work presented in my thesis has
advanced our understanding of the particular subpopulations of blood derived cells that
help mediate a vascular regenerative niche and demonstrated the effectiveness of UCB
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ALDHhi cells, ex vivo-expanded HPC and ALDHhi MSC for regenerative medicine
applications.

5.4 Conclusions
Overall, the findings presented in this thesis demonstrate that UCB cells with high ALDH
activity are a readily available population of pro-angiogenic cells which can be expanded
in ex vivo culture and present a promising source for cell therapy applications in
treatment of CVD. Moreover, I demonstrated that high ALDH activity identifies
subpopulations of progenitor cells with increase vascular regenerative functions from
UCB HPC and also from BM MSC. My work has advanced the development of further
preclinical characterization of candidate cell populations and biomarkers for the future
development of allogeneic and autologous cell therapy.
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ABSTRACT
This unit describes the isolation and application of human umbilical cord blood
progenitors cells to modulate vascular regenerative functions using in vitro co-culture
systems and in vivo transplantation models. Using aldehyde dehydrogenase as a marker
of stem cell function, blood-derived progenitors can be efficiently purified form human
umbilical cord blood using flow cytometry. We describe in vitro approaches to measure
cell-mediated effects on the survival, proliferation and tube forming function of
endothelial cells using growth rate assays and Matrigel tube forming assays.
Additionally, we provide a detailed protocol for inducing acute unilateral hindlimb
ischemia in immune-deficient mice to assess progenitor cell modulated effects on
vascular regeneration by tracking the recovery of blood flow using non-invasive laser
Doppler perfusion imaging. Collectively, we present combined in vitro and in vivo
transplantation strategies for the pre-clinical assessment of human progenitor cell-based
therapies to treat ischemic disease.
Keywords: aldehyde dehydrogenase • stem cells • umbilical cord blood • critical limb
ischemia • angiogenesis
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INTRODUCTION
This section describes the isolation and application of pro-angiogenic progenitor cells
from human umbilical cord blood (UCB) for the development of cellular therapies to
treat ischemic vascular diseases. Angiogenesis, defined as the sprouting of new blood
vessels from pre-existing vessels, represents a central process for tissue repair, and allows
the delivery of circulating pro-angiogenic progenitor cells from multiple lineages to form
a vascular regenerative microenvironment (Rafii and Lyden, 2003).
Due to recent widespread initiatives to HLA-phenotype and cryopreserve human UCB in
North America and Europe, UCB now represents a readily available source of progenitor
cells for cell therapy applications. Umbilical cord blood represents a rich and renewable
source of hematotopoietic (HPC) and endothelial (EPC) progenitor cells that demonstrate
a variety of pro-angiogenic functions. Early in ontogeny and untouched by chronic
vascular disease-related pathologies, human UCB contains expandable precursor
populations of endothelial cells (EC) that represent the building blocks of neovessels
(Asahara et al., 1999; Asahara et al., 1997) and early myeloid progenitor cells that
provide paracrine support of EC survival and vessel forming functions (Putman et al.,
2012).
This unit focuses on the prospective isolation and functional characterization of
progenitor cells from human UCB. First, we describe fluorescence activated cell sorting
(FACS) of lineage depleted UCB mononuclear cells using high aldehyde dehydrogenase
(ALDHhi) activity, a conserved stem cell function that enriches for HPC and EPC
frequencies. Second, we outline co-culture strategies to determine the paracrine
communication between signal-sending progenitor lineages that support signal-receiving
EC survival, proliferation and tube-like structure formation in vitro. Third, we describe in
detail, human progenitor cell transplantation methodologies into immunodeficient
(NOD/SCID) models of critical limb ischemia induced by unilateral femoral artery
ligation and transection. These models have been optimized to permit the survival and
function of delivered human progenitor cells in areas of ischemia, and allow the temporal
quantification of blood flow recovery in live mice using laser Doppler perfusion imaging,
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coupled with detailed characterization of human cell engraftment correlated with the
induction of capillary formation in vivo. Collectively, these technologies represent
valuable platforms to dissect the molecular cross-talk between vascular and
hematopoietic progenitor subsets during regenerative angiogenesis. These vascular
regenerative processes may also be manipulated to promote the repair of ischemic tissues
including the damaged myocardium after infarct, and the recovery of vascular function
following stroke. The protocols presented below are detailed descriptions of those
previously published by our group (Cappocia et al., 2009, Putman et al., 2012).
NOTE: All cell isolation and culture procedures are to be performed in a Class II
biological safety cabinet.
NOTE: Aseptic technique is required for handling of all the solutions and equipment in
contact with living human cells.
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BASIC PROTOCOL 1
ISOLATION OF UMBILICAL CORD BLOOD PROGENITOR CELLS WITH
HIGH ALDEHYDE DEHYDROGENASE ACTIVITY
Using high aldehyde dehydrogenase (ALDHhi) activity, a cytosolic enzyme involved in
retinoic acid metabolism and cellular self-protection from oxidative damage (Hess et al.,
2004; Hess et al., 2006; Cai et al., 2004; Pearce et al., 2005; Storms et al., 2005; Corti et
al., 2006), and progenitor-associated cell surface markers (CD34, CD133), we have
developed fluorescence activated cell sorting (FACS) strategies to enrich for progenitor
cells from hematopoietic, endothelial, mesenchymal lineages (Capoccia et al., 2009).
This isolation is non-toxic and relies on the principle that ALDH-activity is
downregulated during progenitor cell differentiation (Storms et al., 1999). Thus, high
ALDH-activity efficiently isolates highly-purified and viable progenitor subtypes for
characterization of pro-angiogenic functions using traditional molecular approaches (cell
surface marker analyses, Affymetrix microarray, cytokine production by ELISA or
western blot; not discussed in this unit). Furthermore, these starting cell populations can
be used to establish highly proliferative hematopoietic and endothelial progenitor cultures
amenable to co-culture analyses and transplantation into immunodeficient mouse models
of limb ischemia described in detail below.
Materials
50mL heparinized syringe (250U) with 16-gauge needle
15mL or 50mL conical tubes
liquid pipettor and sterile 25mL, 10mL, and 5mL pipettes
1-mL and 200-µL pipettors and sterile filtered tips
RosetteSep® human UCB progenitor enrichment cocktail (Stem Cell Technologies (SCT),
cat. no. 15026)
peripheral buffered saline (PBS) + 2% fetal bovine serum (FBS HyClone)
Ficoll-Hypaque gradient (density 1.077 g/L, SCT)
Sterile glass pipettes
EasySep® Red Cell Lysis Buffer (SCT, cat. no. 20110)
Beckman GPR centrifuge with horizontal rotor
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hemacytometer and inverted light microscope (Zeiss), or automated cell counter
Isolation of UCB Lineage Depleted Mononuclear Cells
1. Using a 50mL heparinized syringe, draw 50mL of human UCB by venipuncture
from the umbilical vein of clamped placental and umbilical cord obtained
immediately after live birth. UCB can be stored at room temperature for up to 24
hours prior to cell processing without a significant loss of viability.
2. To deplete mature T-lymphocytes, B-lymphocytes, monocytes, NK-cells and red
blood cells (optional), transfer UCB sample from syringe into 2-50mL conical
tubes and add RosetteSep™ Human UCB Progenitor Enrichment cocktail at
10µL/mL and incubate for 20 min at room temperature.

RosetteSep™ is comprised of tetrameric antibody complexes recognizing CD2,
CD3, CD14, CD16, CD19, CD24, CD56, CD66b and glycophorin A. Unwanted
mature cells are pelleted with red blood cells after Ficoll-Hypaque centrifugation
(see below).
3. Add an equal volume of room temperature PBS and mix well.
4. Slowly layer 10mL UCB/PBS mixture on the surface of 5mL of Ficoll-Hypaque
solution at room temperature. For large volume samples 30mL UCB/PBS mixture
can be layered on the surface of 15mL Ficoll Hypaque solution.
To maintain the Ficoll-Hypaque / blood interface, hold the receiving tube at a 45º
angle and allow the UCB mixture to carefully flow down the side of the tube to
settle on the top of the Ficoll-Hypaque without mixing.
5. Centrifuge for 20-30 min at 450 x g, at 20ºC, with no brake.
Human UCB progenitor cells are enriched in the cloudy mononuclear cell layer,
above the pelleted RBC and Ficoll-Hypaque and below the clear plasma layer.
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6. Using a sterile pipette, carefully remove the mononuclear cell layer by gently
swirling the pipette tip as cells are drawn, and transfer mononuclear cell layer to a
fresh 15mL or 50mL conical tube.
7. Wash cells by adding excess PBS + 2% FBS (>3 times the volume of the
mononuclear cell layer) and centrifuge for 7 min at 240 x g, at 20ºC, with the
brake on. After centrifugation, aspirate the supernatant, and resuspend the cell
pellet in PBS + 2% FBS, repeat this step 2 times.
The washing step described above is required to reduce platelet contamination
and cellular debris from the mononuclear cell layer and wash remaining FicollHypaque solution from the sample.
8. If visible red cell contamination occurs in the washed mononuclear cell sample
(pink tinge in soluion), lyse residual RBC by adding 25mL of 1X red cell lysis
buffer solution. Allow to stand for 5 min at room temperature, add 25mL of PBS
+ 2% FBS, and centrifuge for 7 min at 240 x g. After centrifugation, aspirate the
supernatant and resuspend the cell pellet in PBS + 2% FBS, repeat this step 2
times. 1-2 rounds of red cell lysis may be required.
Some UCB samples may contain a significant amount of nucleated red blood cells
that resist lysis. However, after 2 rounds of lysis and washing the red
cell:leukocyte ratio should be <2:1, and manual hemacytometer counts will allow
for an accurate quantification of lineage depleted mononuclear cell numbers.
9. After the final wash, resuspend the purified mononuclear cells in 1mL of
Aldefluor™ assay buffer. Count viable cell numbers by trypan blue exclusion
using a hemocytometer or an automated cell counter.
A typical 50mL UCB sample contains 200-300 x 106 undepleted mononuclear
cells. After RosetteSep™ (as above) the total mononuclear cell number is reduced
to 5-50x106 lineage depleted cells allowing for a more efficient isolation of
ALDH-expressing cells by FACS as described below.
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SUPPORT PROTOCOL 1
CELL SEPARATION BASED ON ALDEHYDE DEHYDROGENASE ACTIVITY
The Aldefluor™ reagent kit is used to identify UCB progenitor cells that exhibit high
activity levels of the intracellular enzyme ALDH. Activated Aldefluor™ reagent is an
aminoacetaldehyde moiety conjugated to a Bodipy fluorochrome (BAAA). BAAA is
lipid soluble and freely diffuses into intact and viable mononuclear cells. In the presence
of ALDH, BAAA is converted into Bodipy-aminoacetate (BAA-) anion, and trapped
within the cell due to its negative charge, allowing the accumulation of fluorescent
product proportional to the amount of active ALDH within the cell. BAA- can be cleared
from the cell acting as a substrate for ATP-binding cassette (ABC) transporters. During
the Aldefluor reaction, active efflux of BAA- is minimized by an efflux inhibitor
contained within the Aldefluor assay buffer. After cell sorting, this pharmacological
inhibition can be removed by washing in PBS. Aldeflour reagent is not cytotoxic. Thus,
viable progenitor cells with high ALDH activity can be purified from highly
heterogeneous cell populations without affecting progenitor cell functions in subsequent
assays. A specific inhibitor of ALDH, diethylaminobenzaldehyde (DEAB), is used to
control for background fluorescence. The Aldefluor™ separation protocol detailed below
has been optimized for human umbilical cord blood, but is also applicable to the isolation
of ALDHhi cells from human bone marrow.
Materials
Aldefluor™ kit (Stem Cell Technologies, cat. no. 01700) containing:
Dry Aldefluor™ reagent, 50 μg
DEAB inhibitor, 1.5 mM, in 95% ethanol, 1 mL
2N HCl, 1.5 mL
DMSO, 1.5 mL
Aldefluor™ Assay Buffer, 4 x 25 mL
High-speed fluorescence activated cell sorter, FACS Aria III (Beckton Dickenson)
5mL conical tubes with 500µL PBS+5%FBS (for sorted cell collection)
NOTE: Store kit reagents at 4 – 8ºC as per manufactures instructions. Do not freeze.
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NOTE: The following protocols have been optimized for lineage depleted UCB samples.
The protocol has been slightly modified from the manufacturers instructions to conserve
reagents.
Aldefluor Activation
1. Assemble all kit reagents and warm to room temperature before use.
2. Add 25µL of DMSO to the vial with dry Aldefluor™ reagent, mix well with
pipettor, and let stand at room temperature for 1 minute.
The dry Aldefluor™ reagent is an orange red powder that changes to a bright
yellow green upon addition of DMSO.
3. Add 25µL of 2N HCl to the Aldefluor™ vial, mix well with pipettor, and incubate
the mixture for 15 minutes at room temperature.
4. Add 350µL of Aldefluor™ buffer and mix well. The final concentration of the
solubilized Aldefluor reagent is 300µM.
5. Divide the Aldefluor™ reagent into aliquots and store at -20ºC until needed for
the Aldefluor™ assay.
Aldefluor™ Assay
1. Adjust the cell sample to 5-10x106 cells/mL in Aldefluor™ assay buffer.
2. Add 5µL of DEAB inhibitor to the DEAB control tube. Recap the tube and the
DEAB vial immediately.
DEAB is provided in 95% ethanol and will evaporate if not capped after use.
3. Add 5µL of Aldefluor™ per mL of cell suspension. Mix immediately and add
0.5mL of the cell and Aldefluor™ mixture to the DEAB control tube and recap
each tube. Incubate each tube for 30 min at 37°C (do not exceed 60 min).
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The ALDH enzymatic reaction begins immediately upon the addition of the
activated substrate to the cell suspension. Because the DEAB tube is important in
establishing the sort gates for the ALDHlo versus the ALDHhi populations, it is
important that the aliquot of Aldefluor™ reacted cells is added to the DEAB
control tube without delay.
4. After incubation, centrifuge tubes at 450 x g for 7 min and remove supernatant.
Resuspend each tube in 0.5mL of Aldefluor™ assay buffer
5. Count viable cell numbers using trypan blue exclusion using a hemocytometer or
an automated cell counter. For optimal sorting concentration adjust Aldefluor™
treated cell suspension to 30-40x106 cells/mL in Aldefluor™ assay buffer and
store on ice or at 4°C until cell sorting.
If cell sorting using ALDH activity in combination with cell surface markers
(CD34, CD133, etc) is to be performed, aliquot 0.5 mL of Aldefuor™ treated cells
to individual tubes and add 2-5µL of PE- or APC conjugated antibody to cell
suspension. To prevent efflux of Aldefluor™ product it is important to perform
antibody incubation (20-30 min) in Aldefluor™ assay buffer. Whenever possible
keep the cells on ice or at 4°C to minimize fluorescent product efflux.
Cell Sorting Based on ALDH activity
1. Generate a side scatter (SSC) versus forward scatter (FSC) dot plot. In setup
mode, place the DEAB control sample on the flow cytometer and adjust the
voltages to center the nucleated cell populations to the to the center of the SSC
versus FSC plot. Create region (R1) that includes the nucleated cell population
and excludes anucleated erythrocytes and cell debris based on the UCB FSC
versus SSC profile (Fig. 1A).
Granular cells show high SSC and FSC. Nucleated cells (monocytes,
macrophages, T-lymphocytes, B-lymphocytes, and progenitor cells) show low
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SSC with intermediate FSC. Platelets, erythrocytes and cell debris show low
SSC and FSC (Fig. 1A).
2. Create a SSC versus Aldefluor™ fluorescence dot plot (Fig. 1B) gated on R1. In
set-up mode, adjust the Aldefluor™ fluorescence photomultiplier tube voltage
so that the stained cells in the DEAB control tube are centered in the third log
decade on the dot plot (Fig. 1B). Create a region R2 that includes DEABinhibited cells with low SSC and low Aldefluor™ fluorescence. Switch the flow
cytometer to data acquisition mode and collect 100,000 events in the R1 region.
Even in the DEAB-inhibited sample, all live nucleated cells will demonstrate
Aldefluor™ fluorescence. Thus, the DEAB analyses (Aldefluor™ fluorescence
in the presence of DEAB inhibitor) is a necessary control to distinguish
background cellular fluorescence (ALDHlo cells) versus cells with high ALDHactivity (ALDHhi cells) using the test sample.
3. In set-up mode, place the test sample on the flow cytometer. Without adjusting
the photomultiplier voltage, create a region (R3) that includes low SSC cells
with bright Aldefluor™ fluorescence (ALDHhi cells). Switch the flow cytometer
to data acquisition mode and collect 100,000 events in the R1 region.
4. In sorting mode with the sample chiller on, load ALDHlo cell and ALDHhi cell
collection tubes each containing 500µL Aldefluor™ assay buffer, and collect
the ALDHloSSClo cells (R1 and R2) and ALDHhiSSChi cells (R1 and R3) at
10,000-20,000 events per second (Fig. 1C).
5. After cell sorting, perform a purity check on the collected ALDHlo cell versus
ALDHhi cell tubes. Cell populations should be >99% pure.
6. Centrifuge sorted cell tubes at 240 x g for 7 min and aspirate supernatant. Wash
cells with 5mL PBS + FBS to remove ABC-transporter inhibition and allow the
efflux activated Aldefluor™ from viable cells.
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Sorted cell populations are undamaged by cell sorting and ready for use in the
in vitro co-culture or in vivo transplantation experiments described below. In
addition, UCB ALDHhi cells can be used to establish highly-proliferative
cultures of hematopoietic progenitor cells (Fig. 1D) in X-Vivo 15 basal media +
10ng/mL SCF, TPO, Flt-3 ligand (Lonza, cat. no. 04-744Q) on fibronectin
coated plates, or endothelial progenitor cells (Fig. 1E) in EGM-2 media +
EGF, IGF, FGF, VEGF (Lonza, cat. no. CC-3162) on fibronectin-coated plates.
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Appendix 1. Figure 1. Flow cytometric isolation of human UCB mixed progenitor
cells using high aldehyde dehydrogenase activity.
(A-C) Representative flow cytometry plots showing the selection of ALDHlo versus
ALDHhi mononuclear cells after lineage depletion. (D) Representative photomicrograph
of human hematopoietic progenitors from ALDHhi UCB in culture. (E) Representative
photomicrograph of endothelial progenitor cells in plastic adherent culture.
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BASIC PROTOCOL 2
CO-CULTURE OF UCB ALDHhi CELLS TO ASSESS PARACRINE EFFECTS
ON ENDOTHELIAL CELL SURVIVAL, PROLIFERATION, AND FUNCTION
This protocol was adapted to characterize paracrine and juxtacrine support provided UCB
progenitor cells on mature endothelial cell survival, proliferation and tubule formation in
vitro (Putman et al., 2012). However, these co-culture systems could easily be adapted to
test the potential vascular regenerative paracrine functions of any cell type of interest.
NOTE: For this protocol human microvascular endothelial cells (HMVEC) are selected
to model capillary or small vessel pro-angiogenic responses. Conversely, human
umbilical vein endothelial cells (HUVEC) are used to model pro-angiogenic responses by
larger vessel-resident endothelial cells.
Materials
Endothelial cells (HUVEC or HMVEC expanded in adherent culture, ATCC)
EBM-2 Basal Medium (Lonza, cat. no. CC-3156)
EGM-2 MV SingleQuot Kit & Growth Factors (Lonza, cat. no. CC-4147)
Contains a cocktail of growth factors (EGF, VEGF, FGF, IGF-1) and fetal bovine
serum (5% FBS) supplements to be added to basal media.
Tissue culture treated dishes/plates (Corning; 75cm2 flasks for expansion, cat. no.
430641, 12 well plate – 3512, 24-well plate – 3524 for co-culture assays)
Phosphate Buffered Saline (PBS, prepared ahead)
Trypsin Solution (Gibco, TrypLE™ Express (1X), no Phenol Red, cat. no. 12604-013)
Phosphate Buffered Saline + 5% fetal bovine serum (PBS+FBS, prepared ahead)
ALDH-activity purified UCB cells (ALDHhi and ALDHlo from Basic Protocol 1)
50mL conical centrifuge tubes
Hanging polycarbonate transwell inserts (3µm pore, Corning, Cat. no. 3402)
Matrigel™ Basement Membrane Matrix - Growth Factor Reduced (BD Biosciences, cat.
no. 356231)
Pipettors and 1000µL, 200µL, 20µL sterile tips
Beckman GPR centrifuge with horizontal rotor
hemacytometer and inverted light microscope or automated cell counter
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Cell Culture Incubator at 37°C, 5% CO2
Endothelial Cell Harvest
1. Aspirate growth media (EGM2-MV) and gently rinse culture dish with 10mL
pure PBS (no FBS).
2. Add 1mL Trypsin solution to culture dish and swirl to cover surface. Incubate at
room temperature or 37°C for 2-5 min to dissociate adherent HMVEC.
3. If cells do not lift easily from the growth surface you can force cell into
suspension by hitting the base of the flask against the palm of your hand.
4. Once cells have lifted from flask (check visually on inverted light microscope)
add 10mL PBS + 5% FBS solution and mix by repeated pipetting. Check flask to
ensure no cells are left behind uncollected.
5. Collect cells into a 50mL conical tube and centrifuge at 240 x g for 7 minutes.
6. Aspirate supernatant and resuspend cells in 1 mL of EBM2 (Basal EC Media).
7. Count cells using trypan blue exclusion using a hemocytometer and light
microscope or automated cell counter.
8. Distribute cells into a 50mL tube for each media condition to be used.
Adjust the ratio of cell suspension added to each tube depending on number of
wells needed for assay:
I. GF+ Serum+ (EGM2-MV; fully supplemented)
Positive control conditions for optimal EC survival and growth.
II. GF- Serum- (EBM2; unsupplemented basal media)
Negative control conditions for baseline EC survival.
III. GF+ Serum- (EBM-2 + growth factors)
Suboptimal conditions for EC growth without serum.
IV. GF- Serum+ (EBM-2 + 5% FBS)
Suboptimal conditions for EC growth without growth factors.
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9. Spin all tubes at 240 x g for 7 minutes.
10. Aspirate supernatants and resuspend cells in appropriate media at 106 cells/mL
Endothelial Cell Growth Rate Assay
1. Seed 40x103 HMVEC per well in tissue culture-treated 12-well plate.
Cell densities have been optimized for a 12 well plate format and should be
adjusted accordingly for culture in 6 or 24 well plates.
2. Under each growth condition, add 105 ALDHhi or ALDHlo cells into porous 3µm
hanging transwells suspended above the HMVEC in the 12 well plate (Fig. 2A).
3. Incubate cell culture dishes at 37°C for 72 hours.
4. At 24, 48, and 72 hours, observe cells under stereomicroscope and record
photomicrographs (Fig. 2B).
5. Enumerate trypan blue excluding HMVEC by blinded hemocytometer counts or
automated cell counting to determine the total number and frequency of viable
versus dead cells.
Matrigel Tubule Formation Assay
1. Thaw matrigel overnight in ice bucket in fridge.
2. Plate 200μL into each well of a 24 well plate. Carefully, pipet Matrigel to evenly
cover the base of the well.
It is important to prechill your plate and pipet tips in the fridge to prevent the
Matrigel from solidifying prematurely. Keep plate on an ice block, and Matrigel
in ice bucket. Shake the dish if needed to evenly coat well.
3. Incubate plate at 37°C for at least 30 minutes to allow matrigel layer to set before
plating cells.
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4. Add appropriate media to each well up to a total volume 400μL.
EGM2-MV; positive control
EBM2; negative control and basal media for cell supplementation
5. Seed 50x103 HMVEC to each Matrigel-coated well.
6. Add 20x103 ALDHhi or ALDHlo cells.
7. Observe under stereomicroscope and obtain photomicrographs of 3 fields of view
per well of matrigel at 24, 48 and 72 hours (Fig. 2C).
8. Enumerate number of branch points per field of view and quantify average tube
length using image analysis software such as ImageJ.
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SUPPORT PROTOCOL 2
PREPARING CONDITIONED MEDIA TO ASSESS PARACRINE SUPPORT OF
ENDOTHELIAL CELL FUNCTION
If desired, basic protocol 2 can be adapted for use with cell-conditioned basal media,
prepared in advance, in place of direct co-culture in hanging transwell inserts (Fig. 2A).
These assays demonstrate the added benefit of assessing only paracrine effects without
the possibility of cell migration through the transwell.
1. Seed standardized number of ALDHlo or ALDHhi cells into appropriate sized
culture dish containing EBM-2, basal media without serum or growth factors.
For optimal cell density, seed 400-500x103 cells in a T75-flask (10-15mL), 150200x103 cells in a T25 flask (3-5mL), or 50x103 cells in a 6 well plate (1mL).
2. Incubate culture for 24-48 hours at 37ºC.
3. Using a pipet collect conditioned media into a 50mL conical centrifuge tube and
spin at 450 x g for 5-7 minutes.
4. Collect supernatant and aliquot conditioned media into polystyrene tubes.
5. Store conditioned media at -30ºC until use.
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Appendix 1. Figure 2. Co-culture assays to assess cell-mediated effect on survival
proliferation tube forming capacity of endothelial cells
(A) Schematic overview of hanging transwell co-culture and cell conditioned media
assays to assess endothelial cell proliferation. (B) Representative photomicrograph of
human endothelial cells cultured on plastic. (C) Representative photomicrograph of
human endothelial cells growing on a thin layer of matrigel to assess modulation of tubelike structure formation.
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BASIC PROTOCOL 3
MURINE FEMORAL ARTERY LIGATION AND EXCISION AND
QUANTIFICATION OF VASCULAR REGENERATION IN VIVO
This protocol outlines a surgical procedure for inducing unilateral acute hindlimb
ischemia in immunodeficient mice. This protocol includes a double ligation with
complete resection of the fermoral artery and vein. This procedure induces more severe
ischemia than single ligation or non-resecting models. We have used immune deficient
NOD/SCID mice (Jackson Laboratory, Bar Harbor, ME) to allow the survival and
function of xenotransplanted human progenitor cells with reduced rejection due to
complete knockout of T- and B-lymphocyte function (SCID mutation) and reduced innate
immunity (NOD mutaton).

However, this protocol can be applied to any

immunodeficient mouse strain (NUDE, NOD/SCID IL-2R g null, NOD/SCID/MPSVIII
mice) noting that there are strain specific differences in the magnitude and rate of
recovery of perfusion following human cell transplantation.
NOTE: The procedures described for the transplantation of human progenitor cells into
highly immunodeficient mouse models of limb ischemia requires a dedicated barrier
facility with an aseptic surgical and monitoring suite and sterile housing using hepafiltered ventilated racks.
Materials
Ketamine hydrochloride (100mg/mL, 60-70mg/kg)
Xylazine (20mg/mL, 2-4 mg/kg)
Eye lubricant (Allergan Refresh Lacrilube)
Surgical scissors and forceps
Sterile cotton tipped applicator
5-0 Silk Sutures
Nexaband® Liquid Topical Tissue Adhesive (Abbott Animal Health)
Microsugical inverted microscope (Nikon SMZ2B)
Microinjection Syringes
Mobile Laboratory Animal Anesthesia System (VetEquip, cat. no. 901807)
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Electric hair clippers (Wahl)
Hair removal cream (Nair)
Bacteriostatic soap
Isopropyl alcohol
Betadine solution
Sterile cotton tipped applicators
Cautery tool (Alcon Surgical Optemp II)
Bupreorphine (0.1 mg/kg, subcutaneous)
Heat Pad
Laser Doppler imager (Moor LDI2)
OCT tissue embedding medium
Tissue moulds
Liquid nitrogen
Dry ice
Cryostat microtome
Mouse anti-human HLA-A,B,C antibody (1:500, Beckton Dickenson, cat. no. 557347)
Rat anti-mouse CD31 antibody (1:100 Beckton Dickenson, cat. no. 550274)
vWF antibody (1:200 Millipore, cat. no. AB7356)
DAPI reagent
Immunofluorescent Microscope (Zeiss AxioScope™ or similar)
Anesthesia

3

Induce initial anesthesia by intraperitoneal injection of ketamine hydrochloride

(60-70mg/kg) and xylazine (2-4mg/kg) solution.
For ease of use and to reduce the number of injections needed prepare a working
solution of ketamine and xylazine in saline or sterile water to use to
intraperitoneal injection.

4

Place mouse into anesthesia induction chamber and fill chamber with 2-5%

isoflurane in 100% O2 at a flow rate of 0.8L/min.
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5

Once mouse is unresponsive to external stimuli by foot pinch, place mouse on

surgical surface in supine position and immobilize the right hindlimb by taping the foot to
the surgical surface.

6

Maintain anesthesia for the duration of the surgical procedure using a nose cone

with 1-2% isoflurane in 100% O2 at a flow rate of 0.8L/minute.
Surgery
1. Apply bepanthene ophthalmic ointment to the eyes to prevent drying during
surgery.
2. Shave the hair from the lower limb and inguinal region using an electric shaver
for bulk hair removal. Completely remove residual hair from lower limb by
applying Nair hair removal cream briefly (1 min).
3. Wipe away excess hair removal cream and clean the skin and prepare surgical
field with three rounds of bacteriostatic soap wash followed by isopropyl alcohol
swab and betadine scrub.
From here forward the protocol is most easily completed using a dissecting
microscope.
4. Carefully make a 10-15mm longitudinal incision in the skin following the femoral
vessel from the inguinal crease distally down the midpoint of the thigh using
surgical scissors and forceps.
5. Use moistened sterile cotton tipped applicator and surgical scissors to gently clear
subcutaneous fat away to expose the femoral artery and vein and associated
neurovascular bundle (Fig. 3A). Locate the superficial epigastric artery branch
point as a landmark.
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6. Using the cautery tool, cauterize transversely the subcutaneous fat and the
superficial epigastric artery. This will expose the muscle and neurovascular
bundle underneath.
7. Carefully separate the femoral nerve from the femoral artery and vein starting
near the groin and moving distally towards the knee using forceps and scissors.
Avoid damaging the femoral nerve while separating it from the vessels.
8. Thread silk suture under the femoral artery and vein and gently slide it proximally
toward the groin to maximize the length of the femoral artery and vein to be
excised. Ligate the artery and vein using double surgical knots.
9. Thread silk suture under the femoral artery and vein and gently slide it proximally
to the bifurcation of the popliteal and saphenous arteries that descend into the calf.
Ligate the artery and vein using double surgical knots.
10. Using the cautery tool, cauterize the collateral vessels that emerge from the
femoral artery between the ligation sites.
11. Carefully resect and excise the femoral artery and vein bundle between ligation
sites with surgical scissors. Typically, it is possible to excise a 5mm segment of
the femoral artery and vein between ligation sites. Carefully check the ligation
site for full occlusion and for any signs of bleeding.
12. Close skin incision using silk sutures and/or Nexaband tissue glue.
13. For post-operative pain management, administer buprenorphine (0.1mg/kg) by
subcutaneous injection.
14. Transfer mouse to recovery cage with direct access to water and food and monitor
the mice for 30-60 min ensuring they emerge from anesthesia and retain use of the
surgical limb.

227

It is expected that the mice will show reduced mobility and use of the ischemic
limb after surgery. Mice will demonstrate a notable limp for 24-48 hours postoperatively. Gradually, mice will recover full mobility in the surgical limb. Be
sure to monitor the incision sites daily for up to 7 days and look for signs of
bleeding or excessive grooming that may result in the re-opening of the incision.
If signs of incision damage occur, move mouse to a separate cage without
littermates to allow healing.
15. Allow mice to recover for 24 hours before administration of the compound or cell
type of interest to assess effects on the recovery of blood flow by laser Doppler
perfusion imaging of the mouse hindquarters as described below.
Useful administration techniques include intravenous tail vein injection to deliver
cells or compounds to the general circulation to study the recruitment of injected
cells to the ischemic region. Alternatively, direct intramuscular injection into the
ischemic adductor or gastrocnemius muscle can be used to bypass the
inefficiencies of cellular recruitment to the ischemic region.
Laser Doppler Perfusion Imaging (LDPI) Analyses
NOTE: LDPI timepoints and a representative example of the recovery of limb perfusion
after intravenous injection of 2x105 UCB ALDHhi cells is shown in Fig. 3B.
1. Induce anesthesia as described in the surgery section above.
Depending on the strain of mouse used the injection of xylazine and ketamine to
induce anesthesia may not be necessary and induction using inhaled anesthesia
may be sufficient.
2. Completely remove any residual hair from lower limb by applying hair removal
cream briefly.
Excess hair re-growth will interfere with the accuracy of the laser Doppler
measurements. Typically, residual hair removal will be required every 1-2 weeks
depending on mouse strain and fur color.
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3. Transfer mouse to 37ºC draped heating plate for 5 minutes to stabilize body
temperature.
It is important to ensure stable body temperature in the mouse before LDPI
scanning as decreased body will significantly alter blood flow in the hindlimbs.
4. Maintain anesthesia with 1-2% isoflurane in 100% oxygen at 0.8L/min.
Carefully maintain anesthetic depth to prevent scan artifact from the mouse
moving if too lightly anesthetized or from falsely low measurement of blood flow
if too deeply anesthetized.
5. Place mouse in supine position under laser Doppler perfusion imager and extend
hindlimbs. Follow manufacturer instructions for proper calibration of laser and
measurement of superficial blood flow using consistent settings between
subsequent measures at later time points.
6. Using the LDPI software acquire the perfusion image data. Adjust the background
threshold to display LDPI flux measurements on the mouse hindquarters from the
waist to the tips of the toes.
7. To quantify relative blood flow in the ischemic versus the control limb set a
region of interest on each leg between the toes and heel (Fig. 3A), and measure
the units of flux in the ischemic limb versus the non-ischemic limb.
8. To ensure consistent induction of acute unilateral hindlimb ischemia by the
surgical procedures described above. Relative perfusion in the ischemic limb of
NOD/SCID mice should be <10% of the perfusion flow in the control limb.
9. Repeat measurement of blood flow using the identical protocol at each time point
to track the recovery of perfusion over a 28 day time course.
We recommend performing LDPI at post-transplantation day 0, 3, 7, 14, 21, and
28 (Fig. 3B) in 8-10 mice per cohort to allow for statistical comparison between
the recovery of perfusion in control (PBS injected) versus cellular transplanted
treatments.
Collection of Muscle Samples for Histological Analysis
1. At the predetermined end point of your experiment, euthanize the mice by
cervical dislocation under anesthesia or by CO2 inhalation.
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Depending on the purpose of the experiment we routinely euthanize mice from
each transplantation cohort at day 7; to address the recruitment of human cells to
the ischemic region and to generate a snapshot of active vascular regenerative
processes, at day 14 to address the survival of human cells in the ischemic region
at the midpoint of the regenerative process, and at day 28 to document the overall
extent of vascular recovery. At each endpoint extensive histochemical analyses
can be performed (see below) at the site of surgery in the quadriceps muscle and
distally in the gastrocnemius muscle. We routinely monitor human cell
engraftment and survival, the recovery of capillary density and small neovessel
formation, the induction of EC proliferation and prevention of apoptosis in the
ischemic region, in order to fully document the cellular mechanisms of vascular
recovery.
2. Remove skin and fasciae from the legs and lower limbs of the mouse. Using
dissection scissors remove the superficial thigh muscles by making an incision
beginning laterally across the knee and carefully peeling and cutting back the
muscle from along the femur up towards the groin.
3. Embed the muscle in OCT compound in tissue mould blocks. Align embedded
tissue so that the lateral cut across the knee or ankle is along the base of the block.
4. Dissect the gastrocnemius (calf) muscle by making incisions along the tendons
inserting at the ankle and cut proximally along the lower leg bones towards the
knee.
5. Embed the calf muscle in OCT compound in tissue mould blocks. Align
embedded tissue so that the lateral cut across the knee is along the base of the
block.
Careful placement of each muscle sample in the tissue block allows efficient
cross-sectional cuts through the muscle fibers during cryosectioning
6. Quickly freeze muscle sections suspended in OCT using liquid nitrogen flash
freeze or by placing trays on a dry ice block.
7. Frozen tissue can be stored at -20ºC for up to 7 days. For long-term storage,
transfer to a -80ºC freezer.
8. Cut 10-15μm sections using a cryostat microtome at -14ºC to -18C. Store dry
sections at -20ºC. Transfer dry frozen sections to -80ºC freezer for long-term
storage.
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Human Cell Engraftment and Blood Vessel Density in Hindlimb Muscle
Sections
1. Following standard immunohistochemistry or immunfluorescence protocols
(http://www.vectorlabs.com/catalog.aspx?prodID=1375) detect transplanted cell
recruitment/engraftment using HLA-A,B,C expression to identify human cells.
2. Similary, immunostain for mouse CD31 expression to visualize murine capillary
beds using immunofluorescent microscopy counterstained with DAPI or light
microscopy counterstained with hematoxylin to mark nuclei (Fig. 3C).
3. Similarly, immunostain for mouse vWF expression to visualize larger murine
arterioles using immunofluorescent microscopy counterstained with DAPI or light
microscopy counterstained with hematoxylin to mark nuclei (Fig. 3D).
This labels endothelial cells of larger higher shear stress vessels such as
arterioles. Whereas CD31 staining can be inconsistent in larger vessels vWF
reliably identifies larger vessels in muscle sections (Pusztaszeri et al. 2006).
4. Enumerate HLA-A,B,C+ human cells, CD31+ capillary structures, and vWF+
arterioles by blinded manual counts of 3 fields of view in each of 3 sections for
each muscle sample.
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Appendix 1. Figure 3. Transplantation model of acute unilateral hindlimb ischemia.
(A) Diagram of the vasculature of the mouse hindlimb from the inguinal crease to the
bifurcation of the femoral artery into the saphenous and popliteal arteries which descend
into the calf and lower limb. Ligation sites for femoral artery ligation surgery are
indicated. Representative laser Doppler perfusion images of mouse hindquarters before
and after ligation and transection of femoral artery and vein. Regions of interest are
selected from ankle to toe to quantify relative perfusion in the surgical limb. (B) Outline
and suggested timing for tracking recovery of perfusion in the ischemic limb after
surgical induction of acute ischemia. Number in lower left quadrant of each laser Doppler
perfusion image is the ratio of perfusion in the ischemic limb to the perfusion in the
control limb.

(C,D) Representative photomicrographs of ischemic adductor muscle

sections stained for (C) CD31and (D) vWF.
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COMMENTARY
Background Information
Ischemic disease is characterized by the reduction of blood flow to the heart or peripheral
tissues and encompasses life-threatening disorders such as ischemic heart disease and
critical limb ischemia. Despite advances in the management of these conditions, ischemic
disease remains a leading causes of morbidity and mortality worldwide (Dotsenko, 2010;
Bozdag-Turan et al., 2011). Thus, exogenous stimulation of blood vessel formation by
cell transplantation is under intense investigation for the treatment of ischemic disease.
Numerous studies have established the potential of transplanted bone marrow-derived
mononuclear cells implicated in the co-ordination of regenerative angiogenesis, and have
generated a number of clinical trials investigating treatment of cardiac (Janssens et al.,
2006; Wollert et al., 2004; Schachinger et al., 2006) and limb ischemia (Tateishi-Yuyama
et al., 2002; Higashi et al., 2004) by transplantation. Although these studies have
demonstrated safety in the autologous setting, they have shown only modest
improvements in clinical endpoints (Rosenzweig, 2006). In addition, recent studies in
patients with chronic diabetes or vascular disease-related pathologies demonstrate
compromised progenitor cell content and function (Werner et al., 2007; Werner et al.,
2005; Fadini et al., 2006; Jialal et al.). Thus, the purification of pro-angiogenic cellular
sub-types from non-autologous sources, and characterization of specific sub-type
contributions during the coordination of vascular repair is warranted to improve current
cell-based therapies for ischemic diseases.
Using high aldehyde dehydrogenase-activity, a conserved stem cell function involved in
the protection of long-lived cells from oxidative insult, we have identified a purified mix
of progenitors from human BM (Capoccia et al., 2009), and from UCB (Putman et al.).
We have shown that iv-transplanted ALDHhi mixed progenitor cells can stimulate the
recovery of perfusion in mice with femoral artery ligation-induced limb ischemia
(Putman et al.). However, few transplanted cells showed permanent integration into
newly generated vascular networks. Rather, ALDHhi cells transiently recruited to the
ischemic limb and orchestrated murine capillary formation via unidentified secretory
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mechanisms. This concept termed “stem cell-mediated vascular regeneration” has
become a central process for tissue repair, and provided proof-of-concept for FDAapproval of clinical trials using autologous BM-derived ALDHhi cells to treat ischemic
heart failure and critical limb ischemia.
Critical Parameters and Troubleshooting
Table 1. Troubleshooting Guide for Common Problems
Problem

Possible Cause

Potential Solution

BASIC PROTOCOL 1: Purification of UCB progenitors based on ALDH activity
Incomplete red blood cell
lysis

High frequency of
nucleated red blood cells

Perform a second round of
lysis in ammonium chloride
solution

Clogging during sort

Too much debris or
clumping cells

Keep cells on ice and filter
immediately before sorting

BASIC PROTOCOL 2: Co-culture of UCB progenitors in vitro
Contact inhibition or
overgrowth of HMVEC
during co-culture

Initial seeding of cells at
too high density

Seed cells at a lowered
density. Shorten incubation
endpoint

BASIC PROTOCOL 3: Femoral artery ligation and transplantation in vivo
Bleeding during surgery

Rupture of blood vessel

Euthanize mouse

Excessive necrosis in
mouse surgical limb

Damage to femoral nerve

Euthanize mouse, take care
not to damage the femoral
nerve during surgery

Mouse slow to recover after
anesthesia

Excessive anesthesia

Administer intraperitoneal
saline, place mouse under
heat lamp or on heat pad to
keep warm
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Anticipated Results
A 40-50mL lineage-depleted UCB sample will typically contain 200-300x106
mononucleated white blood cells. Lineage depletion using RosetteSep™ results in the
reduction of total cell numbers to <50x106 cells for the Aldefluor™ assay and FACS.
Approximately 2-3% of lineage depleted cells will demonstrate high ALDH activity (Fig.
1C), and the ALDHhi population should be separated from the ALDHlo cells by greater
than half a log scale. Depending on cell sorting efficiency a typical UCB sample will
yield approximately 2x105-1.5x106 ALDHhi cells for functional experimentation. These
cell numbers represent ample cell numbers to perform the co-culture experiments in a 12well format. Furthermore, we routinely inject 2x105 cells per mouse during
transplantation experiments. Therefore, from a single UCB sample we obtain sufficient
purified cell numbers to transplant 4-8 mice plus PBS controls.
In the in vivo transplantation model, the surgically-induced reduction in perfusion may
differ between individual mouse strains or between surgeons if the surgical technique
differs slightly. We recommend setting a maximum perfusion ratio of 0.1 measured
immediately after surgery as a criterion to exclude mice with potentially incomplete
induction of limb ischemia. In our experience this level of ischemia does not induce loss
of limb or excessive morbidity as long as there is no damage to the femoral nerve.
LDPI performed on live anesthetized mice allows the accurate quantification of the
recovery of perfusion in the ischemic limb over a pre-determined time course. The
recovery of perfusion to the ischemic limb occurs rapidly over the first 7 days. Therefore,
several LDPI measurements should be taken in the first week to closely monitor the
kinetics of recovery. In PBS-injected control animals, the recovery of perfusion may
plateau after 14–28 days at ≈40-50% of the non-ischemic limb depending on the recipient
mouse strain. This baseline recovery in perfusion is sufficient to prevent limb loss and
avoid significant morbidity and mortality.
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Time Considerations
Once familiar with the protocol, the processing of an UCB unit to prepare for Aldefluor
sorting can be completed in approximately 3 hours including all incubations. Depending
on sorted cell concentration and equipment, a lineage depleted UCB sample can be sorted
in 1-2 hours from set-up through shut down. An experienced flow cytometry operator is
recommended to properly perform and troubleshoot the important steps of cell sorting.
Similarly, an experienced animal technician can complete anesthesia, preparation and
surgery on a mouse in 20-30 minutes. Depending on size of LDPI taken, non-invasive
perfusion measurement can be completed in 10-15 minutes per mouse including
temperature stabilization. Generally, 30 minutes is sufficient time for a mouse to recover
from anesthesia and surgery.
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